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EFFECTS OF OXYTOCIN ON HUMAN AGGRESSION 
 
Joseph Louis Alcorn III, B.S. 
Advisory Professor: Scott D. Lane, Ph.D. 
 
Human interaction is comprised of common, yet complex, behaviors and the 
outcomes of these social behaviors can beneficially or detrimentally impact individual 
and public health. One social behavior that can have profound detrimental outcomes 
is aggression. Aggression is a class of social behavior that is particularly prevalent in 
individuals with antisocial personality disorder (ASPD) and comorbid substance use 
disorder (SUD). Aggression in these individuals can manifest at maladaptive levels 
that place considerable burdens on public health and communities. Therefore, 
understanding the neurobehavioral underpinnings of aggression holds substantial 
merit. The goal of this project was to examine the effects of this oxytocin (OT) on 
human aggression. Considerable work has demonstrated that OT engenders the 
promotion of affiliative social behaviors that are mutually beneficial (or prosocial) 
between two individuals. Aggression is characterized, in part, by social behaviors 
that are antisocial (which are opposite to prosocial behavior).  The hypothesis was 
that acute administration of OT would reduce the frequency of human aggression. 
This hypothesis was tested in both individuals with comorbid ASPD and SUD, and 
healthy volunteers.  
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This project employed a well-established laboratory measure of human 
aggression, the Point Subtraction Aggression Paradigm, which measures changes in 
the frequency of aggressive behavior. In ASPD+SUD individuals there was no 
significant reduction in aggressive behavior following OT administration.  However, 
there were non-systematic individual differences on aggressive behavior following 
OT dosing, which suggested modulation of aggressive behavior by OT.  In healthy 
volunteers there was no significant effect of OT dose on aggressive behavior.  
However, in healthy volunteers, an examination of individual differences focused on 
antisocial personality traits revealed that aggressive behavior under OT was 
positively correlated with interpersonal manipulation and anger (Pearson’s r = 0.57). 
Healthy volunteers with higher scores of interpersonal manipulation and anger 
actually showed an increase in their aggressive behavior following OT 
administration.  
 In both ASPD+SUD individual and healthy volunteers, the hypothesis that OT 
would decrease human aggression was not supported. The experiments of this 
dissertation revealed substantial individual differences in aggression following OT 
administration, which is important for future research in examining the therapeutic 
efficacy of OT for the management of aggression in antisocial and substance abuse 
populations.  
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CHAPTER 1: INTRODUCTION 
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Human aggression 
Human social interaction is comprised of complex dynamic behaviors. 
The consequences of human social interaction can be beneficial or detrimental 
to an individual’s daily life and to the community as a whole. In the latter case, 
social interaction can be maladaptive and problematic. One enduring and 
problematic social behavior is aggression. 
A seminal review paper of human aggression notes “In its most extreme 
forms, aggression is human tragedy unsurpassed” (Anderson & Bushman, 
2002, pg 28).  To many people, the word ‘violence’ is interchangeable with the 
word ‘aggression’. However, aggression is specifically used to describe a wide 
range of behaviors; whereas violence is aggression that uses extreme or 
physical harm as its goal (e.g. assault and/or death) (Anderson & Bushman, 
2002).   Aggression is generally defined as any social behavior in which an 
individual presents an aversive stimulus to another individual, who finds the 
aversive stimulus harmful and would seek to avoid it (Baron & Richardson, 
1994). Under this definition, two main classes of aggression emerge: impulsive 
aggression and premeditated aggression. Impulsive aggression is hostile, 
reactive, and anger-driven, whereas proactive aggression is instrumental, 
premeditated, and goal-driven (Bushman & Anderson, 2001). Impulsive 
aggression and premeditated aggression are hypothesized to both exist on a 
dimension rather than as two distinct categories, as aggressive acts typically 
contain elements of both impulsive and premeditated aggression (Bushman & 
Anderson, 2001).  Conceptually, the experiments within this dissertation project 
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will focus on impulsive aspects of human aggressive behavior and the 
biopsychosocial relevance of impulsive aggression research to mental health 
with regard to modulation by oxytocin.  
A widely accepted psychological theory used to describe human 
aggression is the General Aggression Model (GAM). The GAM is a theoretical 
and integrative model which posits the factors that occasion aggressive acts. 
The GAM focuses on processes occurring during one cycle or “episode” of an 
ongoing social interaction in which aggression may or may not occur. These 
processes can be thought of as foci. There are three foci: (i) person and 
situation inputs, (ii) the present internal state in which cognition, affect, and 
arousal all act as routes that mediate the impact of the person and the situation 
inputs, and (iii) outcomes that arise from the appraisal and decision processes 
that underlie aggressive action (i.e. deliberate or impulse action).  The GAM 
provides an important theoretical framework that can be used to integrate many 
different hypotheses and theories of human aggression into one unified model. 
Though this model will not be directly tested in this dissertation, the theoretical 
framework of the GAM serves as an operational model for defining, testing, and 
understanding aggressive behavior. The conceptualization of the GAM gives 
credence to the examination of aggressive behavior during a social interaction 
for the experiments of this dissertation.  
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The GAM provides a psychological framework for understanding an 
aggressive interaction (Figure I.A). During a social encounter in which 
aggressive acts could occur, there are inputs which influence the present state 
of the individual.  These inputs exist as personal and situational factors. 
Personal factors are characteristics such as personality traits, beliefs, values, 
and gender. Situational factors include provocation, frustration, aversive 
stimulation, and aggressive cues. Personal and situational factors are inputs 
Figure I.A: The episodic processes that occur in the General Aggression 
Model (GAM) This model describes the three foci (inputs, routes, and outcomes) 
that governs the probability of an aggressive act. (Anderson, CA & Bushman, BJ 
(2002) Human Aggression. Annu Rev Psychol 53: 27-51; material may be used in 
a thesis without additional permission as stated by Annual Reviews).  
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that can increase the probability of aggressive acts by activating cognitive, 
affect, and arousal knowledge structures present within the individual. These 
knowledge structures then influence the decision to impulsively or thoughtfully 
act. The framework of the GAM provides identification of the psychological, 
environmental, biological, and social factors which influence aggression, 
including cases in which aggression is extreme or maladaptive.  
Understanding complexity of aggression requires knowledge drawn from 
converging evidence in psychiatry, affective and cognitive neuroscience, 
psychopharmacology, and comparative psychology. However, the experiments 
within this dissertation are focused on examining human aggression within the 
context of neurobehavioral models of human social interaction. The 
experimental goals of this dissertation are to generate data that may be both 
experimentally and clinically significant.  The overarching goal for this 
dissertation is two-fold: (i) to provide information about possible therapeutics for 
aggression and (ii) to further basic understanding of human aggression. 
 
Clinical relevance: Antisocial Personality Disorder and Substance Use 
Disorder 
The consequences of human aggression extract a substantial 
detrimental toll on criminal justice systems, mental health institutions, 
communities, families, and individuals. Approximately 1.6 million lives are lost 
each year as a result of human aggression, worldwide (Dahlberg, 2007). 
Further, acts of extreme aggression (i.e. violence) cost billions in U.S. dollars 
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each year, particularly costs in health care, legal systems, work productivity, 
and economic development (Anderson, 1999; Dahlberg, 2007). The harmful 
consequences of aggression are prominent in cluster B personality disorders. 
The cluster B personality that will be central to the experiments in this 
dissertation is Antisocial Personality Disorder (ASPD).  Diagnosis of ASPD 
occurs in approximately 3-6% of the adult population (Anderson et al., 1987).  
Epidemiological research has found an increased risk of homicide (Eronen et 
al., 1996), child abuse (Dinwiddie and Bucholz, 1993), and spousal abuse 
(Dinwiddie, 1992) in individuals with a diagnosis of ASPD. These individuals 
often exhibit maladaptive levels of physical aggression, impulsive aggression, 
and recklessness, in addition to exhibiting higher probabilities of substance 
abuse (Cadoret et al., 1985; Pajer, 1998; Virkkunen 1979). Individuals with 
ASPD often have comorbidity with substance use disorders (SUD) (APA, 2000). 
For example, Regier et al. (1990) conducted a large sample survey of 20, 291 
U.S. citizens and found that individuals who meet diagnostic criteria for ASPD, 
as described by the Diagnostic and Statistical Manuals for Mental Disorders 
(DSM), were twenty one times more likely to develop abuse/dependence of 
alcohol than individuals who did not meet DSM criteria for ASPD. Relevant to 
the goals of this dissertation, individuals with ASPD and a history of SUD are 
considered to be at the greatest risk for heightened aggressive acts and are 
more aggressive than ASPD individuals without a history of SUD (Allen et al., 
1997).  
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 Additionally, ASPD and SUD individuals generally have higher levels of 
trait aggression and psychopathic traits (Alcorn III et al., 2013; Allen et al., 
1997; Cherek et al., 1997; Moeller et al., 1998; Nouvion et al., 2007). Trait 
aggression is a psychological construct that describes stable predispositions 
(i.e., personality traits) that distinguish levels of aggression in ASPD groups 
from non-ASPD groups (Anderson & Bushman, 2002; Buss & Perry, 1992; 
Kalome, 2014). Trait aggression can be psychometrically measured and is 
comprised of subtraits such as anger and hostility, which relate to the affect and 
cognition of individuals who consistently behave aggressively at above normal 
rates (Alia-Klien et al., 2009; Buss & Perry, 1992). For example, an individual 
meeting the diagnostic criteria for ASPD and SUD would likely endorse ratings 
of irritation when frustrated or feeling as if they are likely to “explode” or be “set 
off”; which are indices of higher levels of anger. The higher endorsement of 
experienced anger is an important correlate to aggression. Buss and Perry 
(1992) described anger as “…a prelude to aggression” (pg 457), as it 
represents the affective component that drives the transition from thinking about 
the aggressive act to the actual motor responses in which the aggressive act 
physically occurs. 
ASPD + SUD individuals also have notably higher levels of psychopathic 
personality traits. It is important to distinguish psychopathic traits from 
psychopathy. Psychopathic traits refer to constellation of personality traits 
relating to levels of emotional callousness, interpersonal manipulation, erratic 
lifestyle, and criminal tendencies that exist on a dimension of high vs low 
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(Neumann et al., 2012). Psychopathic traits are derived psychometrically from 
and related to the conceptualization of psychopathy, and are commonly 
measured by questionnaires. The questionnaires are scored based on the 
degree to which the person agrees or disagrees with statements relating to their 
behaviors, beliefs, and personality. Psychopathy is a clinical construct and 
categorical variable used to describe individuals who are characterized by 
symptoms of interpersonal dysfunctions, emotional detachment and disinhibited 
behavior patterns (Anderson & Kiehl, Hare & Neumann, 2008; Kiehl, 2006; 
2012).  The first person to describe the modern conceptualization of 
psychopathy was Philippe Pinel in 1801. The concept of psychopathy originates 
from a group of patients Pinel was overseeing, in which he described their 
behavior as “mania san délire” or “insanity without delirium” (Kiehl, 2006). 
Pinel’s description of these individuals was meant to describe the fact that these 
patients were disinhibited and unscrupulous, but their behavior could not be 
attributed to typical mental disturbances such as hallucinations or delusions. 
Subsequently, Cleckley characterized and delineated the clinical features of 
psychopaths from both community and institutional settings (Hare & Neumann, 
2005; Kiehl, 2006; Hare & Neuman, 2008).  Cleckley published his descriptions 
in the “The Mask of Insanity”, which is still used today to characterize 
psychopaths. From Cleckley’s conceptualization of psychopathy, Hare 
formulized the Psychopathy Checklist (PCL), which was the first clinical 
instrument introduced in 1980 (later revised in 1991) to separate psychopaths 
from non-psychopaths (Hare, 1996). Psychopathy is predicative of criminal 
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recidivism (Hemphill et al., 1998; Leistico, et al., 2008) and is present in 10%-
15% of substance abuse populations (Alterman & Cacciola, 1991; Alterman et 
al., 1993; 1998) and Kiehl (2006) estimated that psychopathy is present in 15-
20% of adult inmates in a maximum security prison. Though the construct of 
psychopathy and the clinical diagnosis  of ASPD share common clinical and 
psychiatric features and similar psychophysiological deficiencies, they are not 
synonymous (Anderson & Kiehl, 2012; Boccardi et al., 2011; Kiehl, 2006; 
Patrick, 2014).  However, the clinical features of psychopathy as measured by 
psychopathic personality traits are important in the clinical profile of ASPD+SUD 
individuals. Alcorn III et al. (2013) found that psychopathic traits were 
substantially higher in ASPD+SUD individuals versus SUD only individuals and 
healthy control individuals and, and were major factors in the difference 
between ASPD+SUD and these two other groups (effect size: ω² = 0.39).  
Higher trait aggression and psychopathic personality traits have a 
positive association with the frequency of aggressive behavior, as measured by 
laboratory tasks of aggression (Alcorn III et al., 2013; Allen et al., 1997; Cherek 
et al., 1997; Moeller et al., 1997; Nouvion et al., 2007).Thus, individuals who 
meet diagnostic criteria of ASPD+SUD have aberrant social behavior, affective 
instability, and poor impulse control. Examining potential therapeutics that might 
aid clinical efforts aimed at the treatment of maladaptive aggressive behavior in 
individuals with ASPD +SUD is warranted. 
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Laboratory task of human aggression: Point Subtraction Aggression 
Paradigm  
The Point Subtraction Aggression Paradigm (PSAP) is a well-established 
and valid laboratory measure of human state aggression. The utility of the 
PSAP has been documented in over a dozen studies including acute and 
chronic drug effects and psychiatric populations (i.e. ASPD and substance 
abusers) (Cherek et al., 2003). In every study using the PSAP, participants are 
informed that they will be anonymously paired with another individual (who is 
actually fictitious) and participants are told that their task is to earn as much 
money as possible. To achieve this goal, participants are able to utilize three 
different button options in the PSAP: A, B, and C which correspond to 
monetarily-reinforced, aggressive, and escape responses, respectively. The A, 
B, and C Buttons are mutually exclusive response options. Before the 
participant makes a choice, Buttons A, B, and C are displayed across the 
computer screen. The first button press response on A, B, or C results in the 
temporary removal of the other response options from the computer screen until 
the response requirement on the selected button has been completed. Button A 
(monetarily-reinforced response) is maintained by reinforcement; the participant 
gains $0.15 cents upon completion. Button A is on an FR100 (100 presses per 
$0.15) schedule of responding. The Button B (aggressive response option) in 
the PSAP is defined as the subtraction of money from the fictitious individual’s 
counter. Completion of Button B (aggressive response option) results in the 
ostensible loss of $0.15 from the fictitious individual’s counter. This is 
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established by instructional control. Button B is maintained on an FR10 
schedule of responding. Aggressive responding on Button B is elicited by 
provocation; which occurs when a loss of $0.15 from the on-screen counter 
occurs. These monetary loses (subtractions) are attributed to the fictitious 
individual paired with the participant. Participants are told that the other 
(fictitious) individual keeps the money subtracted from the participants’ counter 
(providing an ostensible incentive of the “other person” to use Button B). The 
participant is informed that money they subtract of the fictitious individual’s 
counter is not added to their own counter. Lastly, completion of Button C 
(escape response option) responding results in the protection of participant’s 
earnings for a variable interval of time. Button C is maintained on an FR10 
schedule of responding. Responding on Button B (aggressive response option) 
and Button C (escape response option) are maintained by a provocation free 
interval (PFI). The PFI occurs as a consequence of Button B (aggressive) or 
Button C (escape) responding, lasts for an average 125 sec ±20%, and allows 
for suppression of provocations for a variable period of time, which are 
attributed to the other person. Once the PFI has elapsed, provocations 
attributed to the other fictitious individual are again presented until more 
aggressive and escape responding initiates another PFI by using the B or C 
Button. Participants are not informed about the PFI or its function on Button B. 
However, participants are informed that Button C protects their earnings from 
subtractions for a variable period of time. The PFI initiated by Button B 
(aggressive response) or Button C (escape response) option allows for the 
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maintenance of the social deception that another person is present, by 
periodically preventing monetary subtractions.  
Laboratory methods of measuring aggressive behavior (such as the 
PSAP) provide improved precision and manipulation of independent variables - 
including control over the frequency of the presentation of provocative stimuli 
compared to data acquired from non-experimental settings. The PSAP shares 
several important features that allow for the experimental study of aggressive 
behavior. First, the PSAP provides a social context wherein individuals are 
engaged in a form of conflict and thus, fits with the psychological constructs of 
the GAM. Second, aggressive responses are operationally defined as the 
ostensive deliver of an aversive stimulus (i.e. monetary subtractions), and 
aggressive responses (Button B presses) are maintained through the temporary 
cessation of future provocations. Thirdly, the PSAP allows for experimental 
control of variables influencing aggressive behavior (e.g. frequency of 
provocation) and is sensitive to pharmacological effects (both acute and 
chronic). Lastly, physical aggression and violence are sometimes unpredictable, 
and can be difficult to identify and measure outside of laboratory settings. In 
addition, experimenters are able to avoid the possibility of physical injury to 
subjects. Under the conceptualization of the GAM, the PSAP provides a 
suitable paradigm for the study of aggressive behavior.  
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Disregulated neurocircuitry in aggression 
 Conceptually, maladaptive levels of aggression are problem of 
behavioral self-control (Dawes et al., 1997; Patterson & Newman, 1993). This 
fundamental problem of self-control over aggressive acts is clinically relevant as 
repeated levels of aggression that lead to detrimental or aversive outcomes are 
often diagnostic criteria for psychiatric disorders; in particular, ASPD+ SUD 
(APA, 2000).  Siever (2008) captured this idea in neurobiological terms by 
suggesting that aggression might be “grounded in an underlying neurological 
susceptibility”.  The neural circuitry underlying aggression is likely to be 
extensive and complex, involving interconnections between several different 
brain regions. A comprehensive review of all the evidence and brain structures 
involved in human aggression is beyond the scope of this dissertation. 
However, are several key brain regions which are believed to subserve human 
aggression. These regions are the dorsolateral prefrontal cortex (DLPFC), the 
orbital frontal cortex (OFC), the anterior cingulate cortex (ACC), and the 
amygdala.  These regions are all involved in processing of emotional and social 
stimuli.  Siever (2008) provided an integrative review of how dysregulation of 
key brain areas give rise to maladaptive aggression in psychiatric populations. 
Siever (2008) proposed that top down activation in frontal control from the 
DLPFC, OFC, and ACC are reduced, whereas the amygdala is hyper-
responsive to provocation. 
 These DLPFC-OFC-ACC-amygdala circuits modulate the execution and 
inhibition of aggressive acts (Siever, 2008). Dysregulation of this circuitry 
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disrupts self-control in the presence of provoking stimuli. Several converging 
lines of evidence support the hypothesis of reduced frontal functioning and 
over-responsive amygdala drive underlying maladaptive aggressive behavior 
(Bufkin & Luttrell, 2005; Coccaro et al., 2011; Davidson et al., 2000; Siever, 
2008).  Non-human primates with experimentally induced lesions in the 
dorsolateral prefrontal cortex (DLPFC) and the orbital frontal cortex (OFC), 
reliably show increased aggressive behavior (Butter et al., 1970; Raleigh et al., 
1979). Structural and functional imaging in individuals with a history of physical 
aggression and/or violent acts has revealed evidence for cortical thinning and 
volume reduction, reduced cerebral blood flow, and reduced baseline brain 
metabolism in these regions (e.g., DLPFC, OFC, and ACC) (Coccaro et al., 
2011; Goyer et al. 1994; Raine et al., 1997, Raine et al., 1998a; 1998b; Volkow 
et al., 1995). Substantial evidence for limbic hyper-responsiveness comes from 
patients with borderline personal disorder (BPD); an Axis-II psychiatric 
personality disorder that has many clinical features similar to ASPD. 
Psychophysiological and functional neuroimaging studies have demonstrated 
that when individuals with BPD are exposed to negatively-valenced stimuli (e.g. 
faces with negative emotion or traumatic stimuli) the amygdala shows 
hyperactivation (Donegan et al., 2003; Herpetz et al., 2001; Koenigsberg et al., 
2007; Minzenberg et al., 2007; Schmahl et al., 2004).  In pre-clinical studies, 
direct electrical stimulation of the cortiomedial amygdala of male Syrian 
hamsters decreased the latency of attack behaviors, indicating an increase in 
aggressive arousal by amygdala stimulation (Potegal et al., 1996).  
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 Neuroimaging studies examining affective dysregulation in psychiatric 
populations provide further evidence that maladaptive aggression arises from 
both reduced frontal activation and over-responsive limbic activation. Boccardi 
et al. (2011) found volumetric reductions in the gray matter of the ACC and 
OFC, and tissue enlargement of the central and lateral nucleus of the amygdala 
in male psychopaths with a SUD, compared to age-matched male controls.  
Boccardi et al. (2011) described reduction in cortical gray matter in the ACC 
and OFC as being in concert with studies using functional magnetic resonance 
imagining (fMRI) and laboratory paradigms in psychopaths; indicating that the 
structural differences in psychopaths with SUD, compared to controls, reflect 
poor maintenance of cognitive and emotional processing and poor processing 
of information about societal rules. Boccardi et al. (2011) also noted that the 
enlargement of the central and lateral nucleus of the amygdala of psychopaths 
could be related to “…increased propensity of offenders for impulsive 
aggression, abnormal motivation processes, and reduced sensitivity to stress” 
(pg 90). Albein-Urios et al. (2013) utilized fMRI to measure the blood 
oxygenated level dependent (BOLD) signal of cocaine dependent individuals 
with comorbid cluster B personality disorders (e.g., ASPD)  during a paradigm 
of negative emotion appraisal and maintenance, and found that the BOLD 
signal was reduced in the ACC compared to cocaine dependent-only and 
healthy controls. This outcome is indicative of dysfunctional decision making 
about social behavior. These deficiencies are prevalent in cocaine dependent 
and personality disordered individuals. Additionally, Albein-Urios et al. (2013) 
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found that the BOLD signal in the amygdala was positively correlated to 
antisocial-related cognitive beliefs and negative urgency (e.g., strong impulses 
under negative affect). Data from Albein-Urios et al. (2013) indicate that 
personality disordered and SUD individuals have deficiencies related to the 
experience of aversive states, which is important for understanding the 
dysregulated neurocircuitry of maladaptive aggression.  
 
 
Psychopharmacology of aggression: Serotonin, GABA, Testosterone 
 The central nervous system (CNS) evolved to process information about 
signals from the environment. The process by which environmental signals are 
transmitted between synapses is called neurotransmission and the molecules 
which transmit these signals are called neurotransmitters. Another class of 
signaling molecules is called hormones. Hormones communicate signals 
between organs and tissue. Decades of psychopharmacological research have 
identified two chief neurotransmitter systems which are thought to regulate 
aggression: serotonin (5-hydroxytrotamine, 5-HT) and gamma-aminobutyric-
acid (GABA) (Coccaro et al., 2011; de Almeida et al., 2005;  Krakowski, 2003; 
Miczek et al., 2002; Miczek et al., 2004a, 2004b; Moore et al., 2002) The major 
hormone that is hypothesized to modulate aggression across different animal 
species is testosterone (Archer, 2004; Soma, 2006).   
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Serotonin and aggression 
 The major role of the 5-HT neurotransmitter system in the regulation of 
aggressive behavior is to inhibit aggressive responses, specifically impulsive 
aggressive responses (Coccaro et al., 2011; Miczek et al., 2002).  The most 
notable consistent evidence for the association of central actions of 5-HT and 
aggressive behaviors in humans is that cerebral spinal fluid (CSF) levels of the 
5-HT metabolite 5-hydroxy indolacetic acid (5-HIAA), a marker of 5-HT activity,  
in the CSF are inversely correlated with aggressive behavior (Moore et al., 
2002; Krakowski, 2003). This inverse correlation has been found in populations 
with heightened aggressive behavior (Coccaro, 1998; Placidi et al., 2001) 
including violent offenders (Brown et al., 1979; Linnoila et al. 1983). Moore et al. 
(2002) conducted meta-analysis of studies examining this inverse relationship 
between CSF levels of 5-HIAA and antisocial behavior spanning 25 years and 
found a moderate effect size (Cohen’s d = -0.45). The CSF levels of 5-HIAA in 
antisocial groups were approximately one half of one standard deviation below 
control comparison groups. Lower levels of 5HIAA in CSF are indicative of low 
serotonergic activity in the brain (Krakowski, 2003). Evidence from animal 
literature further supports the negative association between low 5-HT activity 
and aggressive behavior. In rats that have had their central levels of 5-HIAA 
experimentally reduced via tryptophan depletion, the rate of mouse killing 
behavior increases (Gibbons et al., 1979). Further, destruction of serotonergic 
neurons in the raphe nucleus of rats increases the rate of mouse killing 
behavior and this effect is reversed by the administration of serotonergic-
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mimetics (Molina et al., 1987). In non-human primates, low CSF levels of 5-
HIAA are associated with severe aggression and impaired impulse control 
(Higley et al., 1992; Mehlman et al., 1994) in both males (Higley et al., 1996a) 
and females (Higley et al. 1996b). Evidence from human 
psychopharmacological studies also supports an inverse relationship between 
serotonergic activity and aggressive behavior.  Acute (Cherek & Lane, 1999, 
2001) and chronic administration (Cherek et al., 2002a) of 5-HT agonists that 
block the reuptake of 5-HT decrease the aggressive behavior of individuals with 
a history of Conduct Disorder (CD). Gowin et al (2010) found that acute 
administration of zolmitriptan, an agonist for the 5-HT1B/D receptor, attenuates 
aggressive behavior under the influence of alcohol.  Conversely, aggressive 
behavior on the PSAP increases following depletion of tryptophan, the rate 
limiting enzyme for 5-HT synthesis, most prominently in individuals who have 
high baseline levels of aggression on the PSAP (Moeller et al., 1996; Bjork et 
al., 1999, 2000). 
 The inverse association between serotonergic activity and aggression is 
well studied, but until recently a drawback was the fact that investigators did not 
know precisely where in the human brain these serotonergic effects might be 
occurring.  Passamonti et al. (2012) experimentally decreased the levels of 5-
HT though acute tryptophan depletion in healthy individuals and subsequently 
scanned these individuals using fMRI during the viewing of angry versus sad 
and neutral faces. The presentation of an angry face is an ecologically valid 
method of examining the neural correlates of reactivity to threats, as an angry 
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face is an aversive stimulus which signals social threat (Green & Phillips, 2004). 
Passamonti et al. (2012) found when viewing angry versus neutral and angry 
versus sad faces, acute tryptophan depletion in healthy volunteers reduced the 
functional connectivity between the amygdala and PFC, specifically in the 
ventral ACC and ventral lateral PFC.  Thus, the actions of 5-HT modulating 
aggressive behavior occur within the same brain regions which subserve 
human aggression. Though the neurotransmitter 5-HT is a major 
neuromodulator of aggression, it is not the only neurotransmitter with known 
pharmacological effects on aggression.  
 
GABA and aggression 
 The neurotransmitter GABA is the major inhibitory neurotransmitter in the 
CNS and GABAergic containing neurons are widely spread across the brain. 
The dose-response function across different GABAergic agents and aggressive 
behavior is non-linear. GABAergic agents are capable of either increasing or 
decreasing aggressive behavior in some contexts and at certain doses (Miczek 
et al., 2002). For example, several benzodiazepines (chlordiazepoxide, 
diazepam, and midazolam) have “bitonic effects” on aggressive behavior. The 
bitonic effects of these benzodiazepines refer to the pattern of increasing 
aggressive behavior at low doses while decreasing aggressive behavior at high 
doses (DiMascio et al., 1973; Miczek et al., 2002).  These bitonic effects on 
aggressive behavior are not only found in humans but also mice, rats, pigs, and 
monkeys (Miczek et al., 2002).  
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 Certain GABAergic agents have been shown to decrease aggressive 
behavior. Both acute and chronic administration of the anticonvulsant tiagabine 
(which increases the level of GABA at the synapse by blocking the reuptake of 
GABA) decreased the frequency of aggressive responding on the PSAP in 
antisocial and substance abuse populations (Gowin et al., 2012; Lieving et al., 
2008). In individuals with a history of CD, acute administration of the 
anticonvulsant gabapentin decreased the frequency of aggressive responding 
as measured by the PSAP at highest dose (800 mg), but increased the 
frequency of aggressive responding at lower doses (200 mg and 400 mg) 
(Cherek et al., 2004).  
 Certain GABAergic agents have been shown to increase aggressive 
behavior. Positive allosteric modulators of the GABAA receptor complex provide 
the most compelling evidence of the aggression-heightening effects of 
GABAergic agents (de Almeida et al., 2005; Heinz et al., 201; Miczek et al., 
2002, 2004).  The most well-established psychoactive compound that is active 
at the GABAA receptor complex and has aggression heightening effects is 
alcohol (for reviews see Miczek et al., 2002, 2004; Hienz, 2011). Experimental 
models in both humans and animals have consistently shown increases in 
aggressive behavior following alcohol consumption, particularly at low to 
moderate doses (Miczek et al., 2004; Heinz, 2011). Germane to this 
dissertation, a study conducted by Moeller et al (1998) found that ASPD 
individuals showed significantly greater increases in the frequency of 
aggressive responding on the PSAP under alcohol compared to non-ASPD 
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individuals.  Moeller et al. (1998) attributed the ASPD findings to the effect of 
alcohol on reducing frontal lobe functioning, and evidence from 
neuropsychological tests that antisocial populations have reduced frontal cortex 
functioning, thereby increasing the susceptibility of ASPD individuals to the 
effects of alcohol.  
 
Testosterone and aggression 
 Another neuromodulator regulating aggression is testosterone. Kouri et 
al. (1995) provided the experimental evidence for the aggression increasing 
effect of testosterone in humans. Kouri et al. (1995) found that chronic 
administration of testosterone increases the frequency of aggressive 
responding on the PSAP in healthy male volunteers.  A hypothesis on the 
association between circulating levels of testosterone and aggression is the 
“Challenge Hypothesis” (Wingfield et al., 1990). The Challenge Hypothesis 
describes the association between changes in testosterone in relation to 
intermale aggression in songbirds during mating seasons. Wingfield et al. 
(1990) posited that an increase in the levels of plasma testosterone in 
songbirds was beneficial to reproduction strategies by engendering mate 
guarding and preventing the encroachment of sexual rivals.  Support for the 
Challenge Hypothesis is found in a variety of vertebrate species including 
songbirds and sparrows (Soma, 2006; Wingfield et al., 1990), cichlid fish 
(Hirschenhauser et al., 2004), chimpanzees (Muller & Wrangham, 2004) and 
humans (Archer, 2004).  The Challenge Hypothesis explains the association 
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between physiological changes in testosterone and aggressive behavior as a 
cost-benefit ratio for maximizing reproductive success.  The “Biosocial Model of 
Status” (Mazur, 1985) is another model that explains the association between 
physiological levels of testosterone and aggression. This model is based on a 
series of situations wherein a primate’s level of testosterone varied as a 
function of competition outcomes. Specifically, winners of competitive outcomes 
show an increase in the level of circulating testosterone and losers of 
competitive outcome show a decrease in their levels of circulating testosterone.  
Mazur (1985) further proposed that competitive outcomes challenge a primate’s 
dominance status and testosterone levels increase and promote aggressive 
behavior in primates as a means of protecting their status. The Challenge 
Hypothesis and the Biosocial Model of Status both predict that circulating levels 
of testosterone promote aggressive behavior in response to current and/or 
future outcomes, in accord with changes in the environment (Mazur, 1985; 
Wingfield et al., 1990).  Support for this prediction in humans comes from 
studies by Carre´et al. utilizing the PSAP methodology to examine the 
association between circulating levels of testosterone and human aggressive 
behavior.  Carre´& McCormick (2008) and Carre´ et al. (2010) demonstrated 
that increases from the baseline concentration of circulating testosterone were 
positively correlated with increases in aggressive behavior on the PSAP.  
Carre´ et al. (2009) found that in men who had higher psychometric scores of 
trait dominance, increased aggressive behavior on the PSAP was observed 
following victory on a competitive task. Additionally, increases from the baseline 
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concentration of circulating testosterone were also observed in these men 
following a victory.  
 In general, increased circulating levels of testosterone are associated are 
increased aggression. Within clinical contexts, in groups with 
psychopathologies there appears to be a positive association between 
circulating levels of testosterone and maladaptive aggression as well as violent 
behavior. Dabbs et al. (1995) studied 692 inmates and found that higher plasma 
levels of testosterone were positively associated with violent criminal charges. 
Charges for rape, homicide, and robbery were respectively, 3.6, 2.1, and 1.5 
times more prevalent in inmates with higher levels of testosterone as compared 
to inmates with lower levels of testosterone. Reviews by Yildirim & Dersken 
(2012a, 2012b) found that high circulating levels of testosterone are a risk factor 
for interpersonal and affective deficits and lifelong antisocial behavior in 
psychopathic males.  
 
Summary  
 The neurochemistry of aggression has been studied in several species. 
Modulation of aggressive behavior involves alterations in neurotransmission, 
chiefly the signal transmission from serotonergic, GABAergic, and testosterone 
systems in the CNS. Currently, there are no approved medications from the 
Food and Drug Administration (FDA) for the treatment and management of 
aggressive behavior (Newman, 2012). Currently, no medication has been 
indicated for the management of aggressive behavior in ASPD and/or SUD 
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individuals (Newman, 2012). Thus, exploration into drug discovery and 
psychopharmacological management of aggression for ASPD +SUD are 
warranted. In recent years, neuropeptides and neuropeptide systems have 
become research targets for treating deficits in the social behavior of psychiatric 
populations (Meyer-Lindenberg et al., 2011; Meyer-Lindenberg & Tost, 2012). 
One neuropeptide of much recent interest is oxytocin (OT). The neuropeptide 
OT and its effect on aggressive/social behavior was the focus of the 
experiments in this dissertation.  
 
 
Scientific and clinical relevance: Oxytocin and the oxytonergic system 
The neuropeptide OT is a hormone produced in the magnocellular 
neurons in the paraventricular nucleus (PVN) and the supraoptic nucleus (SON) 
of the hypothalamus (Carter, 2003; Gimpl & Fahrenholz, 2001).  Axonal 
projections from OT-containing neurons in the PVN reach many  brain regions 
that are important for modulating social behavior, such as the amygdala, 
nucleus accumbens, and frontal cortices (Bethlehem et al., 2013; Meyer-
Lindenberg et al., 201; Ross et al., 2009; Young et al., 2005) (Figure I.B) . 
Release of OT from neural tissue is accomplished via volume transmission, as 
OT is released form the soma, axon, and dendrites (Ludwg & Leng, 2006; 
Neumann & Landgraf, 2012). OT is a nonapeptide and the structure of OT is 
highly conserved across many animal species (Gimpl & Fahrenholz, 2001 
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; Lee et al., 2011; Koehbach et al., 2013). The release of OT into general 
circulation is achieved by coordinated action from the brain and posterior 
pituitary (Ludwig & Leng, 2006; Neumann & Landgraf, 2012). Free circulating 
OT can bind to its receptor.  Only one receptor for OT has been discovered and 
characterized (Gimpl & Fahrenholz, 2001). The OT receptor is a seven 
transmembrane receptor channel rhodopsin-type G-protein (Gαq11) coupled 
receptor coupled to phospholipase C, and is present in central and peripheral 
neural tissue (Ebstein et al., 2012; Gimpl & Fahrenholz, 2001). 
 
 
 
 Figure I.B Axonal projections from OT containing neurons in the PVN 
and SCN of the hypothalamus. Anterior cingulate Cortex, (ACC), Bed 
Nucleus of Stria Terminalis (BNST), Nucleus Accumbens (NAc). Meyer-
Lindenberg, A., Domes, G., Kirsch, P., & Heinrichs, M. (2011) Oxytocin and 
vasopressin in the human brain: social neuropeptides for translational 
medicine. Nature Reviews Neuroscience. 12, 524-538 (September 2011); 
Permission 3491511505185, Nature Publishing Group) 
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Historically the neuropharmacological actions of OT were focused on 
lactation and birth (Carter, 1992; Gimpl & Fahrenholz, 2001). Across rodent, 
sheep, and primate species, OT promotes sexual behavior in both males and 
females, and mammalian maternal behavior (Carter, 1992; Carter et al., 1995; 
Carter, 2008).  Given that OT demonstrated critical roles in mammalian sexual 
and maternal behaviors, several subsequent studies hypothesized that OT is 
critically important for mammalian social monogamy and social bonds (Carter, 
1992; Carter et al., 1995). Indeed, the past four decades of research have 
demonstrated that the oxytonergic system is critically involved in regulating and 
modulating social behavior in the forms of increased social contact, formation of 
partner preferences, and autogrooming of partners (Ahern et al., 2009; Carter et 
al., 1995; Carter, 2014; Donald & Young, 2008; Kiss & Mikkelsen, 2005; Lee et 
al., 2009a; Meyer-Lindenberg et al., 2011). The most well-known animal 
species, from which much of the scientific knowledge about the OT system in 
relation to mammalian social monogamy and social behavior is grounded, is the 
prairie vole. Prairie voles are monogamous rodents found in the Great Plains of 
North America that form lifelong partnerships following mating called pair bonds 
(Williams et al., 1992) and the formation of these pair bonds is dependent on 
OT (Williams et al., 1994). The administration of OT in the formation of pair 
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bonds in prairie voles was a critical discovery in the field of social behavior. 
Young (2009) stated “There is intriguing overlap between the brain areas 
involved in vole pair bonding and those associated with human love” (pg 148).  
Since the OT system is conserved across mammalian species, the OT system 
in humans may have evolved because it is advantageous for humans to form 
social bonds and engage in mutually beneficial (or prosocial) interaction (Carter, 
2002; Carter, 2003; Rilling & Sanfey, 2010). Studies of intranasal OT dosing 
and human social behavior and socio-emotional cognition in psychiatric 
disorders lend support this notion. 
 
Oxytocin research: human social behavior 
In humans, the OT system promotes the occurrence of prosocial 
behaviors. Several studies have established that OT administration increases 
behaviors of cooperation, trust, and generosity following acute administration 
(Baumgartner et al., 2008; Kosfeld et al., 2005; Rilling et al., 2012; Zak et al., 
2007). Most studies involving acute OT dosing have utilized paradigms from 
behavioral economics. These paradigms can quantitatively measure human 
social behavior.  In these paradigms, participants engage in behaviors that may 
be operationally defined as prosocial or antisocial. Two important examples of 
prosocial behaviors are trust and generosity.  Kosfeld et al. (2005) utilized an 
economic paradigm which measured monetary transfers between investors and 
trustees. This paradigm is called the “Trust Game” in which, investors may 
transfer monetary amounts to trustees who may choose to share the proceeds 
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given to them or may keep the entire amount. Kosfeld et al. (2005) 
parametrically manipulated the amount investors could give to trustees and 
found that investors who were given OT made more transfers containing higher 
monetary amounts to trustees, compared to investors who were given placebo. 
Additionally, when provided the opportunity to give the trustee the maximal 
monetary amount possible, 45% of the investors who were given OT chose to 
transfer the maximal amount. Zak et al. (2007) conducted a behavioral 
economic study in which participants assigned to either the OT or placebo 
group and were given $10. All participants were provided the opportunity to split 
the money with a stranger in a one shot decision. More money given to the 
stranger represented more generosity by the participant.  Zak et al. (2007) 
observed that participants who were administered OT were 80% more 
generous than participants given placebo.  
A prosocial behavior germane to this dissertation is cooperation. 
Behavior economic paradigms have shown instances in which OT dosing 
increases cooperation (De Dreu et al., 2010; Rilling et al., 2012). Human 
cooperation has been defined as reciprocal exchange which can lead to an 
immediate mutual benefit or gain (Camerer, 2003; Rilling & Sanfey, 2010). 
Human cooperation falls broadly under the domain of altruism (acts that result 
in economic benefits to another individual or individuals), which is common in 
human societies (Fehr & Fischbacher, 2003; Rachlin & Locey, 2011). Human 
cooperation has been suggested as an evolutionary mechanism and a form of 
self-control because the long-term benefits of cooperation outweigh the long-
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term costs (Rachlin & Locey, 2011).  A behavioral economic paradigm called 
the Prisoner’s Dilemma (PD) arranges social interactions between two partners 
in which choices can result in monetary gain or losses for both individuals.  In a 
standard PD game human participants select between two response options: a 
cooperative response and a noncooperative response (sometimes referred to 
as defection). The interaction of these two response options: lead to monetary 
payoffs. Specifically, the cooperative response option results in equal mutual 
monetary gain for both partners, whereas the noncooperative response option 
either maximizes  individual gain to one person and  loss to the other, or results 
in loss to both people. Under most situations, mutua cooperative responses are 
selected approximately 50% of the time between two partners (Camerer, 2003; 
Rilling & Sanfey, 2011).  Over repeated trials, most people adopt a tit-for-tat 
strategy in reciprocating cooperation following trials of mutual cooperation 
(Camerer, 2003; Fehr & Fischbacher, 2003; Rachlin & Locey, 2011). In studies 
using the PD, OT dosing produced increased rates of cooperative responding 
following both cooperation and defection from the other paired partner (Rilling et 
al., 2012) and within group cooperation during a multiplayer PD (De Dreu et al., 
2010). 
The collective evidence that OT increases cooperative behavior is 
pertinent to the goals of this dissertation and gives rationale for investigating 
aggression in ASPD+SUD. Alcorn III et al. (2013) reported that psychopathic 
and aggressive personality traits are two important clinical features that 
distinguish ASPD+SUD individuals from SUD only and healthy volunteers. In 
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the context of social behavior, Alcorn III et al. (2013) findings are relevant to the 
dissertation hypothesis, as individuals with psychopathic traits have higher 
instances of noncooperation (antisocial behavior) on the PD task (Mokros et al., 
2008; Rilling et al., 2007). Rilling et al., (2007) found that individuals with higher 
psychopathic personality traits show less cooperative responding (pearson’s r 
correlation: r = -0.58) and lower likelihood to cooperate after mutual cooperation 
(pearson’s r correlation: r = -0.64) (Rilling et al., 2007). Mokros et al. (2008) 
found that psychopathic individuals with a criminal history residing within a high 
security psychiatric forensic institution were more likely to choose a 
noncooperative response option (only seeking to maximize individual gain)  
compared to healthy adult volunteers when engaged in PD.   
Across several studies, OT engendered increases in prosocial behavior. 
Psychopathic traits are characterized, in part, by antisocial behavior. These 
traits are prevalent in ASPD+SUD. It follows, therefore, that OT should reduce 
antisocial behaviors such as aggression in those for whom it is exaggerated 
(e.g., ASPD and SUD). Interestingly, Lee et al. (2009b) found that in persons 
with personality disorders (e.g. ASPD) CSF levels of OT were significantly 
inversely correlated with a lifetime of aggression (pearson’s r correlation: r = -
0.33), suggesting central signaling of OT. Additionally, individual differences in 
the OT system have been associated with maladaptive behavior. For example, 
polymorphisms in OT receptor genes have been related to extreme, persistent 
aggressive behavior during childhood (Malik et al., 2012).  Mizcek et al. (2002) 
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and Siever (2008) both suggest that OT contributes to the control of mammalian 
and human aggression.   
 
 
The potential of OT as a therapeutic for impulsive aggression has not been 
tested. However, the idea that OT could be used in psychiatric disorders has 
been gaining support (Meyer-Lindenberg et al., 2011). The neuropeptide OT 
facilitates social cognition in individuals with disorders characterized by deficits 
in social behavior and social cognition. Administration of OT increased the 
inference of emotional states of others and empathic accuracy in individuals 
with autism-spectrum disorders (Domes et al., 2007a; Guastella et al., 2010); 
increased emotional recognition in patients with Schizophrenia (Averbeck et al. 
2012); and reduced neuropsychiatric scores of agitation, dysphoria, and 
irritability in patients with frontotemporal-dementia (Jesso et al., 2011). These 
data provide support for the examination of OT in modulating aggressive 
behavior.  
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Hypotheses and aims 
There is evidence for the therapeutic potential of OT on social behavior 
and socio-emotional processing in psychiatric disorders. There are no FDA 
approved medications for the treatment of aggression in ASPD+SUD (Newman, 
2012).  Substantial work has shown that OT increases prosocial behavior in 
both humans and nonhuman animal species. The converging evidence 
suggests that administration of OT should reduce aggressive behavior in 
humans and is a potential therapeutic target for psychiatric disorders, 
particularly ASPD+SUD. The overall hypothesis of this dissertation is that OT 
administration will decrease human aggressive behavior vs placebo.  
 
Experiment 1 
Aim 1a: To test if OT administration decreases aggressive responding in 
ASPD+SUD individuals 
Hypothesis 1a:  Compared to placebo, acute OT administration will dose-
dependently decrease aggressive behavior in ASPD+SUD individuals  
(48 IU > 24 IU > 12 IU > placebo). 
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Experiment 2  
 
Aim 2a: To test if acute OT dose (24 IU) decreases aggressive behavior. 
Hypothesis 2a: Healthy adult male participants will show reduced aggressive 
responding following OT administration, as compared to placebo.  
 
Aim 2b: To explore if interpersonal manipulation and anger personality 
traits are correlated with aggressive behavior under OT dose (24 IU).   
Hypothesis 2b:  There will be a negative association between psychometric 
scores of interpersonal manipulation and anger and aggressive responding 
under OT dosing. 
 
Aim 2c: To test if acute OT dose (24 IU) changes social judgment 
following an aggressive encounter.  
Hypothesis 2c: Healthy adult male participants will have increased ratings of 
likability of the “other person” under OT, as compared to placebo.  
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CHAPTER 2: EFFECTS OF INTRANASAL OXYTOCIN ON AGGRESSIVE 
RESPONDING IN ANTISOCIAL PERSONALITY DISORDER AND 
SUBSTANCE USE DISORDER 
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Portions of the work presented here are taken from Alcorn III, J.L., Rathnayaka, 
N., Swann, A.C, Moeller, F.G., & Lane, S.D. “Intranasal Oxytocin on Aggressive 
Responding in Antisocial Personality Disorder” (In Press) The Psychological 
Record.  
 
Introduction 
Human social interaction involves complex and dynamic behavior 
patterns. One enduring and problematic form of social behavior is aggression. 
Aggression can be defined as the presentation of an aversive stimulus by one 
individual to another individual who finds the aversive stimulus harmful and 
would seek to avoid it (Baron & Richardson, 1994). The consequences of 
aggression present considerable burdens on public health, criminal justice 
systems, and communities (Arseneault et al., 2000; Kessler, et al., 2006; 
Rasmussen & Levander, 1996).  Aggressive behavior is often heightened in 
individuals with Antisocial Personality Disorder (ASPD) and a history of 
substance use disorders (Alcorn III et al., 2013; Allen et al., 1997; Bjork et al, 
1999; Cherek et al., 1997; Cherek & Lane, 1999).  Examination of behavioral 
and pharmacological modifiers of aggression in these high-risk individuals is of 
interest to scientific, therapeutic and public health endeavors (Patrick, 2008; 
Siever, 2008; Takahashi et al., 2012).  
In the search for effective interventions aimed at improving the social 
functioning of individuals with psychiatric disorders, the neuropeptide oxytocin 
(OT) and the oxytocinergic system may hold promise as an intervention 
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strategy for promoting prosocial behaviors (Meyer-Lindenberg, Domes, Kirsch, 
& Heinrichs, 2011). OT is primarily synthesized in the nuclei of the 
hypothalamus (Lee et al., 2009a; Ludwig & Leng, 2006).  Oxytocinergic axonal 
projections from the hypothalamus reach the prefrontal cortices, amygdala, and 
nucleus accumbens, which are important in modulating social behavior in 
human and nonhuman animals (Gimpl & Farhenholz, 2001; Lee et al., 2009a; 
Meyer-Lindenberg et al., 2011).  OT administration increased prosocial 
behaviors of cooperation, trust, and generosity following acute administration to 
healthy adult humans (Baumgartner et al., 2008; Kosfeld et al., 2005; Rilling et 
al., 2012; Zak et al., 2007). The prosocial effects of OT dosing in nonhuman 
animal studies suggest that this system underpins affiliative behaviors in both 
the social-bonds of monogamous rodents (Young et al., 2011) and parental 
behavior of rodents and primates (Febo et al., 2005; Saltzman & Maestripieri, 
2011). 
In recent studies, OT was shown to facilitate social behavior in 
individuals with disorders characterized by deficits in social behavior and 
cognition (e.g. autism-spectrum disorders, frontotemporal-dementia, and 
schizophrenia) (Meyer-Lindenberg et al., 2011).  Conversely, polymorphisms in 
OT receptor genes have been associated with extreme, persistent aggressive 
behavior during childhood (Malik et al., 2012).  To date, only one study has 
examined the potential impact of OT on human aggressive behavior. Campbell 
& Hausmann (2013) found evidence to suggest that OT administration might 
reduce aggressive behavior in women with high state anxiety. However, 
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Campbell & Hausmann (2013) conducted a between groups design that used 
healthy women volunteers who were tested at one OT dose level and no main 
effect of dose was observed. Given the reported prosocial effects of OT on the 
social behavior of rodents, primates, healthy adults, and individuals with 
diagnosed psychiatric disorders, this experiment sought to examine the 
potential impact of OT on aggressive behavior in individuals with ASPD and 
past substance use disorders.  This combination of comorbidities represents the 
highest risk for violence and aggression (Alcorn III et al., 2013; Arseneault et 
al., 2000; Kessler et al., 2006; Rasmussen & Levander, 1996).   
This experiment was the first placebo-controlled study using a well-
established operant laboratory measure of human aggression (Point 
Subtraction Aggression Paradigm, PSAP) across a range of doses (12, 24, and 
48 International Units, IU) to examine changes in aggressive responding under 
OT dose. The hypothesis of this experiment was that OT would dose-
dependently decrease aggressive responding compared to placebo. 
 
Materials and Methods 
All experimental procedures were reviewed and approved by the 
Institutional Review Board for the University of Texas Health Science Center-
Houston, USA. Prior to study participation, informed consent was obtained from 
all participants. 
 
 
 38   
 
 
Participants  
 Six adult males were recruited into the study via newspaper 
advertisements seeking male individuals on parole or probation. Newspaper 
advertisements were placed in freely distributed papers in the Houston 
metropolitan area. Individuals on parole or probation were recruited because 
the incidences of comorbid ASPD, past SUD and heightened aggressive are 
over represented in this population.  Prior to study participation all participants 
underwent a physical exam to screen for exclusionary medical conditions (e.g. 
HIV, seizures, cardiovascular, kidney or endocrine diseases, diabetes, high 
blood pressure, and history of head trauma or loss of consciousness > 20 
minutes) and current use of prescription medication. Female participants were 
excluded for the following reasons: (i) the male to female ratio for ASPD is 9 to 
1, respectively (APA, 2000), thus female participants would be not 
representative of the target populations desired in this study, (ii) the 
neuropeptide oxytocin increases levels of luteinizing hormone (Evans et al., 
2003) which could potentially affect the regularly occurring menstrual cycles of 
female participants, and (iii) there are no reports of the interactions of oxytocin 
administration with oral contraceptives (i.e. birth control), thus behavioral and 
physiological side effects are unknown. Therefore, females were not recruited 
for both scientific and safety reasons.  
 Prior to study participation all participants underwent screening for 
current and past psychiatric illness using the Structured Clinical Interview of the 
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DSM-IV (SCID) (First et al., 1996) and the SCID-II NP (Personality Disorders; 
First et al., 1997). The SCID-I and SCID-II were administered by a trained 
mental health professional.  The SCID was used to screen for Axis I disorders 
and determine that participants met DSM-IV criteria for past SUD. Participants 
were excluded if they met DSM criteria for Axis I disorders other than past SUD. 
The SCID-II was used to ascertain that all participants met criteria for ASPD 
(i.e. childhood conduct disorder by age 15 and ASPD in adulthood). General 
cognitive capacity was assessed using The Shipley Institute of Living Scale-2 
(Shipley et al., 2009) a test of general cognitive aptitude consisting of a 40-item 
vocabulary test and a 26-item block test. Average composite verbal and block 
score on the Shipley-II was 176.16 (SD = ± 20.6: age-adjusted normative 
percentile with a Weschler Adult Intelligence Scale estimated mean of 86).  All 
six participants were within two standard deviations of the Shipley-II normed 
means and had 12 or less years of education (range 9-12, see Table 1.A) 
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Participant Age Years of 
Education 
Criminal 
History 
Past 
SUDs 
s13121 
 
37 12 aggravated 
assault, drug 
possession, 
theft 
a,b,e 
 
s13146 
 
24 
 
9 
 
burglary 
parole/probation 
violation charge 
 
b 
 
s13214 
 
 
51 
 
12 
 
Burglary 
 
a,b 
s13234 27 11 Parole/probation 
violation 
a,c,d,g,h 
 
s13246 
 
28 
 
12 
 
drug possession 
 
b,d,g,h 
 
s13285 
 
46 
 
11 
 
aggravated 
assault 
 
a,b,c,h 
. 
  
Table 1.A Participant demographics. Participant age, years of education, criminal 
history, and past substance use disorder (SUD) are presented. All six subjects met 
Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV) criteria for 
Antisocial Personality Disorder. All participant demographic data were collected using 
the Structured Clinical Interview of the DSM-IV (SCID-I and SCID-II, personality 
disorders).  Past SUDs (dependence) are coded as following: a= alcohol; b= cannabis; 
c= cocaine; d= hallucinogen; e= inhalant; g= opiate; h= sedative. 
Taken from Alcorn III et al. (In Press). 
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To avoid potential interactions between OT and extraneous drug use and 
alcohol intoxication during study participation, participants with any current SUD 
were excluded, and all participants had to provide clean urine and expire breath 
samples on testing days.  Urine samples were screened for extraneous drugs 
using the Enzyme Multiple Immunoassay Technique Drug Abuse Urine Assay 
(Innovacon; San Diego, CA).  Two positive detections were recorded during this 
study; one participant was positive for cannabis and another participant was 
positive for cocaine. Both participants were precluded from study participation 
until negative urine samples were obtained the following experimental day. 
Expired breath samples were collected each morning of testing to detect 
alcohol consumption.  
 
Apparatus   
 Participants were seated in a 1.2m X 1.8m sound-attenuated 
testing room containing a video graph array (VGA) monitor and a 19cm X 43cm 
X 25cm USB-connected response panel containing four colored buttons (blue, 
yellow, green, and red). The blue, yellow, and green buttons represented the 
‘A’, ‘B’, and ‘C’ response options displayed on the VGA monitor, respectively.  
The red button had no programmed consequence. The VGA monitor and 
response device were linked to Pentium-based computer located outside of the 
testing room which controlled and recorded all experimental sessions.  
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Procedure  
 The Point Subtraction Aggression Paradigm (PSAP) is a well-
established and validated laboratory measure of human state aggression. The 
utility of the PSAP has been documented across many studies, with 
demonstrated sensitivity to acute drug administration (Lane & Cherek, 2000) 
and aggressive response patterns in psychiatric populations, including ASPD 
and substance abuse (Allen et al., 1997; Bjork et al., 1999; Cherek et al., 1997; 
Cherek & Lane, 1999; Cherek et al., 2003).  Participants were informed that 
they would be anonymously paired with another individual (who was actually 
fictitious) and participants were told that their task was to earn as much money 
as possible. To achieve this goal, participants were able to utilize three different 
button options labeled A, B, and C which correspond to monetarily-reinforced, 
aggressive, and escape responses, respectively. The A, B, and C Buttons were 
non-reversible response options. Before the participant made a choice, Buttons 
A, B, and C were displayed across screen on the VGA monitor. The first 
response on A, B, or C resulted in the temporary removal of the other response 
options from the computer screen until the selected response option 
requirement was completed. Button A (monetarily-reinforced response) was 
maintained on an FR100 (100 presses) schedule of responding. The participant 
gained $0.15 cents for each completed FR100 on button A.  Completion of 
Button B (aggressive response) responding resulted in the ostensible loss of 
$0.15 from the fictitious other person’s counter. In accord with the operational 
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definition of aggression, the aggressive response option is defined as the 
ostensible subtraction of money from the fictitious individual’s counter.  Button B 
(the aggressive response) was maintained on an FR10 schedule of responding. 
Aggressive responding was elicited by provocation; which occurred 
probabilistically on average every 125 sec ± 20% and resulted in a loss of $0.15 
from the participant’s counter. These monetary loses (subtractions) were 
attributed to the fictitious individual paired with the participant. Participants were 
told that the other (fictitious) individual kept the money subtracted from the 
subject’s counter.  The participant was informed that money he subtracts from 
the fictitious individual’s counter is not added to his own.  Thus, the aggressive 
option was not maintained by monetary gain.  Completion of Button C (FR10; 
escape response) responding resulted in the protection of subject’s earnings for 
a variable interval of time (a provocation-free interval averaging 125 sec ± 
20%).  Because both Button B (aggressive response) and Button C (escape 
response) option produce a provocation-free interval, they also provide support 
for the social deception that another person is present by reducing (but not 
preventing) subtractions throughout the PSAP sessions. In the present study, 
responding on Button C was not analyzed as because not all participants used 
Button C and those that did, did so sparingly. To establish all PSAP 
contingencies and the social context, participants read a printed set of 
instructions describing the response requirements for all three response options 
and consequences on each option (the instructions only attribute the 
provocation free interval to Button C).  If the participant asked questions 
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pertaining to the PSAP, the instructions were repeated verbally from the printed 
instructions and clarified by a trained research assistant. Each study day, 
participants had completed four PSAP sessions at 30min, 90min, 150min, and 
210min post dose (Session 1, 2, 3, and 4, respectively).  Each PSAP session 
lasted 25min.  One participant (s13825) did not complete a PSAP 210min post 
dose. At the end of each experimental day, participants completed a short 
open-ended questionnaire to assess the veracity of the instructional deception 
in the PSAP.  All participants reported being paired with another individual on 
every experimental day.  
 
 
Drug administration   
 Dose order was counterbalanced across all six participants. Prior to dose 
administration, all participants were trained on the dosing procedures using 
1.5ml of saline to ensure accurate were administration and comfort with the 
drug administration procedures.  Participants were administered intranasal 
doses (12, 24, and 48 IU) of synthetic OT (Syntocinon, nasal spray: Novartis®). 
The drug administration apparatus was a 3cc (3 ml) needleless-syringe 
attached to a nasal atomizer for intranasal administration. Each dose (12, 24, 
and 48 IU) and placebo was administered at a total volume of 1.5 ml intranasal 
(≈0.75 ml per nostril).  Participants were administered the nasal-spray fluid of 
either OT or placebo dose at a volume of 0.75ml per nostril (1.5ml total) under 
the supervision of a research assistant. All administrations were completed 
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within 8min. One spray is 4 IU and each 4 IU spray is equivalent to 0.1 ml. 
Thus, 12, 24, and 48 IU of OT is equal to 0.3, 0.6, and 1.2 ml of nasal spray 
fluid. For drug preparation, OT doses were brought to their corresponding 
volume (ml) in a 3cc needleless-syringe, and then each syringe was brought to 
a full volume of 1.5 cc by adding saline.  This approach was used to blind 
participants to dose contents.  The placebo dose contained only saline, and 
was also administered at a total volume of 1.5 ml (0.75 ml per nostril). Table 1.B 
outlines intranasal dose levels. 
 
Dose Volume (ml) of OT. Corresponding volume 
(ml) of  placebo  
Placebo 0 ml 1.5 ml 
 
OT (12 IU) 0.3 ml 1.2 ml 
 
OT (24 IU) 0.6 ml 0.9 ml 
 
OT (48 IU) 1.2 ml 0.3 ml 
   
 
 
 
 
 
 
 
 
 
Table 1.B Outline of dose levels. Presented are the dose levels that were 
used for intranasal administration in Experiment 1. Dose levels varied in the 
concentration of OT. All Participants inhaled a total volume of 1.5ml of spray.  
IU = international unit.  
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Psychometric measures: 
 The Buss-Perry Aggression Questionnaire: (BPAQ; Buss, & Perry, 1992) 
is a self-report measure of trait aggression consisting of 29-items.  It is well 
validated in populations with both Axis I and Axis II disorders.   
 The Barratt Impulsivity Scale: (BIS-11; Patton et al., 1995) is a self-report 
measure of the personality trait of impulsivity consisting of 30-items.   
 The Self-Report Psychopathy Scale III :(SRP-III; Paulhus et al., 2010; 
Mahmut et al., 2011). The SRP-III is a self-report measure of the clinical 
construct of psychopathy consisting of 64-items developed from the well-
established Psychopathy Checklist-Revised (Hare & Neumann, 2008).  
 Impulsive Premeditative Aggression Scale: (IPAS; Stanford et al., 2003). 
The IPAS is a self-report measure of trait aggression, validated in prison 
populations, consisting of 30-items measuring aggressive acts within the last 6 
months (Stanford et al., 2003). 
 The BPAQ, BIS-11, SRP-III, and IPAS were given a day prior to PSAP 
testing after consent was obtained.  
 The Profile of Mood States: Short Form (POMs: Shacham, 1983) is a 
self-report measure of psychological distress consisting of 38-adjective items on 
a 0-4 Likert-rating scale ranging from “Not at all” to “Extremely”. The POMS 
provides a total mood disturbance score and six subscale scores measuring six 
distinct mood states: Depression-Dejection, Anger-Hostility, Tension-Anxiety, 
Fatigue, Vigor, and Confusion-Bewilderment. The POMS was given 30 min 
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prior to dose (OT and placebo) and prior to each PSAP session following dose 
(OT and placebo). POMS data for each subscale were transformed into a 
difference score (∆ score) of Post-Dose minus Pre-Dose, to assess changes in 
mood following OT dosing. 
 
Cardiovascular measures 
 Previous studies have noted that OT administration increases heart rate 
(HR) variability, an index of parasympathetic activity (Kemp et al., 2012).  In 
both human and rodent species, OT dose has been reported to decrease blood 
pressure (BP) (Petersson et al., 1996; Rosseland et al., 2013). HR and BP were 
measured using a sphygmomanometer (BpTru Vital Signs Monitor, Coquitlam, 
Canada) after each session of the PSAP. Cardiovascular data (HR/BP) were 
collected to provide physiological confirmation of an active dose. All 
cardiovascular data were taken given 30 min prior to dose (OT and placebo) 
and 6 min after each PSAP session following dose (OT and placebo).  All 
cardiovascular data were transformed into a difference score (∆ score) of Post-
Dose minus Pre-Dose. 
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Outline of study days   
Study Day Description OT Dose 
 
1 
 
Baseline for PSAP 
 
 
 
2 
PSAP with either OT or PLC 12, 24, or 48 IU of OT 
 
3 
 
PSAP with either OT or PLC 
 
12, 24, or 48 IU of OT 
 
4 
 
PSAP with either OT or PLC 
 
12, 24, or 48 IU of OT 
 
5 
 
PSAP with either OT or PLC 
 
12, 24, or 48 IU of OT 
Daily Schedule (Dose Days)   
Time point  Session Event 
8:30 am 
 
Dose Administration OT or PLC, POMS, HR/BP 
 
30 min after dose 
9:00 am 
Post-Dose Session 1 POMS, PSAP, HR/BP 
 
 
90 min after dose 
10:00 am 
 
Post-Dose Session 2 
 
POMS, PSAP, HR/BP 
 
150 min after dose 
11:00 am 
Post-Dose Session 3 POMS, PSAP, HR/BP 
 
210 min after dose 
12:00 pm 
Post-Dose Session 4 POMS, PSAP, HR/BP 
 
 
 
 
 
 
 
Table 1.C Outline of study days. 
OT = oxytocin. PLC = placebo. POMS = Profile of Mood Scale. PSAP = 
Point subtraction aggression paradigm.  HR= heart rate. BP = blood 
pressure. IU = international unit.  
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Statistical Analyses across all doses and sessions 
All statistical tests were conducted using the statistical program STATA 
version 11.1. To test for main effects of dose and session, and the interaction of 
dose by session, two-way repeated measures Analysis of Variance (RM 
ANOVA), with two within-subjects factors (dose and session), were conducted 
on the following variables: the overall aggressive response rates (reponses per 
minute; from all doses and sessions), ∆ scores from all cardiovascular data, 
and ∆ scores from each subscale of the POMS.  
Behavioral, cardiovascular, and mood data were dependent variables in 
the RM ANOVA. Dose and session were the independent variables in the RM 
ANOVA. To correct for violations against sphericity that could be associated 
with RM, p-values were corrected using Huynh-Feldt epsilon correction. All p-
values from all RM ANOVAs are reported with both the uncorrected and Huynh-
Feldt corrected p-values from the RM ANOVA model. Only the corrected p-
values (pHuyn-Feldtcorr) were used to signify statistical significance.  
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Behavioral data analyses at the pharmacological peak effect  
Following the two-way RM ANOVA on the overall aggressive response 
rate across all doses and sessions, analysis of behavioral data focused on 
session 2, 90 min after dosing because the accumulation of neuropeptides in 
the cerebrospinal fluid (CSF) can be seen 30 min after intranasal 
administration, and levels continue to rise up to 80 min and remain stable 90-
120 min after administration (Born et al., 2002).  Therefore, the pharmacological 
peak effect was expected at approximately 90 min. The pharmacological peak 
effect was chosen because across all six subjects there were no observed 
trends by dose or by session of OT on aggressive behavior. To analyze 
behavioral data at the pharmacological peak effect, the overall aggressive 
response rate (aggressive responses per minute), the distribution of inter-
response times (IRT) of aggressive responding, and the overall monetary 
response rate on the A button (monetary responses per second) were used as 
dependent variables.  These two response options (A and B) are measured in 
different response rate units, because monetary (Button A) responding occurs 
more frequently than aggressive (Button B) responding during PSAP sessions 
(Cherek et al., 2006; Lane & Cherek, 2000).  
 This experiment was the first study to analyze IRT distributions of 
aggressive responding from the PSAP. This was an exploratory analysis of 
aggressive responding. The rationale for examining the distribution of IRTs 
during bouts of aggressive responding at the peak effect was because interim 
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graphical analysis of the overall aggressive response rates revealed unique 
patterns of change in aggressive responding under OT.  It was then 
hypothesized that inspection of IRT distributions on a single-subject level might 
reveal orderly changes in aggressive responding under OT across participants 
that the overall aggressive response rate may have not detected (Iversen, 
1991; Payla, 1992). Only the IRTs on the aggressive response option (Button 
B) were analyzed, as there were no trends in Button A (monetary) responding 
across doses, and these data were not related to the primary study hypothesis. 
 The overall aggressive response rate and IRT distribution of 
aggressive responding were both analyzed because they represent two 
potentially unique response dimensions. The overall aggressive response rate 
and IRT distributions (also known as the local response rate) of aggressive 
responding vary independently. In IRT distributional analysis, an increase in the 
interval between aggressive responses (i.e. rightward shift in IRT distribution) 
would demonstrate a decrease in the rate of responding within a bout of 
aggressive responding (FR 10). By extension, this could suggest that the social 
salience of provocation from the “other person” was altered. To analyze IRT 
data, the difference in time between consecutive responses emitted during a 
bout of aggressive responding (FR 10) was calculated. For each individual 
participant, the cumulative frequency distributions of IRTs on the aggressive 
response option were analyzed in order to examine the shifts in IRT 
distributions as a function of OT dose. Inspection of IRT distributions on a 
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single-subject level, such as this experiment, provides an additional level of 
behavioral analysis to infer changes in behavior at the millisecond timescale. 
All behavioral data from session 2 (90 min post-dose; the 
pharmacological peak effect) were analyzed at three levels of analysis. First, 
statistical tests were conducted on overall response rate of aggressive 
responding. The second level of analysis was visual inspection of individual 
subject data at the session containing the pharmacological peak effect. The 
third level of analysis was statistical testing of participant’s IRT distributions at 
the pharmacological peak effect, comparing all there dose levels of OT to 
placebo 
 
Results 
Overall aggressive response rate data across all doses and sessions 
A two-way RM ANOVA on the overall aggressive response rate found no 
statistically significant main effects of dose (F (3, 15) = 0.05, p = 0.98, pHuyn-
Feldtcorr = 0.98) or session (F (3, 14) = 1.2, p = 0.34, pHuyn-Feldtcorr = 0.35). There 
was a significant interaction of dose by session, but not after Huyn-Feldt epsilon 
correction for repeated measures (F (3, 42) = 2.34, p = 0.03, pHuyn-Feldtcorr = 
0.15).  Data from the overall aggressive response rate for all dose levels 
averaged across all PSAP sessions are presented in Figure 1.A. 
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Figure 1.A Average overall aggressive response rate across dose levels.  
Presented are mean (S.D.) data of the overall aggressive response rate for all six 
subjects, across all four sessions, and all four dose levels.  IU = international unit.  
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Pharmacological peak effect data  
In the first-level of analysis, statistical tests were conducted on both 
aggressive and monetary behavior at 90 min post dose (session 2).  The 
assumptions of normality and homogeneity of variance were tested for both the 
overall aggressive responses rate and the overall monetary responses rate. For 
the overall aggressive responses rate, Shapiro-Wilk’s test of normality (S-W = 
0.928, df (22), p = 0.07) and Levene’s test of homogeneity of variance (F (3, 20) 
= 0.11, p = 0.84) were not significant. For monetary responses rate, Shaprio-
Wilk’s test of normality (S-W = 0.93 df (22), p = 0.11) and Levene’s test of 
homogeneity of variance (3, 20) = 2.14, p = 0.18) were not significant.  A one-
way RM ANOVA on the overall aggressive responses rate across dose levels at 
session 2 (90 min post dose) was not statistically significant (F (3, 20) = 0.56, p 
= 0.4). A one-way ANOVA on the overall monetary responses rate across all 
dose levels session 2 (at 90 min post dose) was not found to be statistically 
significant (F (3, 20) = 1.26, p = 0.3).  Descriptive summary of the aggressive 
responding at the session containing the pharmacological peak effect (90 min 
post-dose; session 2) is found in the appendix material.  
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The second level of analysis focused on graphical inspection of each 
individual participant’s behavioral data (aggressive and monetary responding) 
at 90 min post dose.  Overall aggressive response rates at 90 min post dose for 
each individual subject are presented in Figure 1.B. Three participants (s13121, 
s13234, and s13285) showed decreases in overall aggressive response rate at 
the 12IU OT dose compared to placebo. All other participants showed no 
changes in the overall aggressive response rate at the 12IU OT dose.  At the 
24IU dose, one participant (s13214) showed a decrease in the overall 
aggressive response rate. Three participants (s13121, s13146, and s13234) 
showed increases in the overall aggressive response rate, and two participants 
(s13246 and s13285) showed no changes in the overall aggressive response 
rate. Finally, at the 48IU OT dose two participants (s13214 and s13285) 
showed decreases in the overall aggressive response rates, three participants 
(s13121, s13146, and s13234) showed increases in the overall aggressive 
response rates, and one participant (s13246) showed no change in the overall 
aggressive response rate. As shown in Figure 1.C, no changes in the overall 
monetary response rate were observed across doses for any participants. The 
absence of change in monetarily reinforced responding provides evidence that 
changes in aggressive responding at 90 min post OT dose were specific to the 
aggressive response option and are not a stimulatory or sedative effect of OT 
on motor coordination.  
 
  
Figure 1.B Overall a
and all three 
Aggressive response rate (responses per minute
(90 min post dose) on the aggressive response option (y
across placebo and three doses of oxytocin (x
 a= Session 2 data 
experimenter error. 
Taken from Alcorn III et al. (In Press). 
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Figure 1.C Overall monetary 
and all three doses of o
Monetary response rate (responses per 
(90 min post dose) on the monetary
axis) across placebo and three doses of oxytocin (x
a= Session 2 data is 15 min instead of 25 min, due to 
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Taken from Alcorn III et al. (In Press). 
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The third level of analysis employed statistical and graphical 
comparisons of the IRT distributions on the aggressive option. Kolmogorov-
Smirnov (K-S) tests were conducted to compare IRT distributions under each 
OT dose and placebo.  K-S tests were chosen because IRT distributions were 
not normally distributed, thus the K-S tests were used because they make no 
assumptions regarding underlying distributions (Corder & Foreman, 2009).  To 
correct for multiple comparisons, the Benjamini–Yekutieli false discovery rate 
was employed (Benjamini & Yekutieli, 2001). The Benjamini–Yekutieli false 
discovery rate determined that a critical p-value (p < 0.01) should be used to 
signify statistical significance. Figure 1.D shows cumulative frequency 
distributions of IRTs on the aggressive response option (Button B) for each 
subject at each dose. Twelve of the seventeen K-S tests of the IRT distributions 
under active OT doses were significantly different from placebo. For s13121, 
the distribution of aggressive IRTs was found to be significantly different from 
placebo only at the 24IU OT dose (D = 0.18, p < 0.01).  For s13146, the 
distribution of aggressive IRTs was found to be significantly different from 
placebo at the 12IU (D = 0.43, p < 0.01) OT dose. For s13214, the distributions 
of aggressive option IRTs were found to be significantly different from placebo 
under all OT doses: 12IU (D = 0.54, p < 0.01), 24IU (D = 0.35, p < 0.01), and 
48IU (D = 0.49, p < 0.01). For s13234, the distributions of aggressive IRTs were 
found to be significantly different from placebo under 24IU (D = 0.36, p < 0.01) 
and 48IU (D = 0.413, p < 0.01) OT doses. For s13246, the distributions of 
aggressive IRTs were found to be significantly different from placebo under the 
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12IU (D = 0.218, p < 0.01) and 24IU (D = 0.58, p < 0.01) OT dose. For s13285, 
the distributions of aggressive IRTs were found to be significantly different from 
placebo under the 12IU (D = 0.99, p < 0.01) and 24IU (D = 0.33, p < 0.01).  
Measures of central-tendency for the distribution of IRTs on the aggressive 
option are presented in Figure 1.E as box and whisker plots. 
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Figure 1.D Inter-response times across placebo and all three 
doses of oxytocin for each participant.  
Data are shown as cumulative frequency distributions of IRT data on 
the aggressive response option across all doses from all participants.  
Note: different scaling on the x- and y-axes for each individual 
participant. * = data lost due to experimenter error. a = session lasted 
15min instead of 25min, due to experimenter error. ** = p< 0.01, 
statistically significant from placebo, after false discovery rate 
correction. An increase in IRT value is indicative of decreased rate of 
responding during a bout of aggressive responding, whereas a 
decrease in IRT value is indicative of increased rate of responding 
during a bout of aggressive responding.  IU = international unit.  
ms = millisecond 
Taken from Alcorn III et al. (In Press) 
  
 
 
 
 
 
 
 
Figure 1.E Median (Inter
(in milliseconds
all three doses of o
Data are presented from session 2 
scales on the y
experimenter error. a = session lasted 15
experimenter error.
Taken from Alcorn III et al. (In press).
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To summarize the behavioral data (overall response rate and IRT 
distribution) for each participant at the pharmacological peak effect, in two 
participants (s13121 and s13146), a decrease and no change in the overall 
aggressive response rates were seen under the 12IU OT dose, respectively. 
Conversely, for s13121 and s13146, increases in overall aggressive response 
rates were seen under the 24IU and 48IU OT doses. The IRT distributions 
under OT were only significantly different from placebo at the 24IU and 12IU 
dose for s13121 and s13146, respectively; the IRT distributions for both of 
these participants at the respective dose levels were both shifted leftwards 
indicating increased local response rates. In two participants (s13214 and 
s13285), decreases in overall aggressive response rates were observed 
following OT dosing compared to placebo.  For s13214, decreases in overall 
aggressive responses rate were observed under the 24 and 48IU OT doses. In 
s13214 IRT distributions under all three dose levels were significantly different 
from placebo and under all three doses IRT distributions were shifted leftward. 
For s13285, decreases in overall aggressive response rate were observed 
under the 12IU and 48IU OT doses, but not under the 24IU dose. In the same 
participant, IRT distributions were significantly different than placebo under the 
12IU and 24IU OT doses; under these doses IRT distributions were shifted 
leftward. For participant s13234, an increase in the overall aggressive response 
rate was seen under the 24IU and 48IU OT doses. In the same participant, this 
increase in overall response rate was accompanied by significant rightward 
shifts in IRT distributions under the same dose levels. For participant s13246, 
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we observed no change in overall aggressive response rate between OT doses 
and placebo.  However, for s13246, IRT distributions were significantly different 
from placebo under the 12IU and 24IU OT doses; under both dose levels the 
IRT distributions were shifted leftward.  In conclusion, while there were 
observed several differences from placebo in overall aggressive response rates 
and IRT distributions following OT dosing, there were no systematic or orderly 
dose-response relationships overall.  Thus, OT appeared to exert effects 
specifically on operationally-defined aggressive responding (rate changes were 
not observed for monetary-reinforced responding). However, these effects were 
marked by substantial individual differences.   
 
Cardiovascular data across all doses and sessions  
All cardiovascular data (∆ scores) were tested using three different two-
way RM ANOVAs all testing for main effects of dose and session, and 
interaction of dose by session.  After Huyn-Feldt epsilon correction, no RM 
ANOVA on any cardiovascular measure found any statistically significant main 
effects of dose or session, or any interaction of dose by session. Descriptive 
statistics of all cardiovascular data (∆ scores) are presented in Tables 1.C 
through 1.E. Summaries of the results from all RM ANOVAs on all 
cardiovascular data (∆ scores) are found in Table 1.F. Descriptive statistics of 
all raw cardiovascular data by session and dose are in the Appendix material. 
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Minutes Post-Dose 
(Post-Dose session) 
Placebo OT (12 IU) OT (24 IU) OT 48 (IU) 
30 min  (1) -7.8 (2.8) -8 (5.1) -7 (2.5) -9.5 (4.4) 
90 min  (2) -11.3 (5.4) -12.2 (5) -9.2 (6.1) -12.7 (9.4) 
150 min (3) -12.6 (6.3) -13.5 (4.7) -14 (10) -13.5 (9) 
210 min (4) -15.6 (6.2) -17.4 (6.2) -12 (5.9) -15.2 (10) 
Minutes Post-Dose 
(Post-Dose session) 
Placebo OT (12 IU) OT (24 IU) OT 48 (IU) 
30 min  (1) 
 
3.3 (7.1) -2.2 (10.2) 2.3 (6.6) 1 (9) 
90 min  (2) 
 
-0.2 (9.1) 0.2 (13.3) 1.5 (8.6) 7.2 (20.5) 
150 min (3) 0.3 (7.1) 0.3 (14.1) 2.7 (9.4) 3.7 (6.7) 
 
210 min (4) 
 
7.2 (9.6) 
 
2.6 (15.9) 
 
6.8 (8.8) 
 
0.2 (5.8) 
Table 1.D Descriptive statistics of heart rate (∆ scores). 
 Data are presented as mean (S.D.) for each dose and each session. 30min, 
90min, 150min, and 210min post dose (Session 1, 2, 3, and 4, respectively). 
(∆ Scores: Post-Dose minus Pre-Dose). IU = international unit.  
 
Table 1.E Descriptive statistics systolic blood pressure (∆ scores). 
 Data are presented as mean (S.D.) for each dose and each session. 30min, 
90min, 150min, and 210min post dose (Session 1, 2, 3, and 4, respectively).  
(∆ Scores: Post-Dose minus Pre-Dose). IU = international unit.  
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Minutes Post-Dose 
(Post-Dose session) 
Placebo OT (12 IU) OT (24 IU) OT 48 (IU) 
30 min (1) 
 
0 (7.9) 0.3 (4.6) 0 (7.2) 0.6 (3.3) 
90 min (2) 
 
1.5 (4.9) 0.2 (7.5) 4.5 (8.6) 1.8 (5.1) 
150 min (3) 
 
0.5 (5) -0.8 (8.6) 2.3 (9.4) 0.3 (7.0) 
210 min (4) 5.4 (8.3) 1.2 (12.4) 6.8 (8.8) 1.2 (6.8) 
Table 1.F Descriptive statistics of diastolic blood pressure (∆ scores). 
Data are presented as mean (S.D.) for each dose and each session. 30 min, 
90 min, 150 min, and 210 min post dose (Session 1, 2, 3, and 4, respectively). 
 (∆ Scores: Post-Dose minus Pre-Dose). IU = international unit. 
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Dependent 
Variable 
Effect (df) F-score p(uncorr) p(Huyn-Feldtcorr) 
Heart Rate 
(∆ Scores) 
     
 Main     
 Dose (3, 15) 0.63 0.61 0.60 
  
Session  
 
(3, 14) 
 
5.03 
 
0.01 
 
0.06 
  
Interaction 
    
  
Dose X 
Session 
 
(9, 42) 
 
0.58 
 
0.81 
 
0.8 
Systolic BP 
(∆ Scores) 
     
 Main      
 Dose (3, 15) 0.42 0.74 0.62 
 Session  (3, 14) 2.24 0.13 0.13 
 Interaction     
 Dose X 
Session 
(9, 42) 1.33 0.25 0.29 
Diastolic BP 
(∆ Scores) 
     
 Main     
 Dose (3, 15) 0.65 0.6 0.6 
 Session  (3, 14) 2.1 0.15 0.15 
 Interaction     
 Dose X 
Session 
(9, 42) 0.7 0.71 0.64 
Table 1.G Summaries of the RM ANOVAs on all cardiovascular data (∆ scores) 
p(uncorr) = uncorrected p-value. p(Huyn-Feldtcorr)= corrected p-value for repeated measures. 
(∆ Scores: Post-Dose minus Pre-Dose) 
 
  
 67   
 
 
POMS Data across all doses and sessions 
All POMS data (∆ scores) were analyzed using six separate two-way RM 
ANOVAs (one for each subscale) all testing for main effects of dose and 
session, and interaction of dose by session. For planned multiple comparisons 
of each POMS subscale (∆ scores), the Benjamini–Yekutieli false discovery 
rate (Benjamini & Yekutieli, 2001) was employed (to correct for multiple 
comparisons across the multiple subscales) in addition to the Huyn-Feldt 
corrected p-values. The Benjamini–Yekutieli false discovery rate determined 
that a critical p-value (p < 0.004) should be used to signify statistical 
significance.  After correction, no RM ANOVA on any POMS subscale found a 
statistically significant main effect of dose or session, or any interaction of dose 
by session. Descriptive statistics of all POMS subscales (∆ scores) are 
presented in Table 1.G. Summaries of the results from all RM ANOVAs on all 
POMS data (∆ scores) are found in Table 1.H. Descriptive statistics of all raw 
POM subscales by session and dose are in the Appendix material 
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Subscale Placebo OT (12 IU) OT (24 IU) OT 48 (IU) 
Depression-
Dejection 
-0.87 (1.7) 0.22 (0.6) -0.4 (0.6) 0.1 (0.5) 
 
Vigor 
 
-0.82 (3.1) 
 
-0.7 (2.1) 
 
-1.2 (1.9) 
 
-0.5 (1.6) 
 
Confusion-
Bewilderment 
 
0 (0.5) 
 
0 (0) 
 
0.1 (0.4) 
 
0 (0) 
 
Tension-
Anxiety 
 
-0.22 (1.8) 
 
-0.4 (1.6) 
 
-0.4 (1.3) 
 
-0.4 (0.9) 
 
Anger-
Hostility 
 
-0.4 (0.9) 
 
0.1 (0.42) 
 
0 (0) 
 
0.2 (0.8) 
 
Fatigue 
 
-1 (2.5) 
 
0.26  (2.7) 
 
0 (2.1) 
 
0.2 (0.8) 
 Table 1.H Descriptive statistics of all POMS subscales (∆ scores) 
Data are presented as mean (S.D.) for all POMS subscales. 
(∆ Scores: Post-Dose minus Pre-Dose) 
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Dependent 
Variable 
Effect (df)  F-score p(uncorr) p(Huyn-Feldtcorr) 
Depression- 
Dejection 
(∆ Scores) 
     
 Main     
 Dose (3, 15) 2.04 0.15 0.19 
  
Session  
 
(3, 14) 
 
1.24 
 
0.33 
 
0.32 
  
Interaction 
    
  
Dose X 
Session 
 
(9, 42) 
 
1.06 
 
0.41 
 
0.36 
Vigor 
(∆ Scores) 
     
 Main      
 Dose (3, 15) 1.89 0.17 0.19 
 Session  (3, 14) 2.94 0.07 0.08 
 Interaction     
 Dose X 
Session 
(9, 42) 1.2 0.32 0.34 
Confusion- 
Bewilderment 
(∆ Scores) 
     
 Main     
 Dose (3, 15) 0.4 0.77 * 
 Session  (3, 14) 1.07 0.34 0.35 
 Interaction     
 Dose X 
Session 
(9, 42) 1.03 0.43 * 
      
      
      
      
Table 1.I Summaries of the RM ANOVAs on all POMS data (∆ scores) 
*= corrected p-values not specified by the model.  
p(uncorr) = uncorrected p-value. p(Huyn-Feldtcorr)= corrected p-value for repeated measures  
(∆ Scores: Post-Dose minus Pre-Dose) 
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Dependent 
Variable 
Effect (df)  F-score p(uncorr) p(Huyn-Feldtcorr) 
Tension-
Anxiety 
(∆ Scores) 
     
 Main     
 Dose (3, 15) 0.06 0.98 0.94 
 Session  (3, 14) 2.45 0.11 0.15 
 Interaction     
 Dose X 
Session 
(9, 42) 2.34 0.03 0.14 
Anger-
Hostility 
(∆ Scores) 
     
 Main      
 Dose (3, 15) 2.11 0.14 0.14 
 Session  (3, 14) 1.03 0.41 0.54 
 Interaction     
 Dose X 
Session 
(9, 42) 0.76 0.66 0.54 
Fatigue 
(∆ Scores) 
     
 Main     
 Dose (3, 15) 0.55 0.66 
 
0.57 
 Session  (3, 14) 2.34 0.12 
 
0.17 
 Interaction     
 Dose X 
Session 
(9, 42) 0.32 0.96 0.79 
Continued from previous page 
 
Table 1.I Summaries of the RM ANOVAs on all POMS data (∆ scores) 
p(uncorr) = uncorrected p-value. p(Huyn-Feldtcorr)= corrected p-value for repeated measures  
(∆ Scores: Post-Dose minus Pre-Dose) 
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Psychometric data 
Analyses of the psychometric scores (SRP-III, BPAQ, BIS-11 and IPAS) 
did not reveal any notable associations with overall aggressive response rates 
or IRT distributions.  Psychometric scores were comparable across participants. 
Total scores from psychometric scales are presented in the Appendix A 
material.   
 
Discussion 
  In individuals with ASPD and past SUD, changes in aggressive 
response rates and IRT distributions were observed following OT dosing, but 
these were not systematic or dose related.  Notably, the changes did appear 
specific to aggressive (social) behavior; OT dosing did not appear to alter 
monetary-reinforced (non-social) responding.  This observation is consistent 
with the reported role of OT in modulating social behavior (Meyer-Lindenberg et 
al., 2011).  For three participants (s13121, s13146, s13234), increases in 
aggressive response rate were observed at the 24IU and 48IU OT doses.  
However, these changes were unrelated to shifts in IRT distributions.  Shifts in 
IRT distributions reflect changes in local response rate during response bouts 
on the aggressive option. While OT doses appeared to modify IRT distributions, 
changes were also not dose related. While most participants responded faster 
during aggressive bouts (typically at higher doses), rightward shifts (slower 
responding) were also observed.  
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 The neuropeptide OT has been reported to increase the saliency of both 
positive and negative social stimuli (Gamer et al., 2010; Guastella et al., 2008; 
Stripens et al., 2012). This function of OT is thought to reflect promotion of 
prosocial behaviors (Bartz et al., 2011) and decrease in avoidance, such as 
response to an angry face (Evans et al., 2010). Given that aggressive 
responding on the PSAP is maintained by avoidance from provocation (Cherek 
et al., 1990) and occurs in bouts of responding, changes in the time to complete 
the FR 10 on the aggressive response option (e.g. IRT distribution) could reflect 
changes in the social saliency of provocations. Changes in IRT distributions 
following OT administration may cautiously be interpreted as modification in the 
social salience of provocation used to elicit an aggressive response. However, 
the lack of orderly effects implies that OT effects on aggressive behavior were 
also modulated by variables that were not adequately measured in the 
experiment (e.g., individual differences) or non-experimental sources of 
variability. This possibility is supported by a study from Bartz et al. (2011), in 
which empathic accuracy was selectively improved in less socially proficient 
individuals following oxytocin administration. Acute OT administration (24 IU) 
has been shown to interact with state anxiety level to reduce aggressive 
behavior of women with high state anxiety (Campbell & Hausmann, 2013). 
Additionally, Norman et al. (2010) found that higher levels of loneliness 
(diminished social support) were significantly correlated with reduced cardiac 
reactivity following acute OT administration. It appears that on both behavioral 
and biological levels, the effects of OT administration are modulated by 
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individual differences. Furthermore, the relationship between OT dose and 
neurobehavioral changes may be non-linear.  
 This study has several limitations. First, our sample of participants was 
small and homogenous. All six participants met criteria for ASPD and past SUD, 
had similar psychometric scores on personality assessments (see Appendix), 
and had criminal and drug use histories. Thus, we are limited in drawing 
inferences about the effects of OT on aggressive behavior to this subset of 
individuals. Future studies may wish to consider using larger sample of 
participants, including a separate group of healthy individuals to compare with a 
clinically relevant sample. A second limitation of the present study is that data 
analysis was limited mostly to qualitative rather than quantitative techniques.  
While both approaches have relative advantages and disadvantages, 
expanding the present study to a larger sample would provide increased 
statistical power for future studies, which would allow greater generalizability 
and potentially better understanding of the direction and magnitude of effects 
following acute intranasal OT administration. Thirdly, the experimental design 
did not assess aggressive responding in between OT dose days (e.g., return to 
non-dosing baseline conditions between doses).  Thus, this experiment was not 
able to assess stability in aggressive responding across dosing days.  Future 
studies may endeavor to implement designs that assess stability (or change) in 
social behavior across the study (i.e., an A-B-A-C-A-D design).  Lastly, there 
was no statistically significant result on cardiovascular data (HR/BP) or self-
reported mood (POMS). Therefore, outside of the differences that were 
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observed on aggressive responding, we do not have additional confirmation 
that OT was biologically or behaviorally active.  Previous studies using 
intranasal OT dosing have observed cardiovascular changes (Kemp et al., 
2012). The present lack of orderly dose-related cardiovascular effects warrants 
further experimentation in a non-clinical group of healthy adults.  
 The hypothesis of this experiment was that OT would produce dose-
dependent decreases in rates of aggressive responding.  This hypothesis was 
tested in individuals who met criteria for ASPD and past SUD, believing these 
individuals are a clinically relevant group and perhaps uniquely sensitive to OT 
effects, as previous studies have observed diminished OT function in this 
population (Lee et al.,  2009b; Malik et al., 2012). The results imply that OT had 
individual effects on aggressive responding. However, the direction and 
magnitude of the effect are not clear, and as such the results remain 
inconclusive. The results are best interpreted as qualitative information for 
future studies seeking to study OT effects on social behavior in high-risk 
populations.  Further work is needed to understand individual differences that 
plausibly moderate OT effects on aggressive responding. 
 It should be noted that while many studies have touted the prosocial 
effects of oxytocin (Bakermans-Kranenburg & van IJzendoorn, 2013), more 
nuanced experiments report that prosocial behaviors are not enhanced (or even 
decreased) in the absence of key social cues, and a broader range of behaviors 
may occur, e.g., competition and ratings of envy (De Dreu et al., 2012, 
Declerck, et al, 2010; Shamay-Tsoory et al., 2009). Acute OT administration 
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may actually decrease trust and cooperation in individuals with Borderline 
Personality Disorder (Bartz et al., 2010), a psychiatric disorder that shares 
much common symptomatology with ASPD+SUD. Thus, mixed or equivocal 
effects are not without precedent.   
 This experiment observed some evidence of modulation of aggressive 
behavior via OT administration, but the effects were not systematic and the 
controlling variables remain unclear.  Given that (i) OT receptors are prevalent 
in the cortico-limbic circuitry (Gimpl & Farhenholz, 2001; Ludwig & Leng, 2006; 
Lee et al., 2009a); (ii) that individuals with ASPD and past SUD have disrupted 
functioning in this same circuitry (Siever, 2008); and (iii) that OT appears to be 
evolutionarily conserved in regulating mammalian social and maternal behavior, 
the possibility that OT has anti-aggressive properties in individuals with 
deficiencies in affective control and social interaction remains a viable 
hypothesis and target for future experimentation. 
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 CHAPTER 3: EFFECTS OF ACUTE OXYTOCIN DOSE ON AGGRESSIVE 
RESPONDING IN HEALTHY MALE CONTROLS 
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Introduction  
In Experiment 1, there was qualitative evidence of modulation of 
aggressive behavior following oxytocin (OT) administration in a sample of 
Antisocial Personality Disordered (ASPD) and Substance Use Disordered 
(SUD) participants. The effects of OT were not systematic across subjects. 
Specifically, the direction and magnitude of OT effects were not clear.   
There were several limitations in the first experiment with ASPD+SUD 
participants that precluded definitive interpretation of OT effects on aggressive 
responding.   The first limitation was the design. The design of Experiment 1 did 
not assess any changes in ongoing levels of aggressive responding that could 
have arisen following OT dosing (e.g., returning to baseline, or non-dose, 
conditions). Thus, the design in the first experiment might not have been 
optimal to assess the rate of responding following repeated OT administration. 
The second limitation is that individual differences under OT dosing were not 
assessed. The possibility of individual differences across ASPD+SUD 
participants could not be thoroughly investigated because these participants 
were a relativity homogenous sample in terms of substance use history, 
criminal charges, and personality traits (see Appendix).  
OT is known to regulate affiliative behavior and social cognitions. 
Experiment 1 did not assess if OT changed social judgment of the “other 
person” in the Point Subtraction Aggression Paradigm (PSAP).  Modulation of 
social judgment towards prosocial cognitive processing has been reported 
following acute OT administration (Domes et al., 2007a; Guastella et al., 2008; 
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Guastella et al., 2010; Kosfeld et al., 2005; Zak et al., 2007). Experiment 1 did 
not measure change in social cognition in the context of aggression as 
measured by the PSAP.  
To overcome these limitations in experimental design, Experiment 2 of 
this dissertation changed the experimental design to reduce intra-and inter-
subject subject variability within and across test days.  First, aggressive 
responding was normalized to a baseline (pre-dose) session. Additionally, 
intervening non-dose baseline test days were introduced in order to obtain 
stable behavior patterns prior to dosing. This strategy was better able to assess 
baseline shifts in aggressive responding that could be a product of unintended 
or uncontrolled factors. Lastly, the design of Experiment 2 utilized a single dose 
level of OT (24 IU), the most commonly reported dose of OT in the literature 
(Bakermans-Kranenburg & van IJzendoorn, 2013; Shahrestani et al., 2013). 
These experimental changes were undertaken to measure the frequency of 
aggressive behavior under more stringent experimental conditions. 
The rationale for Experiment 2 follows from converging evidence that the 
oxytonergic system modulates human prosocial behavior such as cooperation, 
trust, and generosity (De Dreu et al., 2010; Kosfeld et al., 2005; Rilling et al., 
2012; Zak et al., 2007). These behaviors stand in contrast to antisocial 
behaviors such as aggression. Oxytonergic axonal projections from the 
hypothalamus reach the prefrontal cortices and central amygdala, which are 
important brain regions in mediating social behavior for both human and 
nonhuman animals (Carter, 2014;Gimpl & Fahrenholz, 2001; Lee et al., 2009a; 
 79   
 
Meyer-Lindenberg et al., 2011; Young et al., 2011). The OT receptor is 
prevalent throughout the neurobiological circuitry underpinning social behavior 
(Gimpl & Fahrenholz, 2001; Lee et al., 2009a) and the OT system is 
evolutionarily conserved in regulating affiliative or prosocial mammalian 
behavior (Lee et al., 2009a; Koehbach et al., 2013; Saltzman & Maestripieri, 
2011). Thus, increases in prosocial behavior should manifest as decreases in 
antisocial behaviors, including aggression.  
 
Experiment 2 Hypothesis and aims. 
The primary hypothesis of Experiment 2 is that acute administration of 
OT will decrease human aggressive behavior.  Additionally, it was hypothesized 
that OT effects on aggression would be related to individual differences (related 
to psychopathy and aggression); and OT would modulate social judgment by 
increasing likability ratings. Accordingly, the following three aims were 
proposed. To test this hypothesis, three aims were proposed. 
 
Aim 2a: To test if acute OT dose (24 IU) decreases aggressive behavior.  
Rationale: To date, the majority OT studies in human participants have 
employed between-subjects design (Bakermans-Kranenburg & van IJzendoorn, 
2013; Bethlehem, et al., 2013) and have focused on prosocial behaviors. This 
experiment will test if acute administration of OT decreases the frequency of 
aggressive responding, an antisocial behavior, in healthy male participants 
using a within-subjects design.  
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Hypothesis 2a: Compared to placebo, OT administration will reduce aggressive 
behavior in healthy adult male participants.  
 
Aim 2b: To explore if personality traits of interpersonal manipulation and 
anger are correlated with aggressive behavior under OT.  
Rationale:  Psychiatric and clinically relevant personality traits such as 
psychopathy exist on a spectrum.  All people, including those without 
psychiatric disorders, demonstrate some level of clinically relevant traits. 
Therefore, exploring the association between clinically relevant personality traits 
and aggressive responding under OT dosing could provide unique information 
regarding the manner in which OT modulates aggression as a function of 
individual differences in antisocial traits. The personality trait of interpersonal 
manipulation was selected because (i) interpersonal manipulation is a 
psychopathic trait and is prominent in ASPD+SUD individuals (Alcorn III et al., 
2013) and (ii) individuals with higher levels of interpersonal manipulation  have 
higher levels of aggression (Nouvion et al., 2007; Vaillancourt & Sunderani, 
2011). Anger was selected as an important trait because anger reactivity and 
poor anger regulation are risk factors for individuals with a history of violent 
behavior (Alia-Klien et al., 2009), and because anger is a major affective 
component that accompanies aggressive behavior (Buss & Perry, 1992). Lee et 
al. (2009b) reported that in personality-disordered individuals, cerebrospinal 
fluids of OT were inversely correlated to acts of aggression. Alcorn III et al. 
(2013) reported that psychopathic and aggressive personality traits were two 
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key psychometric measures that characterized ASPD+SUD individuals from 
healthy volunteers. By extension, antisocial traits such as interpersonal 
manipulation and anger should be negatively correlated with aggression 
following OT dosing. This aim focuses on individual differences that could 
moderate OT effects.  
Hypothesis 2b:  Personality traits of interpersonal manipulation and anger will 
be negatively correlated with aggressive responding following OT dosing. 
 
Aim 2c: To test if acute OT dosing (24 IU) changes social judgment 
following an aggressive encounter.  
Rationale: Given that OT is a neuropeptide which modulates socio-emotional 
behaviors and cognitions, this aim tests the effect of OT dose on social 
judgment of the “other person” in the PSAP. To measure changes in social 
judgment, this aim will measure how much participants rate the likability of the 
“other person” in the PSAP. By measuring social judgment, this aim tests if OT 
dosing changes social judgment following a social interaction that elicits 
aggression. Given that OT in humans increased both trust behavior (Kosfeld et 
al., 2005) and generosity (Zak et al., 2007) towards strangers, and that 
affiliative social behavior towards a conspecific is known to be modulated by OT 
(Carter et al., 1995; Williams et al., 1994); acute OT dosing should modify 
participant’s judgment of the “other person”.   
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Hypothesis 3: Healthy adult male participants, OT dosing will increase prosocial 
ratings of likability compared to placebo.  
 
Materials and Methods 
All experimental procedures in this study were reviewed and approved 
by the Institutional Review Board for the University of Texas Health Science 
Center-Houston, USA. Prior to study participation, informed consent was 
obtained from all participants. 
 
Participants:  
Participants were recruited from a community sample by local 
newspaper advertisements. Potential subjects (18-50 years of age) were first 
screened though an initial phone interview to obtain information about 
recreational drug use, psychiatric, and medical history. Potentially eligible 
participants were scheduled for more extensive in-person screening. Prior to 
study participation all participants underwent a physical exam to screen for 
exclusionary medical conditions (e.g. HIV, seizures, cardiovascular, kidney or 
endocrine diseases, diabetes, hypertension, and history of head trauma or loss 
of consciousness > 20 minutes) and current use of prescription medication. 
These selection criteria were modeled after a recent review of safety, side-
effects, and subjective reactions associated with intranasal OT administration 
by MacDonald et al. (2011). All potential participants had no medical history of 
head trauma, loss of consciousness (>20 min), hypertension, diabetes, or 
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cardiovascular, kidney, or endocrinological diseases/disorders (e.g. thyroid or 
adrenal diseases), and preservative allergies. Female participants were 
excluded from this experiment for the following reasons, (i) the neuropeptide 
oxytocin increases levels of luteinizing hormone (Evans et al., 2003) which 
could have potentially affect the regularly occurring menstrual cycles of female 
participants, and (ii) currently there are no data about interactions of oxytocin 
administration with oral contraceptives (i.e. birth control), introducing possible 
behavioral and physiological side effects. All participants were interviewed 
using the Structured Clinical Interview for the DSM-IV (SCID). The SCID-I is a 
semi-structured interview for making diagnosis of Axis I Disorders (First et al., 
1996) and the SCID-II NP is a semi-structured interview for making diagnosis of 
Axis II Disorders (Personality Disorders; First et al., 1997). The SCID-I and 
SCID-II were administered by a trained mental health professional. The SCID-I 
and SCID-II NP was used to ensure that all potential participants did not meet 
DSM-IV criteria for any psychiatric disorders.  Participants who qualified for 
study participation were provided informed consent about the study. All qualified 
participants were male, had no medical complications, and had no history of 
DSM-IV Axis I psychotic, anxiety, substance dependence, and/or mood 
disorders and DSM-IV Axis II personality disorder.  
 Extraneous drug use was monitored by daily urine samples and expired 
alcohol breath samples prior to beginning participation. Urine samples were 
screened for extraneous drugs using the Enzyme Multiple Immunoassay 
Technique Drug Abuse Urine Assay (Innovacon; San Diego, CA). Expired 
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breath samples were used for detecting alcohol consumption, prior to 
participation. Expired breath samples were analyzed using an Alcosensor III. 
Psychoactive medication was prohibited during study participation and caffeine 
consumption was prohibited upon entering the laboratory.  
 
Exclusion: 
 Participants were excluded if they did not use the aggressive response 
option or if aggressive responding was below two aggressive responses per 
minute. This criterion was selected because the hypothesis of this experiment is 
that OT dose decreases aggressive behavior and cannot be examined if 
aggressive responding does not occur or if aggressive responding occurs at a 
rate close to zero (i.e., below two aggressive responses/minute; a floor effect). 
Additionally, if stability criteria could not be established within five consecutive 
days of study participation, participants were excluded. Table 2.A lists the 
number of participants excluded from study participation. The Shipley Institute 
of Living Scale-2 (Shipley et al., 2009) is a test of general cognitive aptitude 
consisting of a 40-item vocabulary test and a 26-item block test. The Shipley 
Institute-2 was used to assure that behavioral data in the PSAP were not 
confounded by associations with deficits in cognitive abilities.  Average 
composite verbal and block score on the Shipley-II was 210.4 (SD = ± 21.8: 
age-adjusted normative percentile on the Weschler Adult Intelligence Scale 
estimated mean of 106.2). Thirty five participants were consented to 
Experiment 2, of which 17 completed the study.  Reasons for exclusion from 
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participation are presented in Table 2.A.  Demographics of participants who 
completed the experiment are presented in Table 2.B.  
 
Reason for exclusion number of participants 
Aggressive responding on the PSAP 
did not meet criteria. 
12 
 
More than two positive detections of 
extraneous drug use or BAL.  
 
1 
 
Failure to show up for more than two 
consecutive study days (without prior 
contact). 
 
3 
 
Declined study participation prior to 
dose. 
 
2 
 
 
 
 
Demographic variable Descriptive statistic 
Sample size (n = 17) 
Age 
Mean (S.D.) 
 
32 (9.2) 
Years of Education 
Mean (S.D.) 
 
13.6 (2.1) 
Ethnicity   
African American (%) 53 
White (%) 17.6 
Hispanic (%) 29.4 
 
 
 
Table 2.A The number of participants excluded from study participation. 
Table 2.B Participant demographics. 
 
 86   
 
Procedure: 
 Details of the Point Subtraction Aggression Paradigm (PSAP) and the 
apparatus in which sessions of the PSAP were conducted are identical to those 
listed in the materials and methods of Experiment 1. The escape response 
option (Button C) was not analyzed in this experiment as not all participants 
used the escape response and those who did use the C button often did so 
non-systematically. Thus, direct comparison of escape responding to both 
aggressive and monetarily-reinforced responding under both OT and placebo 
dose was not possible. 
 
Stability criteria:   
 To reduce intra-subject variability this experiment included baseline (no-
dose test days) in between those days in which participants were dosed. All 
participants had to meet stability criteria on a baseline day prior to dosing. 
Stability criteria was defined as (i) no ascending or descending trends in 
aggressive responding and (ii) participant‘s aggressive response rate 
(aggressive response per minute) was ≤ 0.25 on the coefficient of variation (CV: 
SD/mean) across all PSAP sessions on baseline days. On experimental days in 
which participants were scheduled to be dosed, the dose was not given unless 
their aggressive response rate (aggressive response per minute) during their 
baseline (Pre-Dose) session was within ±25% of the mean aggressive 
responding on the preceding baseline day. If a participant’s aggressive 
responding on the baseline (Pre-Dose) session was ≥ ±25% of his mean 
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baseline aggressive responding, neither OT nor placebo dose was introduced. 
Instead, an additional baseline day was run. These stability criteria were used 
to ensure that each participant’s aggressive behavior was stable between 
doses and any shifts in baseline responding did not bias dosing data. These 
criteria were modeled after previous studies utilizing the PSAP with acute drug 
administration (Cherek et al., 1990; Cherek et al., 1999). 
 
Physiological measures 
 Cardiovascular data were collected to provide confirmation of active OT.  
Heart rate (HR) and blood pressure (BP) were measured using a 
sphygmomanometer (BpTru Vital Signs Monitor, Coquitlam, Canada) after each 
session of the four PSAP sessions. Cardiovascular data (HR/BP) were 
collected to examine changes in autonomic nervous system activity after OT 
dosing, which can provide physiological confirmation of an active dose. All 
cardiovascular data were transformed into a difference score (∆ score) of Post-
Dose minus Pre-Dose.  
Body temperature (BT) was collected orally (sub-lingual) using a 
thermometer (Lumeon, Jacksonville, FL) four times prior each PSAP session. 
The decision to include BT data in this experiment was based on data in the 
literature showing that OT dose can decrease body temperature (Hicks et al., 
2013). All BT data were transformed into a difference score (∆ score) of Post-
Dose minus Pre-Dose.  
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Psychometric measures 
The Social Visual Analog Scale (VAS) is a self-report measure of social 
judgment rating of the likability of other individuals. The Social VAS consisted of 
one question, “Right now, the person I’m paired with is” ranging from “Very 
likable” to “Very unlikeable”, with scores ranging from 6 – 0, respectively. All 
Social VAS data were collected after each of the four PSAP sessions. Social 
VAS ratings were transformed into a difference score (∆ score) of Post-Dose 
minus Pre-Dose.  
The Self-Report Psychopathy Scale III (SRP-III; Paulhus et al., 2010; 
Mahmut et al., 2011) is a self-report measure of the clinical construct of 
psychopathy. The SRP-III consists of 64-items on a 1-5 point Likert-rating scale 
ranging from “Disagree Strongly” to “Agree Strongly”. The SPR-III provides a 
total score in addition to four subscale scores measuring interpersonal 
manipulation, callous affect, erratic lifestyle, and criminal tendencies. The 
subscale of interpersonal manipulation was used for correlational analysis 
based on Vaillancourt & Sunderani (2011). 
The Buss-Perry Aggression Questionnaire (BPAQ; Buss & Perry, 1992) 
is a self-report measure of trait aggression consisting of 29-items on a 1-5 point 
Likert-rating scale ranging from “Not like me at all” to “A lot like me”. The BPAQ 
provides a total score in addition four subscale scores measuring physical 
aggression, verbal aggression, anger, and hostility. The subscale of anger was 
used for exploratory correlational analysis based on Alia-Klien et al. (2009).  
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The Profile of Mood States: Short Form (POMS; Shacham, 1983) is a 
self-report measure of psychological distress consisting of 38-adjective items on 
a 0-4 Likert-rating scale ranging from “Not at all” to “Extremely”. The POMS 
provides a total mood disturbance score and six subscale scores measuring six 
distinct mood states: Depression-Dejection, Anger-Hostility, Tension-Anxiety, 
Fatigue, Vigor, and Confusion-Bewilderment. These measures were used to 
monitor subject mood throughout the course of the experiment. All POMS data 
were collected before each of the four PSAP sessions. POMS data for each 
subscale were transformed into a difference score of Post-Dose minus Pre-
Dose (∆ score), and were used to assess dose-related changes in mood. 
 
Drug Administration:  
Drug administration procedures were identical to those drug 
administration procedures detailed in Experiment 1.  However, only one dose 
level (24 IU) of OT was used. Given that the three post-dose PSAP sessions of 
the PSAP sessions occurred over a span of more than two hours, a single dose 
of OT spray was hypothesized to be sufficient to observe acute effects.  An 
outline of intranasal administration is detailed in Table 2.C.  
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Dose Volume (ml) of OT. Corresponding volume 
(ml) of  placebo  
Placebo 0 ml 1.5 ml 
 
OT (24 IU) 0.6 ml 0.9 ml 
 
 
 
 
 
Design: 
 Participants completed a minimum of four study days. However, this 
experiment contained contingencies to establish behavioral stability on 
aggressive responding prior to dosing. Therefore, some participants 
participated in the study for more than four days to achieve stability prior to and 
in-between doses. Participants came to the lab 2-4 days a week, from 8:00 am 
to approximately 12-1 pm for each study day.  Participants completed four 
PSAP sessions on each study day (both baseline and dose days). On study 
days in which participants were dosed, the first session occurred 30min before 
dose administration and the remaining three PSAP sessions occurred at 30min, 
90min, and 150min post-dose. Each PSAP session lasted 25min.  Mood and 
temperature data were collected prior to PSAP sessions. Cardiovascular and 
likability ratings were collected after the PSAP sessions. An outline of 
experimental days is presented in Table 2.D. 
 
 
Table 2.C Outline of dose levels. 
Presented are the dose levels that were used for intranasal administration in 
Experiment 2. Dose levels varied in the concentration of OT. All Participants 
inhaled a total volume of 1.5ml of spray. IU = international unit.  
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Outline of study days   
Study Day Description Comment 
 
1 
 
Baseline for PSAP  
 
May have required several 
days 
 
2 
PSAP with either OT  
dose (24 IU) or PLC 
 
 
3 
 
Baseline for PSAP 
 
May have required several 
days 
 
4 
 
PSAP with either OT 
dose (24 IU) or PLC 
 
Daily Schedule (Dose Days)   
Time point  Session Event 
30 min before dose 
8:30 am 
 
Baseline (Pre-Dose) BT, POMS, PSAP, Social 
VAS, HR/BP 
 
9:00 am Dose Administration OT (24 IU) or PLC 
 
30 min after dose 
9:30 am 
 
Post-Dose Session 1 
 
BT, POMS, PSAP, Social 
VAS, HR/BP 
 
90 min after dose 
10:30 am 
Post-Dose Session 2 BT, POMS, PSAP, Social 
VAS, HR/BP 
 
150 min after dose 
11:30 am 
Post-Dose Session 3 BT, POMS, PSAP, Social 
VAS, HR/BP 
 
 
 
 
 
 
 
Table 2.D Outline of study days. 
OT = oxytocin. PLC = placebo. BT = body temperature. POMS = Profile of 
Mood Scale PSAP = Point subtraction aggression paradigm.  Social VAS = 
Social VAS (likability ratings). HR= heart rate. BP = blood pressure.  
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Data Analyses 
The data analysis strategy for the behavioral data in Experiment 2 was 
similar to Experiment 1 (Chapter 2) and is detailed in the ensuing sections. Only 
the dependent variables (behavioral, physiological, social judgment, and mood) 
collected from the two study days in which participants were dosed were 
analyzed (OT, placebo).  
 
Behavioral data 
The dependent measure of aggression in the PSAP was the number of 
aggressive response rate (aggressive responses per minute). On days in which 
participants were given a dose of OT (24 IU) or placebo, aggressive response 
rates from each of the subsequent post-dose sessions (30 min, 90 min, 150 min 
post-dose represent post-dose sessions 1, 2, 3, respectively) were normalized 
to the baseline (pre-dose) session and were calculated as a percent of baseline 
= (aggressive response rate, percent of baselinePre-Dose: (Post-Dose Session/ 
Pre-Dose Session) *100).  This normalized aggressive response rate was used 
to compare aggressive responding under OT to placebo dose. 
 Unlike Experiment 1 (chapter 2), the peak effect was identified 
behaviorally for each individual subject.  Behavioral peak effect of OT was 
defined as the session containing the biggest change in responding from the 
baseline under OT (24 IU) dose. For example, if a participant’s biggest change 
in aggressive responding under OT occurred at 90 min post-dose, then the 90 
min post dose session under placebo was used. This method of defining peak 
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effect follows from behavioral pharmacological studies examining aggressive 
responding in the PSAP (Cherek & Lane, 2001), choice proportions in decision 
making tasks (Lane et al., 2008; Lane & Gowin, 2009), self-administration of 
drugs (Stoops et al., 2012), drug subjective effects (Stoops et al., 2008; Rush et 
al., 2011), and drug discrimination procedures (Sevak et al., 2009).  All of the 
cited studies examined different drug effects over the course of several 
sessions throughout the respective experiments, but focused on peak effects. 
The corresponding session under placebo was used to test for differences in 
aggressive responding vs OT. In other words, if the peak effect for OT was 
observed in the session 90min post-dose, then it was compared to the session 
that was 90min post-dose under placebo. Across all participants, 29.4% of peak 
effects occurred 30 min post-dose, 23.5% of peak effects occurred 90 min post-
dose, and 47.1% of peak effects occurred 150 min post-dose.  
 
Physiological data  
 Cardiovascular (HR/BP) and BT data were collected to examine changes 
in physiological activity. Physiological data were tested to provide confirmation 
of biologically active OT effects, compared to placebo.  All physiological data 
were transformed into a difference score (∆ score) of Post-Dose minus Pre-
Dose.  
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Psychometric data 
 To explore the correlation between aggressive responding under OT and 
personality traits of interpersonal manipulation and anger (aim 2b), scores from 
the interpersonal manipulation subscale from the SRP-III and the anger 
subscale on the BPAQ were both independently standardized to have a mean 
of 0 and a standard deviation of 1. Standardized scores (Z-Scores) of 
interpersonal manipulation and anger were added together to create a 
composite score.  Descriptive summaries of all subscales and total scores from 
the SRP-III and BPAQ are presented in Appendix 2.  
 
Missing data 
 One participant dropped out prior to receiving the placebo dose and 
completing the psychometric data. To handle missing data from this participant, 
imputation was conducted.  The sample mean of aggressive response rate 
(percent of baselinePre-Dose), Social VAS, and all physiological data for each 
post-dose session under placebo was imputed for this subject to provide non-
biased but balanced cells for statistical analysis.  Psychometric scores were 
also imputed using the sample mean all psychometric measures.  
 
 
 
 
 95   
 
Statistical Analyses 
All statistical tests were conducted using the statistical program STATA 
version 11.1. A two-way Repeated Measures Analysis of Variance (RM 
ANOVA) tested for main effects of dose and session, and the interaction of 
dose by session. The two within-subjects factors were dose (Placebo vs OT) 
and session (30, 90, and 150 min post-dose). The following variables were 
analyzed: aggressive response rates (percent of baselinePre-Dose), ∆ scores from 
the Social VAS data, ∆ scores from all cardiovascular data, ∆ scores from all 
BT data, and ∆ scores from each subscale of the POMS. Behavioral, Social 
VAS, cardiovascular, BT, and mood data were dependent variables in the RM 
ANOVA. Dose and session were coded in the RM ANOVA model as factors. To 
correct for violations against sphericity that could be associated with RM, p-
values were corrected using Huynh-Feldt epsilon correction. All p-values from 
all RM ANOVA are reported with both the uncorrected and Huynh-Feldt 
corrected p-values (pHuyn-Feldtcorr) from the RM ANOVA. Only the Huyn-Feldt 
corrected p-values were used to evaluate statistical significance.  
Since behavioral peak effect data were individually selected for each 
participant and behavioral peak effects did not occur at the same time point 
across participants, peak effect data were analyzed separately. For behavioral 
peak effect data, a paired samples t-test was to compare aggressive response 
rates (percent of baselinePre-Dose), under OT dose to placebo. Assumptions of 
normality and homogeneity of variance were evaluated using the Shapiro-Wilk 
test and Levene’s test, respectively. If violations in normality and/or 
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homogeneity of variance occurred, a Wilcoxon Signed-Rank Test was 
conducted, the nonparametric version of a paired-samples t-test.  
 Correlational analysis for aim 2b was conducted using Pearson’s 
correlation coefficient.  Given that there were six POMS subscales were 
collected and ∆ scores were collected at three time points across two dose 
levels, the Benjamini–Yekutieli false discovery rate was employed (Benjamini & 
Yekutieli, 2001) to correct for multiple comparisons. The Benjamini–Yekutieli 
false discovery rate determined that the corrected critical p-value for all POMS 
data was p <0.003. 
 Grubbs test for outliers (Grubbs, 1969) was conducted on all dependent 
variable prior to the two-way RM ANOVA. Grubbs test revealed outliers in 
aggressive response rate (percent of baselinePre-Dose), Social VAS (∆ scores), 
HR, Diastolic BP, and the Tension-Anxiety subscale of the POMS.  For these 
variables, analyses were conducted with and without the outliers. 
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Results 
Behavioral Data 
All aggressive response rates (percent of baselinePre-Dose) were tested 
using a two-way RM ANOVA testing for main effects of dose (Placebo vs OT) 
and session (sessions at 30, 90, and 150 min post-dose), and interaction of 
dose by session. The RM ANOVA found no statistically significant main effect of 
dose or session.  There was no statistically significant interaction of dose by 
session.  The results of the RM ANOVA without the outlier found no statistically 
significant main effect of dose or session, or any interaction of dose by session. 
Descriptive statistics for aggressive response rates (percent of baselinePre-Dose) 
are presented in Table 2.E.  Summary results from the RM ANOVAs are 
presented in Table 2.G. Visual presentation of aggressive response rates 
(percent of baselinePre-Dose) with and without the outlier are presented in Figures 
2.A through 2.D, for both the OT and placebo dose.   
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Aggressive  
Response Rate 
Minutes since Dose 
(Post-Dose Session) 
Mean (S.D.) 
Placebo 
n = 17 
  
 30 min 102 (28) 
 90 min 105 (45) 
 150 min 138 (115)1 
112 (48.3)2 
OT  (24 IU) 
n = 17 
  
 30 min 97 (34) 
 90 min 101 (24) 
 150 min 103 (54) 
Table 2.E Descriptive statistics of aggressive responding  
(percent of baselinePre-Dose) across all post-dose sessions for both doses.  
Presented are mean (S.D.) of the aggressive response rate data (percent of 
baselinePre-Dose). Superscript 1 refers to data with the outlier. Superscript 2 refers to 
data without the outlier. IU = international unit. n = sample size. 
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Dependent 
Variable 
Effect (df) F-score p(uncorr) p(Huyn-Feldtcorr) 
Aggressive  
Response Rate1 
     
 Main     
 Dose (1, 16) 0.78 0.39 0.39 
  
Session  
 
(2, 32) 
 
1.51 
 
0.23 
 
0.24 
  
Interaction 
    
  
Dose X 
Session 
(2, 32) 1.65 0.21 0.22 
Aggressive  
Response Rate2 
     
 Main      
 Dose (1,16) 0.63 0.48 0.48 
 Session  (2, 32) 1.05 0.36 0.36 
 Interaction     
 Dose X 
Session 
(2, 31) 0.6 0.56 0.56 
Table 2.G Summaries of the RM ANOVAs on aggressive response rates 
 (percent of baselinePre-Dose).  
Aggressive Response Rate1 refers to RM ANOVA model with the outlier in the 
aggressive response rate data (percent of baselinePre-Dose).  
Aggressive Response Rate2 refers to RM ANOVA model without the outlier in the 
aggressive response rate data (percent of baselinePre-Dose).  
 p(uncorr) = uncorrected p-value. p(Huyn-Feldtcorr)= corrected p-value for repeated measures 
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Behavioral peak effect data 
Peak effect data of aggressive response rates (percent of baselinePre-
Dose) under OT (mean = 101.8, S.D. = 58.5) and placebo (mean = 110.4, S.D. = 
44.3) were tested for violations of statistical assumptions. Shapiro-Wilk test of 
normality (S-W = 0.99, df (32), p = 0.99) was not significant and the Levene’s 
test of homogeneity of variance (F (1, 32) = 0.67, p = 0.41) was not significant. 
A paired-samples t-test comparing aggressive response rate (percent of 
baselinePre-Dose) at the peak effect data under OT to placebo dose for 
aggressive responding was not significant, t (16) = (-0.44, p = 0.65). Figure 2.E 
shows a dot plot of individual participant data for aggressive response rate 
(percent of baselinePre-Dose), at the peak effect data under OT and placebo dose. 
   
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 2.E Distributions of aggressive response rates 
(percent of baseline
Presented are the distributions of aggressive response rates at 
the peak effect for both dose levels. Black diamonds represent 
individual dat
represent the median value of aggressive response rates
(percent of baseline
Placebo median = 105 (IQR: 70 
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Pre-Dose) at the behavioral peak effect. 
a points for each participant. Orange crosses 
Pre-Dose). OT median = 110 (IQR: 72 
- 149).  IU = international unit
 
 
 
 
 
 
 
 
– 130). 
. 
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Behavioral data and personality traits. 
The Pearson r correlation coefficient between average aggressive 
response rates (percent of baselinePre-Dose) under OT and standardized scores 
of interpersonal manipulation + anger was statistically significant (r (16) = 0.57, 
p =0.01).  This result is opposite to the hypothesis of aim 2b. A scatter plot of 
average aggressive response rate under OT and combined interpersonal 
manipulation + anger scores is presented in Figure 2.F. Correlation coefficients 
between average aggressive response rate (percent of baselinePre-Dose) under 
placebo and standardized scores of combined interpersonal manipulation + 
anger were not statistically significant with the outlier (spearman rho (16) = -
0.03, p =0.9) or without (r (16) = -0.15, p = 0.54).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 2.F Scatterplot of aggressive response rates 
under OT dose and combined 
Manipulation and Anger. 
Plotted are mean aggressive response rates under OT on the y
subscales scores of Interpersonal Manipulation and Anger (Z
Mean refers to the mean of all three post
from each post-dose session 
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Social VAS data 
All Social VAS ratings of “likability” (∆ scores)  were tested using a two-
way RM ANOVA testing for main effects of dose (Placebo vs OT) and session 
(sessions at 30, 90, and 150 min post-dose), and interaction of dose by 
session. The RM ANOVA found no statistically significant main effect of dose or 
session.  There was no statistically significant interaction of dose by session.  
The results of the RM ANOVA without the outlier found no statistically 
significant main effect of dose or session, or any interaction of dose by session. 
Figures 2.G and 2.H show Social VAS ratings of “likability” for both OT and 
Placebo across all post-dose sessions. Descriptive statistics for all sessions 
across both dose levels are found in Table 2.H. Summary results from RM 
ANOVAs on Social VAS ratings of “likability” (∆ scores) are found in Table 2.I. 
 In subsequent exploratory analyses, raw Social VAS ratings (not 
converted into a difference score) were correlated with number of provocations, 
using all sessions and doses. To account for repeated measures, intraclass 
correlations coefficient (ICC) were calculated.  No statistically significant 
correlation was found between raw Social VAS ratings and the number of 
provocations the participant experienced on the PSAP, rICC (136) = -0.14, p = 
0.12, when the outlier in the Social VAS rating was present. There was no 
statistically significant correlation between raw Social VAS ratings and the 
number of provocations the participant experienced on the PSAP, rICC (135) = -
0.17, p = 0.06, when the outlier in the Social VAS ratings was removed. 
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Minutes since dose 
(Post-Dose Session) 
Placebo OT (24 IU) 
30 min  (1) -0.4 (0.9) 0.06 (0.65) 
 
90 min  (2) 
 
-0.18 (1.3) 
 
-0.35 (1.22) 
 
150 min (3) 
 
-0.81 (1.5)1 
-0.55 (1.2)2 
 
-0.41 (1.3) 
Table 2.H Descriptive statistics of Social VAS ratings (∆ scores) across 
all post-dose sessions for both doses.  
Data are presented as mean (S.D) for all Social VAS ratings.  
Superscript 1 refers to data with the outlier included. Superscript 2 refers to 
data without the outlier. (∆ scores: Post-Dose minus Pre-Dose). 
 IU = international unit. 
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Dependent 
Variable 
Effect (df) F-score p(uncorr) p(Huyn-Feldtcorr) 
Social VAS 
(∆ Scores)1 
     
 Main     
 Dose  
(1, 16) 
 
0.45 
 
0.52 
 
0.52 
  
Session 
 
(2, 32) 
 
2.51 
 
0.09 
 
0.09 
 Interaction     
  
Dose X 
Session 
 
(2, 32) 
 
2.16 
 
0.13 
 
0.13 
Social VAS 
(∆ Scores)2 
     
 Main     
 Dose (1, 16) 0.50 0.50 0.50 
 Session (2, 32) 2.02 0.15 0.15 
 Interaction     
 Dose X 
Session 
(2, 31) 1.98 0.13 0.13 
Table 2.I Summaries of the RM ANOVAs on all Social VAS ratings (∆ scores). 
Social VAS (∆ Scores)1 refers to RM ANOVA model with the outlier in Social VAS rating data.  
Social VAS (∆ Scores)2 refers to RM ANOVA model without the outlier in Social VAS rating data. 
p(uncorr) = uncorrected p-value. p(Huyn-Feldtcorr)= corrected p-value for repeated measures. 
(∆ scores: Post-Dose minus Pre-Dose). 
 
 Figures 2.G and 2.H 
across all post
Presented are the 
different post-
Minutes since dose: 30 Min, 90 Min, and 150 Min 
Post-Dose Session 1, 2, and 3, respectively. 
presented as mean (S.D.).
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Social VAS ratings of “likability” 
-dose sessions for both doses. 
Social VAS ratings over the course of three 
dose time points (sessions) for both dose levels
represent 
All data are 
 Figure 2.G contains data with the 
 
. 
  
. 
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Cardiovascular data 
 
All HR data (∆ scores)  were examined using a two-way RM ANOVA 
testing for main effects of dose (Placebo vs OT) and session (sessions at 30, 
90, and 150 min post-dose), and interaction of dose by session. The RM 
ANOVA found no statistically significant main effects of dose or any interaction 
of dose by session. When the outlier was present in the data, there was a 
statistically significant effect of session. However, when the outlier was 
removed from the data, there was no statistically significant effect of session.   
All Systolic BP data (∆ scores)  were examined using a two-way RM 
ANOVA testing for main effects of dose (Placebo vs OT) and session (sessions 
at 30, 90, and 150 min post-dose), and the interaction of dose by session. 
There were no statistically significant effects of dose or session. There was no 
statistically significant interaction of dose by session. 
All Diastolic BP data (∆ scores) were examined using a two-way RM 
ANOVA testing for main effects of dose (Placebo vs OT) and session (sessions 
at 30, 90, and 150 min post-dose), and interaction of dose by session. A 
statistically significant main effect of dose was found both, when the outlier was 
present in the data and when the outlier was removed from the data. There 
were no statistically significant effects of session or interaction of dose by 
session. Figures 2.I and 2.J show Diastolic BP data (∆ scores) for OT and 
Placebo across all post-dose sessions with and without the outlier.  
A statistically significant main effect of dose was found in the Diastolic 
BP data. Post-hoc analysis using Tukey’s honest square difference (Tukey, 
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1949) on Diastolic BP data without the outlier indicated OT significantly 
decreased BP across all participants (p = 0.05). Descriptive statistics for all 
cardiovascular data for all sessions across both dose levels are provided in 
Table 2.J. Summaries of the results from all of the RM ANOVAs on  all 
cardiovascular data (∆ scores) are provided in Table 2.K. Summaries of all raw 
cardiovascular data are found in the Appendix material. 
 
Cardiovascular 
measure 
Minutes since dose 
(Post-Dose 
Session) 
Placebo OT (24 IU) 
HR 
(∆ Scores) 
   
 30  min  (1) -2.8 (9.3)1 
-4.7 (4.5)2 
-2.9 (5.5) 
  
90  min  (2) 
 
-5.1 (5.2) 
 
-4.2 (6.7) 
  
150 min (3) 
 
-6.1 (8.5) 
 
-4.6 (6.3) 
Systolic BP 
(∆ Scores) 
   
 30 min   (1) 3.9 (6) -0.3 (6.8) 
  
90 min   (2) 
 
5.6 (7.8) 
 
2.2 (4.7) 
  
150 min (3) 
 
6.5 (6.5) 
 
3.2 ( 6.4) 
Diastolic BP 
(∆ Scores) 
   
 30 min   (1) 4.1 (6) 0.2 (4.4) 
  
90 min   (2) 
 
5.6 (7.8)1 
4.5 (5.3)2 
 
1.1 (5.2) 
  
150 min (3) 
 
4.4 (4.9) 
 
2.8 (5.9) 
 
 
Table 2.J Descriptive statistics of all cardiovascular data (∆ scores).  
Data are presented as mean (S.D) for all cardiovascular data. Superscript 1 refers to data 
with the outlier. Superscript 2 refers to data without the outlier.  
(∆ scores: Post-Dose minus Pre-Dose). IU = international unit. 
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Dependent 
Variable 
Effect (df) F-score p(uncorr) p(Huyn-Feldtcorr) 
HR 
(∆ Scores)1 
     
 Main     
 Dose (1, 16) 0.16 0.69 0.69 
  
Session  
 
(2, 32) 
 
4.41 
 
0.02 
 
0.02 
  
Interaction 
    
  
Dose X 
Session 
 
(2, 32) 
 
0.39 
 
0.68 
 
0.68 
HR 
(∆ Scores)2 
     
 Main     
 Dose (1, 16) 0.49 0.49 0.49 
 Session  (2, 32) 2.05 0.14 0.14 
 Interaction     
 Dose X 
Session 
(2, 31) 0.07 0.93 0.93 
Systolic BP 
(∆ Scores) 
     
 Main      
 Dose (1, 16) 2.75 0.11 0.11 
 Session  (2, 32) 1.64 0.2 0.2 
 Interaction     
 Dose X 
Session 
(2, 32) 1.76 0.18 0.18 
      
      
      
      
      
      
Table 2.K Summaries of the RM ANOVAs on all cardiovascular data (∆ scores). 
HR (Scores)1 refers to RM ANOVA model with the outlier in the HR data.   
HR (Scores)2 refers to RM ANOVA model without the outlier in the HR data. 
 p(uncorr) = uncorrected p-value. p(Huyn-Feldtcorr)= corrected p-value for repeated measures.  
(∆ scores: Post-Dose minus Pre-Dose). 
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Dependent 
Variable 
Effect (df) F-score p(uncorr) p(Huyn-Feldtcorr) 
Diastolic BP 
(∆ Scores)1 
     
 Main     
 Dose (1, 16) 6.73 0.01 0.01 
 Session  (2, 32) 0.83 0.44 0.44 
 Interaction     
 Dose X 
Session 
(2, 32) 1.02 0.37 0.37 
Diastolic BP 
(∆ Scores)2 
     
 Main     
 Dose (1, 16) 4.51 0.04 0.04 
 Session  (2, 32) 0.98 0.38 0.38 
 Interaction     
 Dose X 
Session 
(2, 31) 0.79 0.46 0.46 
(Continued from the previous page) 
 
Table 2.K Summaries of the RM ANOVAs on all cardiovascular data (∆ scores). 
Diastolic BP (Scores)1 refers to RM ANOVA model with the outlier in the Diastolic BP data.   
Diastolic BP (Scores)2 refers to RM ANOVA model without the outlier in the Diastolic BP data.  
p(uncorr) = uncorrected p-value. p(Huyn-Feldtcorr)= corrected p-value for repeated measures. 
(∆ scores: Post-Dose minus Pre-Dose). 
 
 Figures 2.I and 2.J Diastolic BP (
post-dose sessions for both doses
Presented are the Diastolic BP over the course of three different 
post-dose time points
are presented as mean (S.D.). 
Minutes since dose: 30 Min, 90 Min, and 150 Min represent 
Post-Dose Session 1, 2, and 3, respectively. 
presented as mean (S.D.). 
outlier. Figure 2.J contains data without the outlier.
 IU = international unit
 
Diasto
lic BP 
(∆ 
Score
s: 
Post-
Dose 
minus 
Pre-
Dose) 
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∆ scores) across three 
.  
 (sessions) for both dose levels. All data 
* = p<0.05, main effect of dose.  
All data are 
Figure 2.I contains data with the 
 
. IU = international unit. 
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Body Temperature data 
All BT  data (∆ scores) were examined using a two-way RM ANOVA 
testing for main effects of dose (Placebo vs OT) and session (sessions at 30, 
90, and 150 min post-dose), and the interaction of dose by session. The RM 
ANOVA found no statistically significant main effect of dose or session, or any 
interaction of dose by session. Descriptive statistics of BT data (∆ scores) 
across all sessions and both dose levels are presented in Table 2.L. Summary 
of RM ANOVA output on BT data (∆ scores) is found in Table 2.M. 
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Minutes since Dose 
(Post-Dose Session) 
Placebo OT (24 IU) 
30 min  (1) -0.08 (1.08) -0.46(1.04) 
 
90 min  (2)  
 
-0.14 (1.19) 
 
-0.13 (1.12) 
 
150 min (3)  
 
0.02 (1.36) 
 
-0.33 (0.82) 
Dependent 
Variable 
Effect (df) F-score p(uncorr) p(Huyn-Feldtcorr) 
BT 
(∆ Scores) 
     
 Main     
 Dose (1, 16) 0.75 0.40 0.40 
  
Session  
 
(2, 32) 
 
2.26 
 
0.12 
 
0.12 
  
Interaction 
    
 Dose X 
Session 
(2, 32) 0.13 0.87 0.87 
Table 2.M Summary of the RM ANOVA on BT data (∆ scores). 
p(uncorr) = uncorrected p-value. p(Huyn-Feldtcorr)= corrected p-value for repeated measures.  
(∆ scores: Post-Dose minus Pre-Dose). 
 
Table 2.L Descriptive statistics of BT data (∆ scores). 
Data are presented as mean (S.D.) of all BT data.  
 (∆ scores: Post-Dose minus Pre-Dose). IU = international unit. 
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POMS data 
All POMS subscales scores (∆scores) were analyzed with seven 
separate two-way RM ANOVAs (one for each subscale)  all testing for main 
effects of dose (Placebo vs OT) and session (sessions at 30, 90, and 150 min 
post-dose), and interaction of dose by session. For planned multiple 
comparisons of each POMS subscale (∆ scores), the Benjamini–Yekutieli false 
discovery rate (Benjamini & Yekutieli, 2001) was employed (to correct for 
multiple comparisons across the multiple subscales) in addition to the Huyn-
Feldt corrected p-values. The Benjamini–Yekutieli false discovery rate 
determined that a critical p-value (p < 0.003) should be used to signify statistical 
significance.  
After correction, a significant main effect of dose was found for the 
fatigue subscale of the POMS (F (1, 16) = 9.05, p
 (uncorr) = 0.002, p(corrHuyn-Feldt) = 
0.002). Post-hoc analysis using Tukey’s honest square difference (Tukey, 1949) 
indicated that under OT, participants reported less fatigue (p = 0.05), as 
compared to placebo.   
The RM ANOVA found no other statistically significant main effects of 
dose, or session or any interaction of dose by session. Descriptive statistics of 
POMS subscale data averaged across all sessions are presented in Table 2.N. 
Summaries of the results from all RM ANOVAs on all POMS subscales (∆ 
scores) are found in Table 2.O. Descriptive statistics of all raw POM subscales 
by session and dose are in the Appendix material 
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Subscale Placebo  OT (24 IU) 
Depression-Dejection 0 (0.41) -0.2 (0.5) 
 
Vigor 
 
-0.1 (2.8) 
 
1.0 (3.4) 
 
Confusion-
Bewilderment 
 
0.2 (0.5) 
 
-0.1 (0.4) 
 
Tension-Anxiety 
 
0.1 (0.7) 
 
0.2(1.3)1 
0.1(0.8)2 
Anger-Hostility 0.2 (0.6) -0.1 (0.8) 
Fatigue 0.8(1.5) -0.6(1.6) 
 Table 2.N Descriptive summaries of all POMS subscales (∆ scores). 
Data are presented as mean (S.D) from all POMS subscales. Superscript 1 
represents data with the outlier. Superscript 2 represents data without the 
outlier. (∆ scores: Post-Dose minus Pre-Dose). IU = international unit.  
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Dependent 
Variable 
Effect (df) F-score p(uncorr) p(Huyn-Feldtcorr) 
Depression- 
Dejection 
(∆ Scores) 
     
 Main     
 Dose (1, 16) 1.38 0.26 0.26 
  
Session  
 
(2, 32) 
 
0.58 
 
0.57 
 
0.54 
  
Interaction 
    
  
Dose X 
Session 
(2, 32) 0.94 0.40 0.37 
Vigor 
(∆ Scores) 
     
 Main      
 Dose (1, 16) 9.05 0.008 0.008 
 Session  (2, 32) 0.37 0.69 0.63 
 Interaction     
 Dose X 
Session 
(2, 32) 1.49 0.24 0.24 
Confusion- 
Bewilderment 
(∆ Scores) 
     
 Main     
 Dose (1, 16) 4.31 0.54 0.54 
 Session  (2, 32) 4.12 0.03 0.03 
 Interaction     
 Dose X 
Session 
(2, 32) 0.71 0.50 0.50 
      
      
      
      
Table 2.O Summaries of the RM ANOVAs on all POMS data (∆ scores) 
p(uncorr) = uncorrected p-value. p(Huyn-Feldtcorr)= corrected p-value for repeated measures.  
(∆ scores: Post-Dose minus Pre-Dose). 
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Dependent 
Variable 
Effect (df) F-score p(uncorr) p(Huyn-Feldtcorr) 
Tension-
Anxiety 
(∆ Scores)1 
     
 Main     
 Dose (1, 16) 0.20 0.66 0.66 
 Session  (2, 32) 0.73 0.49 0.48 
 Interaction     
 Dose X 
Session 
(2, 32) 3.15 0.06 0.08 
Tension-
Anxiety 
(∆ Scores)2 
     
 Main     
 Dose (1, 16) 0.09 0.77 0.77 
 Session  (2, 32) 0.15 0.86 0.86 
 Interaction     
 Dose X 
Session 
(2, 31) 2.78 0.07 0.08 
      
      
      
      
      
      
      
      
      
Continued from the previous page 
 
Table 2.O Summaries of the RM ANOVAs on all POMS data (∆ scores) 
Tension-Anxiety (Scores)1refers to RM ANOVA model with the outlier in the Tension-Anxiety data. 
Tension-Anxiety (Scores) 2refers to RM ANOVA model without the outlier in the Tension-Anxiety data. 
p(uncorr) = uncorrected p-value. p(Huyn-Feldtcorr)= corrected p-value for repeated measures.  
(∆ scores: Post-Dose minus Pre-Dose). 
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Dependent 
Variable 
Effect (df) F-score p(uncorr) p(Huyn-Feldtcorr) 
Anger-
Hostility 
(∆ Scores) 
     
 Main      
 Dose (1, 16) 1.31 0.27 0.27 
 Session  (2, 32) 3.33 0.04 0.08 
 Interaction     
 Dose X 
Session 
(2, 31) 0.16 0.85 0.71 
Fatigue 
(∆ Scores) 
     
 Main     
 Dose (1, 16) 12.97 0.002 0.002** 
 Session  (2, 32) 2.64 0.08 0.09 
 Interaction     
 Dose X 
Session 
(2, 32) 0.32 0.73 0.73 
Continued from the previous page 
 
Table 2.O Summaries of the RM ANOVAs on all POMS data (∆ scores) 
p(uncorr) = uncorrected p-value. p(Huyn-Feldtcorr)= corrected p-value for repeated measures.  
** = statistically significant after false discovery rate correction. 
(∆ scores: Post-Dose minus Pre-Dose). 
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Post-Hoc Power analysis 
 
This experiment was modelled after previous studies of OT using similar 
numbers of participants (Bakermans-Kranenburg & van IJzendoorn, 2013; 
Bethlehem et al., 2013) and previous studies using the PSAP methodology 
(Cherek et al, 2003; 2006). A post-hoc power analysis was conducted using 
Gpower 3.3, to provide post-hoc power estimates based on obtained effect 
sizes from the data. Table 2.P presents all effect sizes for all aims and their 
associated obtained power.  
Aim Effect size Obtained power 
2a: Aggressive 
Response Rate 
(Average) with outlier 
 
Cohen’s d = 0.21 
 
0.12 
 
2a: Aggressive 
Response Rate 
(Average) without outlier 
 
Cohen’s d = 0.14 
 
0.08 
 
2a: Aggressive 
Response Rate 
(Peak Effect) 
 
Cohen’s d= 0.11 
 
0.07 
 
2b: Personality Traits 
and Aggression 
 
Cohen’s f²= 0.49 
 
0.77 
 
2c: Social VAS ratings 
 with outlier 
 
 
Cohen’s d= 0.16 
 
0.09 
2c: Social VAS ratings 
 without outlier 
 
Cohen’s d= 0.15 
 
0.08 
 
 
 
 
 
 
Table 2.P Summary of post-hoc power analyses from the data. 
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Discussion 
The goal of Experiment 2 was to test if OT decreases human aggressive 
behavior. This experiment was designed to reduce the intra-subject and inter-
subject variability that was observed in Experiment 1 (chapter 2). In the 
previous experiment (chapter 2), changes in aggressive responding under OT 
were observed; however, these changes in aggressive responding were neither 
systematic nor orderly.  This experiment was designed to reduce subject 
variability in an attempt to (i) test the hypothesis that OT would reduce 
aggressive behavior and (ii) elucidate the direction of change in aggressive 
behavior following OT dosing. No statistically significant main effect of OT on 
aggression was found. The hypothesis that acute OT administration reduces 
aggressive behavior was not supported.  
Interestingly, there was a broad range of changes in aggressive 
responding on the PSAP under OT. Some participants increased their 
aggressive responding, whereas other participants decreased their aggressive 
responding under OT, suggesting (as in Experiment 1) individual differences 
played a role in moderating the effects. A positive correlation between the 
personality traits of interpersonal manipulation + anger and aggressive 
responding following OT dose was observed. This result is contrary to the 
hypothesized direction, in which it was predicted that those with highest levels 
of antisocial traits would show the greatest reductions.  This finding suggests 
that these antisocial personality traits (interpersonal manipulation and anger) 
might moderate the effects of OT on aggression. A study design that examined 
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the role of those two personality factors in a moderation- or mediation-based 
design (which would require a much larger sample size) could address this 
hypothesis more directly.  
If replicated and extended, this result may be clinically important 
because interpersonal manipulation and anger are key indicators of antisocial 
behavior. Alcorn III et al. (2013) found that psychopathic and aggressive 
personality traits were two key psychometric measures that identified 
ASPD+SUD individuals from SUD alone and healthy volunteers. Thus, by 
extension, OT may increase aggressive behavior in individuals who share 
personality traits consistent with ASPD+SUD groups. Additionally, this result 
could explain some of the variability observed in Experiment 1, in which 
increases in aggressive responding were observed in some participants 
following OT administration in ASPD+SUD.  However, this reasoning is 
speculative, and systematic replication of Experiment 1 using the design of this 
experiment would be needed to confirm this idea. Another interpretation of the 
positive correlation between interpersonal manipulation + anger and aggressive 
responding under OT is the possibility of a group by dose interaction. To fully 
test this notion, individuals who meet full diagnostic criteria for comorbid 
ASPD+SUD and healthy controls would need to be tested  using the design of 
Experiment 2, using pre-dose and post-dose sessions, and the same 
psychometric  questionnaires (e.g., interpersonal manipulation and anger). The 
hypothesis would be that ASPD+SUD individuals would increase in their 
aggressive responding following administration whereas healthy volunteers 
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(with lower interpersonal manipulation/anger) would decrease or show no 
change in their aggressive responding under OT.  
There are precedents in the OT and aggression literature to suggest a 
group by dose interaction.  Winslow & Insel (1991) found that in squirrel 
monkeys, behavioral responses (aggressive displays, sexual behavior, and 
approach behavior) following central administration of OT depend on 
dominance status. In dominant but not subordinate squirrel monkeys, 
aggressive, sexual, and approach behavior to a conspecific was increased 
following central administration of OT. Additionally, these behavioral responses 
in dominant squirrel monkeys were blocked following administration of an 
antagonist of OT. Similarly, Bartz et al. (2010) compared trust and cooperative 
behavior following OT administration in borderline personality disordered 
individuals (BPD) and healthy volunteers and found a significant group by dose 
interaction. Bartz et al. (2010) reported that BPD individuals receiving OT 
exhibited decreased levels of trust and cooperative behavior, whereas higher 
levels of trust and cooperative behavior were observed in healthy volunteers.  
Group by dose interactions have also been reported in aggressive responding. 
Cherek et al. (2002b) reported that, compared to individuals with a history of 
conduct disorder (CD), individuals without a history of CD increased in their 
aggressive responding on the PSAP following acute administration of baclofen, 
a gamma-aminobutyric acid-B agonist; individuals with a history of CD actually 
decreased aggressive responding on the PSAP following acute administration 
of baclofen.   
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Experiments 1 and 2 provide an initial suggestion that individual 
differences in antisocial personality traits modulate to human aggressive 
responding following acute OT administration. Experiment 2 provides insight 
about which target individual differences to be considered for future research in 
this area.  
There was not a statistically significant main effect of OT on ratings of 
likability. OT dose did not alter social judgments of the “other person” following 
interactions on the PSAP. The rationale for measuring ratings of “likability” was 
to test if OT changed social judgment of the “other person” following a social 
interaction that elicits aggressive responding. Thus, this aim was proposed in 
order to elucidate a possible source of socio-cognitive variability that could have 
occurred under OT and possibly be related to aggressive behavior. However, 
there was no effect of OT on social cognition within this experiment and 
changes in aggressive behavior following OT were not associated with changes 
in social judgment.   
 Unlike Experiment 1, Experiment 2 OT significantly reduced BP in 
participants. This result provides confirmation that OT was biologically active, 
as previous literature has also reported decreases in BP following OT 
administration (Petersson et al., 1996; Rosseland et al., 2013).  The 
discrepancy in a main effect of OT on diastolic BP could be related to the fact 
that ASPD+SUD populations have reduced resting cardiovascular functioning 
(Lorber, 2004; Patrick, 2008) or to altered blood pressure in substance abuse 
 127  
 
populations (Dickley et al., 2002), or to differences in sample sizes between the 
two experiments.  
Experiment 2 found a statistically significant main effect of OT on 
decreasing fatigue. Previous studies in both healthy and clinical populations 
have reported changes in mood following OT.  Healthy participants under OT 
reported decreased ratings of vigor on the POMS following a visual memory 
task (Bruins et al., 1992) and alcoholic patients undergoing detoxification 
reported decreased ratings of tension and anxiety on the POMS following OT 
dosing (Pedersen  et al., 2013).  Thus, across different contexts, dose related 
changes in mood have been reported.  However, given that there were no 
statistically significant main effects of OT on participant’s behavior or social 
judgments in this experiment, the context in which dose related decreases in 
fatigue occurred is unclear. Future investigations are needed to appropriately 
identify possible controlling variables in dose related changes in mood. 
This experiment has several limitations that impact interpretation of the 
results. First, for the majority of the data collected, the calculated effect sizes 
are small (range: 0.11 - 0.49).  A meta-analytic study of OT effects conducted 
by Bakermans-Kranenburg & van IJzendoorn (2013) found small to moderate 
effect sizes (Cohen’s d:  0.2 - 0.5), comparing OT to placebo dose in various 
disorders ranging from autism-spectrum to social anxiety to schizophrenia. 
Sources of the discrepancies between these moderate effects sizes and the 
small effect size obtained in this study are unclear, but may relate to 
measurement techniques and/or study design. Additional limitations relate to 
 128  
 
the positive correlation found between personality traits of interpersonal 
manipulation + anger, and aggressive behavior under OT. This correlation was 
found in a non-clinical sample using combined scores of these two personality 
traits.  Generalizability of this finding to ASPD+SUD populations should be 
cautious as additional research with these individuals is needed to appropriately 
address this issue. These personality traits (anger and interpersonal 
manipulation) were selected based on a statistical profile ASPD+SUD 
individuals in Alcorn III et al. (2013) as well as previous studies in clinical 
populations (Alia-Klein et al., 2009; Vaillancourt & Sunderani, 2011). However, 
this combination of personality traits does not have an established cut-off score 
that would distinguish clinically relevant groups. Thus, these personality traits 
are a proxy for antisocial characteristics rather than clinical marker of 
ASPD+SUD pathology.  
Another limitation of Experiment 2 relates to the limited dose range.  This 
experiment used one dose level (24 IU) which was the middle dose for 
Experiment 1 and a commonly used dose level in OT studies (Bakermans-
Kranenburg & van IJzendoorn, 2013; Shahrestani et al., 2013 ). Future studies 
examining individual differences in acute OT effects on aggression and other 
antisocial behaviors should test across a full does range (when logistically 
feasible). Additionally, Experiment 2 provided no biological index (e.g., CNS or 
peripheral markers of OT levels) following intranasal administration. Currently, 
there are no pharmacokinetic data about the absorption and distribution of 
neuropeptides following intranasal administration. The best approximation in 
 129  
 
these data is the main effect of OT dose on BP. This is a limitation of intranasal 
administration procedures due to uncertainty around OT levels actually present 
in the CNS during testing. Lastly, both experiment 1 and 2 are limited to 
aggressive behavior under OT in males. The present experiments do not 
address gender effects with OT. 
Collectively, the results of Experiment 2, (i) extend the data of acute OT 
effects in relation to moderating social behavior, (ii) elucidate sources of 
individual differences related to aggressive behavior in the context of the OT; 
and (iii) tentatively suggest that OT may not be an efficacious therapeutic for 
managing aggression in individuals with antisocial traits or diagnosis of 
ASPD+SUD.   
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CHAPTER 4: DISCUSSION AND FUTURE DIRECTIONS 
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Concluding commentary on Experiments 1 and 2: 
The goal of this dissertation was to examine the effects of oxytocin (OT) 
on human aggression.  Aggression represents a class of antisocial behavior 
that is particularly prevalent in individuals with Antisocial Personality Disorder 
(ASPD) and substance abuse (Allen et al., 1997; Moeller et al., 1998; APA, 
2000; Alcorn III et al., 2013). Aggression in these individuals can manifest at 
maladaptive levels that place a burden on society and public health systems. 
The overarching hypothesis of this dissertation was that OT would decrease 
aggressive behavior.  This hypothesis was tested in two different experiments 
but was not supported. The experiments of this dissertation provide limited 
information about the association between OT and human aggression and 
suggest that personality traits may be a factor in predicting individual 
differences in response to OT.  
 The goal of Experiment 1 was to test the hypothesis that OT decreases 
aggression in ASPD and substance use disordered (SUD) participants, and to 
potentially provide an indication of which OT dose level would provide the 
biggest reduction in aggression. Experiment 1 was the first study to test if OT 
would dose-dependently decrease aggression in a clinically relevant population, 
across a range of doses. The hypothesis of Experiment 1 was not supported.  
Data from Experiment 1 suggested that the experimental design was 
susceptible to high intra-subject and inter-subject variability which prevented 
clear conclusions about the direction and magnitude of OT dosing on 
aggressive behavior. In order to better understand individual differences, a 
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single subject data analytic approach was conducted.  At the single-subject 
level, an exploratory analysis of inter-response time (IRT) distributions in 
aggressive responding was conducted in conjunction with the primary 
dependent measure of overall aggressive response rate (i.e. aggressive 
responses per minute). Experiment 1 was the first study to analyze IRT 
distributions of aggressive responding on the Point Subtraction Aggression 
Paradigm (PSAP). The decision to analyze IRT distributions was motivated by 
the possibility that IRT distributions could reveal information about OT on 
aggression. IRT analyses provide information at fine-grained temporal 
resolution; this information is unique from the overall response rate. Across both 
levels of behavioral analysis (i.e. overall aggressive response rate and IRT 
distributions), changes in aggressive responding following OT administration 
were observed.  However at both levels of analysis, these changes in 
aggressive responding were neither orderly nor systematic across participants, 
and in some instances not within the same participant. Experiment 1 concluded 
that observed changes in behavior under OT were specific to aggression (a 
social behavior) and were not a product of stimulation or sedation from OT 
administration. Support for these conclusions was provided by the observation 
that there were few changes in monetary-reinforced responding (non-social 
behavior), which occurs at a high rate and indexes motor coordination. 
However, the variability that was dose related could not be distinguished from 
non-experimental sources of variability, such as shifts in baseline responding.  
Additionally, identification of any variability related to individual differences (e.g., 
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ASPD characteristics, specific drug of abuse, and history of violence) could not 
be identified in the data. The conclusions in Experiment 1 were therefore 
restricted to qualitative rather than quantitative interpretations.  
 To overcome the intra-subject and inter-subject variability of Experiment 
1 in ASPD+SUD participants, Experiment 2 was designed to reduce variability 
in order to test the hypothesized effects of OT on aggressive behavior. The 
hypothesis of Experiment 2 was that OT administration will reduce aggressive 
behavior. In addition to testing the hypothesis under more stringent 
experimental control, Experiment 2 explored whether personality traits related 
to aggression in the context of ASPD+SUD (e.g., interpersonal manipulation 
and anger, Alcorn III et al., 2013) were related to changes in aggression under 
OT. In addition to testing aggression, a sub-hypothesis of Experiment 2 was 
that OT would increase prosocial judgment of the “other person” in the Point 
Subtraction Aggression Paradigm (PSAP). The rationale for this aim was based 
on prior evidence from human and non-human studies that OT increases 
prosocial cognition (Domes et al., 2007a; Guastella et al., 2008; 2010) and 
affiliative behaviors towards a conspecific (Carter et al., 2008; Lee et al., 2009a; 
Williams et al., 1994). 
 Experiment 2 reduced intra-subject sources of variability by establishing 
stable baseline responding before each dose. However, there were no 
statistically significant main effects of OT on aggressive behavior or social 
judgment. Instead, there was higher than anticipated levels of between subject 
variability following OT dosing, which suggesting individual differences may 
 134  
 
have influenced the results. The aim of examining personality traits was to 
identify a source of variability that might be significantly associated with 
aggression under OT.  Correlational analysis of interpersonal manipulation and 
anger personality traits and aggression under OT revealed a statistically 
significant positive association; individuals who reported higher levels of 
interpersonal manipulation + anger were positively correlated with higher levels 
of aggressive behavior. Importantly, these two personality traits are part of a 
constellation of clinically relevant personality factors that statistically identify 
ASPD+SUD individuals from SUD only and healthy volunteers (Alcorn III et al., 
2013). In relating the results of Experiment 2 to the goals of Experiment 1, this 
positive association between interpersonal manipulation + anger and 
aggressive behavior under OT suggests that OT may not be an efficacious 
therapeutic for treating aggression observed in populations characterized by 
those traits (e.g., ASPD and SUD). The results of Experiment 2 (i) provided 
information that could be used for further investigations of OT on antisocial 
behavior, and (ii) identified a source of individual difference variability that may 
be relevant for understanding the clinical utility of OT as a therapeutic.   
 There are two differences in data analysis between Experiments 1 and 2. 
First, IRT distributions were not analyzed in Experiment 2. The rationale for not 
including analysis of IRT distributions in Experiment 2 is that analysis of IRT 
distributions is restricted to single subject level and statistical comparisons 
pooled from data across participants are not meaningful (Iversen, 1991; Payla, 
1992).  A second difference in data analysis between Experiment 1 and 
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Experiment 2 relates choosing the peak effect. In Experiment 1, the 
pharmacological peak effect was chosen because there were no orderly or 
systematic effects of OT on aggressive behavior across sessions or 
participants. Therefore, the session conducted 90 minutes after dose 
administration was chosen as the pharmacological peak effect because this 
time point approximates the average post-dose time point in which 
neuropeptides reach their highest level of central nervous system (CNS) 
accumulation in humans (Born, 2002).  The peak effect in Experiment 2 was 
identified behaviorally, because there was a baseline (pre-dose) session from 
which the maximal change in aggressive responding following OT dose could 
be identified.  This allowed for the possibility of individual differences in the time 
course of biological and psychological effects across participants, which are 
commonly seen in behavioral pharmacology (Cherek & Lane, 2001; Lane et al., 
2008; Lane & Gowin, 2009; Rush et al., 2011; Sevak et al., 2009; Stoops et al., 
2008). 
 Experiments 1 and 2 provide unique types of information about 
aggressive behavior following acute OT administration. Neither experiment was 
consistent with the overall hypothesis but each identified statistically significant 
individual differences in response to OT that were specific to aggressive 
behavior. These differences were observed both via confirmatory and 
exploratory data analytic approaches. Confirmatory and exploratory data 
analyses are two methods of conducting research, and when used together 
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provide a broader understanding of data that is important for understanding and 
furthering scientific investigation (Tukey, 1980). 
 
Aggression and Oxytocin 
 The rationale for the overall hypothesis of this dissertation follows from 
the “prosociality model of OT function” (Ebitz & Platt, 2014). In this model, 
endogenous release of OT or exogenous administration of OT during a social 
interaction is thought to promote the generation of prosocial behaviors in 
response to social signals from conspecifics. Given that aggression is 
characterized, in part, by social behaviors that are opposite to prosocial 
behavior, it was predicted that aggression following OT dosing should 
decrease.  In Experiments 1 and 2, there were individuals whose aggressive 
behavior under OT followed in the predicted direction (i.e., their aggressive 
behavior decreased under OT). However, aggressive behavior across all 
individuals did not systematically follow this model’s predicted direction. In 
Experiments 1 and 2, there were individuals whose aggressive behavior 
increased following OT dosing. The prosociality model of OT function does not 
account for effects of OT dosing that increase the aggressive behavior of these 
individuals. Thus, a limitation of this model is that it does not account for 
instances in which OT administration results in behavior that is not prosocial.  
 There is some evidence in both human and non-human animal literature 
which to suggesting that OT does not always promote prosocial behavior. For 
example, Shamay-Tsoory et al. (2009) found that OT administration increased 
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schadenfreude (gloating at the expense of others) in human participants when 
monetary losses were incurred to another (fictitious) person. Bartz et al., (2010) 
found that OT diminishes cooperation and trust in individuals with borderline 
personality disorder (BPD). Chang et al. (2012) found that in rhesus monkeys, 
OT increased selfish choices when monkeys were faced with the choice of 
either giving a reward to itself or to another monkey. De Dreu (2012) reported 
increased threat perception of individuals from other groups following OT 
administration. To account for the contexts in which OT does not uniformly 
engender prosocial behavior, Ebitz & Platt (2014) proposed “the adaptive 
component process model of OT function”. According to the adaptive 
component process model of OT function, endogenous release or exogenous 
delivery of OT engenders social behavior patterns that are adaptive in response 
to perceived signals from conspecifics during social interactions. OT increases 
prosocial behavior in contexts when prosocial behavior is perceived by the 
organism to be adaptive and reduces prosocial behavior in contexts when it is 
not perceived by the organism to be adaptive. In this model, behavioral 
responses following OT release or administration can vary across different 
individuals and contexts.  The adaptive component process model also 
describes the variation in the activity of the OT system with respect to variation 
in social behavior.  For example, prairie voles are a monogamous rodent 
species that form pair-bonds dependent on the endogenous release of OT 
following mating (Williams et al., 1994). There is a related vole species called 
meadow voles that are polygamous and do not form pair-bonds following 
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mating. Insel & Shapiro (1992) demonstrated that prairie voles had higher 
densities of the OT receptor in their nucleus accumbens (NAcc) and prelimbic 
cortex (PLC) compared to meadow voles. The adaptive component process 
model states that in prairie voles, affiliative signals following mating result in the 
endogenous release of OT, which in turn activates reward processing circuitry 
in the NAcc and PLC to form pair-bonds. Since meadow voles have lower 
densities of OT receptors in their NAcc and PLC compared to prairie voles, pair 
bonds don’t form in meadow voles when OT is released during the same 
interaction (i.e., mating). Thus, the adaptive component process model of OT 
function can account for variation in social behaviors following OT 
administration and release.   However, the adaptive component process model 
of OT function does not directly model OT in the context of aggressive behavior 
in psychiatric groups, or how expression of aggressive behavior following OT 
would vary across individuals. It is possible, however, that humans have (a) 
greater variation in expression of both OT and OT receptor density and (b) 
greater variation in complexity and history of social interactions. These factors 
may have contributed to the variation among participants in the present 
experiments, and would in this extended manner, be consistent with the notions 
posited by the adaptive component process model of OT function. 
 In the context of human aggression, the general aggression model 
(GAM) posits cognitive and emotional variables within a person that lead to 
aggressive acts. For example, the GAM describes how individuals, who 
experience more anger, are more likely to express acts of aggression in 
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response to provocation (Anderson & Bushman, 2002). Within the context of 
Experiment 2 of this dissertation, anger was identified as a predictor of 
aggressive behavior following OT administration. In Experiment 2, individuals 
with higher anger related personality traits increased in their aggressive 
behavior under OT.  However, the GAM is a theoretical model that broadly 
accounts for the episodes of human aggression, and does not make specific 
predictions regarding OT or other biochemical systems.  
 Aggression is a social behavior mediated in part by the OT system. 
Given that in Experiments 1 and 2 there were instances of increased 
aggression following OT administration in some individuals but not in others, 
future studies OT in human  aggressive behavior should consider individual 
differences related to both personality and biological factors .   
 
Future Directions 
 This dissertation provides a small step in examining aggression and its 
relation to the OT system.  The experiments reported individual differences in 
aggression following OT administration. Future investigations of individual 
differences (using a biopsychosocial model) could examine biological variables 
in conjunction with personality variables. For example, examining the interaction 
between endogenous levels of testosterone, psychopathic and anger traits, and 
OT may help explain the variability in aggression following OT administration. 
Winslow & Insel (1991) reported that central administration of OT resulted in 
increased aggression in dominant squirrel monkeys but not subordinate squirrel 
 140  
 
monkeys.  Winslow & Insel (1991) also reported that dominant squirrel monkeys 
had higher levels of testosterone compared to subordinate squirrel monkeys. 
Since (a) higher levels of testosterone have been known to predict aggression 
in both humans and non-humans (Archer, 2004; Soma, 2006; Carré et al., 
2011) and (b) higher levels of testosterone are found in individuals with 
persistent antisocial behavior (Yildirim & Derksen, 2012a) and individuals with 
interpersonal affective deficits (Yildirim & Derksen, 2012b), future studies 
should test if baseline differences in levels of testosterone predict aggression 
following OT administration.  Such a study could follow from Experiment 2 of 
this dissertation, since psychopathic and aggressive personality traits were 
associated with increased aggression under OT, and these traits are prevalent 
in antisocial individuals (Alcorn III et al., 2013; Nouvion et al., 2007) who are 
also reported to have higher levels of testosterone (Yildirim & Derksen, 2012a). 
  Another future direction would be to examine the interaction between 
serotonin (5-hydroxytryptamine; 5-HT) and OT administration in aggression. In 
this dissertation, some individuals showed decreased aggression following OT 
administration. 5-HT is a known modulator of aggression in both human and 
non-human animal species and decreased central levels of serotonin are 
associated with increased levels of aggression (Higley et al., 1992; Krakowski, 
2003; Mehlman et al., 1994; Moore et al., 2002). Levels of 5-HT could interact 
with OT and may help explain the variability in aggression following OT 
administration. Krakowski (2003) suggested that 5-HT is an important 
modulator for social bonds. Dölen et al. (2013) reported that the processing of 
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social rewards during rodent social interaction requires coordinated activity from 
OT and 5-HT.  Given that administration of drugs that increase 5-HT 
transmission are known to decrease human aggressive behavior (Cherek & 
Lane, 1991, 2001; Cherek et al., 2002a; Gowin et al., 2010) and increase 
feelings of sociability (Kirkpatrick et al., 2014), it is possible that OT could 
interact with baseline levels of 5-HT.  Specifically, in individuals with higher 
baseline levels of 5-HT, OT might actually decrease aggression. By contrast, in 
those with high baseline levels of testosterone, OT might increase aggression. 
 Future studies also could examine associations between aggression and 
variation in the OT receptor gene. One key target is the C allele of the OT 
receptor gene single nucleotide polymorphism (SNP) rs1042778. Malik et al. 
(2012) found that males with a history of childhood-onset aggression had a 2.5 
fold over-representation of the C allele in the SNP rs1042778, compared to 
males who had no history of childhood-onset aggression. Interestingly, in this 
sample of individuals with childhood-onset aggression, 83% met diagnostic 
criteria for a history of conduct disorder, which is a childhood disorder required 
to precede full diagnostic criteria for ASPD in adulthood (APA, 2000). Given that 
antisocial personality traits accounted for part of the individual difference 
variability in aggression following OT administration in Experiment 2, the allelic 
expression of SNP rs1042778 could be an additional source of individual 
difference variability in the expression of aggression following OT 
administration.  
 142  
 
 Lastly, an important future direction is the impact of childhood trauma in 
mediating or moderating effects of OT on human aggressive behavior.  Studies 
with rhesus monkeys showed that rearing conditions modulated CNS 
expression of OT.  Specifically, Winslow et al (2003) observed that lower 
cerebral spinal fluid levels of OT were found in rhesus monkeys that were not 
maternally reared, compared to those that were maternally reared.  The rhesus 
monkeys that were not maternally reared also showed higher displays of 
aggressive behavior compared to those that were maternally reared.  Childhood 
trauma is known to be a predictor of emotional response to affective stimuli 
following OT, and a predictor for later violence (Widom, 1989). In individuals 
with BPD, the acute effects of oxytocin on stress reactivity were predicted by 
childhood trauma (Simeon et al., 2011).  Specifically, in individuals with BPD 
who were given an acute OT dose, emotional response to stress was 
attenuated, and childhood trauma was the strongest predictor of oxytocin's 
attenuation of the emotional response to stress. Regarding the association 
between childhood trauma and aggression, Gowin et al. (2013) found that a 
history of childhood trauma was a significant predictor of increased aggressive 
behavior.  The elucidation of relationships among childhood trauma, OT, and 
aggression appears warranted.  
 The suggested studies could provide information about individual 
differences in biological factors and personality traits, and personal history that 
would provide excellent tests of the adaptive component process model of OT 
function (Ebitz & Platt, 2014). 
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Conclusion 
 In conclusion, Experiments 1 and 2 revealed substantial individual 
differences in aggression following OT administration. Unfortunately, the 
directional hypothesis that OT would systematically decrease aggression was 
not supported. These experiments indicate that further information regarding 
variables that influence acute OT effects are required before conclusions can 
be reached about the utility of OT in the management of aggression.  
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APPENDIX MATERIAL FOR EXPERIMENT 1 (CHAPTER 2) 
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A1.A Summary of the behavioral data from the PSAP  
 
Aggressive Response Rate 
Minutes Post-Dose 
(session) 
 
Placebo 
 
OT (12 IU) 
 
OT (24 IU) 
 
OT 48 (IU) 
30 min (1) 7.5 (4.7) 7.49 (2.7) 6.04 (3.2) 10.05 (3.4) 
90 min (2) 9.58 (4.6) 6.94 (5.7) 9.96 (6.3) 11.07 (6) 
150 min (3) 8.46 (2.9) 8.58 (4.8) 12.11 (9.2) 10.1 (4.4) 
210 min (4) 13.3 (8.4) 13.88 (8.1) 10.13 (5.3) 8.63 (1.6) 
Mean (S.D.) on the aggressive response option (responses per minute) for 
each dose and each PSAP session. 
Taken from Alcorn III et al. (In Press)  
 
 
 
Monetarily-reinforced Response Rate 
Minutes Post-Dose 
(session) 
 
Placebo 
 
OT (12 IU) 
 
OT (24 IU) 
 
OT 48 (IU) 
30 min (1) 4.54 (0.5) 4.57 (0.3) 4.59 (0.5) 4.1 (0.7) 
90 min (2) 4.49 (0.5) 4.45 (0.5) 4.62 (0.3) 4.08 (0.7) 
150 min (3) 4.75 (0.6) 4.76 (0.4) 4.41 (0.3) 4.64 (0.8) 
210 min (4) 4.5 (0.4)  4.58 (0.4)  4.6 (0.4)  4.53 (0.8)  
Mean (S.D.) on the monetary-earning response option (responses per second) 
for each dose and each PSAP session. 
Taken from Alcorn III et al. (In Press)  
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A1.B Descriptive summaries of Inter-Response Times  
Median (Inter-Quartile Range) Inter-response Times in milliseconds for each 
participant at each dose on the aggressive response option.  Data are 
presented from session 2 (90min Post-Dose). 
 
 
Subject Placebo OT (12 IU) OT (24 IU) OT 48 (IU) 
s13121 
Median (IQR) 
Range 
 
172 (156-188) 
125-578 
 
 
172 (156-187) 
110-484 
 
156 (141-187) 
94-437 
 
172 (157-203) 
125-515 
s13146 
Median (IQR) 
Range  
 
187(172-188) 
110-580 
 
157 (141-172) 
109-515 
 
        a 
 
 
 
172 (171-188) 
110-391 
s13214 
Median (IQR) 
Range  
 
328 (297-359) 
218-579 
 
250 (234-297) 
156-563 
 
281 (250-343) 
172-578 
 
266 (265-297) 
218-453 
 
s13234 
Median (IQR) 
Range  
 
 
172 (156-172) 
125-218 
 
 
172 (156-187) 
140-203 
 
 
187 (172-203) 
140-250 
 
 
187 (172-203) 
78-469 
 
s13246 
Median (IQR) 
Range 
 
 
187 (171-203) 
109-578 
 
 
172 (156-188) 
110-578 
 
 
172 (156-188) 
109-548 
 
 
172 (156-202) 
109-516 
 
s13285 
Median (IQR) 
Range 
 
172 (172-187) 
156-219 
 
219 (219-250) b 
218-250b 
  
188 (172-188) 
156-220 
 
172 (156-175) 
141-188 
 
a = 24 IU dose data lost for this subject due to hardware malfunction 
b = session for this subject was 15 min instead of 25 min, due to experimenter 
error. 
Taken from Alcorn III et al. (In Press)  
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A1.C summaries of cardiovascular data  
 
Heart Rate Data 
 
Minutes since Dose 
 (session) 
 
Placebo 
 
OT (12 IU) 
 
OT (24 IU) 
 
OT 48 (IU) 
-30 min 80.16 (10.7) 77.33 (11.3) 81.6 (13.7) 80 (15.7) 
30 min  (1) 72.33 (11.5) 68.5 (8.7) 74.76 (11.7) 70.5 (15.7) 
90 min  (2) 68.83 (10.8) 65.16 (9.6) 72 (12.6) 67.5 (11.3) 
150 min (3) 67.5 (6.6) 63.8 (9.4) 67.1 (10.3) 66.5 (10.8) 
210 min (4) 65.4 (8.1) 61.2 (7.5) 68 (12.5) 66.6 (11.3) 
Mean (S.D.) on the Heart Rate (beats per minute) for each dose and each 
session.  Minutes since dose (-30 refers to the Pre-Dose values. 30, 60, 150, 
210 min, refer to sessions 1, 2, 3, 4, respectively). IU =international unit. 
Taken from Alcorn III et al. (In Press)  
 
 
 
Systolic Blood Pressure Data 
 
Minutes since Dose 
(session) 
 
Placebo 
 
OT (12 IU) 
 
OT (24 IU) 
 
OT 48 (IU) 
-30 min 114 (10.6) 115.66 (14.3) 116.5 (11.7) 116 (10.4) 
30 min  (1) 118 (11) 116.5 (11.2) 118.8 (8.1) 117 (7.9) 
90 min  (2) 114 (11.8) 118 (10.9) 118 (8.2) 123.8 (8.4) 
150 min (3) 115 (8.9) 119 (12.8) 119 (9.8) 120.3 (11.8) 
210 min (4) 121(9.7) 119 (7.9) 123 (8.3) 115 (8.7) 
Mean (S.D.) on the Systolic Blood Pressure (mmHG) for each dose and each 
session. Minutes since dose (-30 refers to the Pre-Dose values. 30, 60, 150, 
210 min, refer to sessions 1, 2, 3, 4, respectively). IU =international unit. 
Taken from Alcorn III et al. (In Press)  
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Diastolic Blood Pressure Data 
 
Minutes since Dose 
(session) 
 
Placebo 
 
OT (12 IU) 
 
OT (24 IU) 
 
OT 48 (IU) 
-30 min 75.16 (5.9) 77.8 (9.9) 75.5 (11.5) 76.8 (8.8) 
30 min  (1) 75.16 (10.5) 78.1 (8.2) 75.5 (9.5) 77.5 (7.1) 
90 min  (2) 76.66 (9.2) 78 (8.6) 80 (7.9) 78.6 (8.2) 
150 min (3) 75.66 (6.4) 77 (7.5) 77.8 (8.9) 77.1 (9.7) 
210 min (4) 79.2 (9.2) 76.8 (4.3) 80.6 (10.5) 76.4 (9.4) 
 
Mean (S.D.) on the Diastolic Blood Pressure (mmHG) for each dose and each 
session. Minutes since dose (-30 refers to the Pre-Dose values. 30, 60, 150, 
210 min, refer to sessions 1, 2, 3, 4, respectively). IU =international unit. 
Taken from Alcorn III et al. (In Press)  
 
 
 
 
 
A1.G Psychometric total scores for all ASPD+SUD participants. 
 
Participant SRP-III BPAQ BIS-11 IPAS-IA IPAS-PM 
s13121 
 
196 69 52 29 30 
s13146 169 77 63 27 24 
s13214 184 52 70 31 29 
s13234 166 88 61 39 22 
s13246 205 88 76 37 23 
s13285 178 88 67 22 28 
SRP-III = Self Report of Psychopathy Scale – III Total Score; BPAQ = 
Buss-Perry Aggression Questionnaire Total Score; BIS-11 = Barratt 
Impulsiveness Scale – 11 Total Score; IPAS-IA = Impulsive 
Premeditated Aggression Scale – Impulsive Subscale Total Score; IPAS-
PM = Impulsive Premeditated Aggression Scale – Premeditated 
Subscale Total Score. 
Taken from Alcorn III et al. (In Press)  
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A1.H Psychometric Measures. 
 
Self-Report of Psychopathy –III (SRP-III) 
 
Please rate the degree to which you agree with the following statements about you.  
You can be honest because your name will not be connected to these answers.  
 
 
 
1. I‟m a rebellious person.   
2. I‟m more tough-minded than other people.       
3. I think I could "beat" a lie detector.   
4. I have taken illegal drugs (e.g., marijuana, ecstasy).       
5. I have never been involved in delinquent gang activity.  
6. I have never stolen a truck, car or motorcycle.  
7. Most people are wimps.   
8. I purposely flatter people to get them on my side.   
9. I‟ve often done something dangerous just for the thrill of it.   
10. I have tricked someone into giving me money.  
11. It tortures me to see an injured animal.        
12. I have assaulted a law enforcement official or social worker.   
13. I have pretended to be someone else in order to get something.    
14. I always plan out my weekly activities.         
15. I like to see fist-fights.   
16. I‟m not tricky or sly.        
17. I‟d be good at a dangerous job because I make fast decisions.   
18. I have never tried to force someone to have sex.  
19. My friends would say that I am a warm person.      
20. I would get a kick out of „scamming‟ someone.   
21. I have never attacked someone with the idea of injuring them.  
22. I never miss appointments.   
23. I avoid horror movies.           
24. I trust other people to be honest.       
25. I hate high speed driving.          
26. I feel so sorry when I see a homeless person.   
27. It's fun to see how far you can push people before they get upset.   
28. I enjoy doing wild things.   
29. I have broken into a building or vehicle in order to steal something or vandalize.     
30. I don‟t bother to keep in touch with my family any more.       
31. I find it difficult to manipulate people.        
32. I rarely follow the rules.    
33. I never cry at movies.    
1  2  3  4  5  
Disagree 
Strongly  
Disagree  Neutral  Agree  Agree   
Strongly  
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34. I have never been arrested.    
35. You should take advantage of other people before they do it to you.      
36. I don‟t enjoy gambling for real money.        
37. People sometimes say that I‟m cold-hearted.    
38. People can usually tell if I am lying.         
39. I like to have sex with people I barely know.   
40. I love violent sports and movies.     
41. Sometimes you have to pretend you like people to get something out of them.  
42. I am an impulsive person.    
43. I have taken hard drugs (e.g., heroin, cocaine).    
44. I'm a soft-hearted person.          
45. I can talk people into anything.    
46. I never shoplifted from a store.    
47. I don‟t enjoy taking risks.          
48. People are too sensitive when I tell them the truth about themselves.    
49. I was convicted of a serious crime.  
50. Most people tell lies everyday.     
51. I keep getting in trouble for the same things over and over.   
52. Every now and then I carry a weapon (knife or gun) for protection.   
53. People cry way too much at funerals.   
54. You can get what you want by telling people what they want to hear.   
55. I easily get bored.        
56. I never feel guilty over hurting others.   
57. I have threatened people into giving me money, clothes, or makeup.  
58. A lot of people are “suckers” and can easily be fooled.   
59. I admit that I often “mouth off” without thinking.   
60. I sometimes dump friends that I don‟t need any more.    
61. I would never step on others to get what I want.      
62. I have close friends who served time in prison.  
63. I purposely tried to hit someone with the vehicle I was driving.  
64. I have violated my parole from prison. 
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Buss-Perry Aggression Questionnaire (BPAQ) 
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Barratt Impulsivity Scale-11 (BIS-11) 
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Impulsive-Premeditated Aggression Scale (IPAS) 
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A1.I Summary of POMS data (∆ Scores: Post-Dose minus Pre-Dose).  
D = Depression-Dejection; V = Vigor; Confusion = Confusion-Bewilderment; TA 
= Tension Anxiety; AH = Anger-Hostility; F = Fatigue. Min_PostDose = minutes 
since dose (30, 60, 150, 210, refers to session 1, 2, 3, 4, respectively). 
 IU =international unit. Top number represents the mean. Bottom number 
represents the S.D.  
 
Placebo Dose 
 
 
 
OT Dose (12 IU) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                          
                    1.95      2.59      0.89      2.07      1.52      3.51
         210       -0.60     -1.20      0.40      1.60     -0.40      0.40
                                                                          
                    2.04      2.48      0.41      1.75      0.84      2.80
         150       -1.17     -3.17     -0.17     -0.67     -0.50     -1.33
                                                                          
                    2.04      2.90      0.00      0.84      0.82      2.14
          90       -1.17      0.00      0.00     -0.50     -0.33     -1.17
                                                                          
                    1.22      3.10      0.41      1.67      0.82      1.86
          30       -0.50      1.00     -0.17     -1.00     -0.33     -1.67
                                                                          
Min_PostDose           D         V        CB        TA        AH         F
                                                                          
                    0.89      3.16      0.00      1.34      0.89      4.22
         210        0.40     -2.00      0.00      0.60      0.40      1.60
                                                                          
                    0.82      2.14      0.00      1.47      0.00      2.95
         150        0.33     -0.83      0.00      0.17      0.00      0.50
                                                                          
                    0.41      0.89      0.00      1.55      0.00      2.32
          90        0.17      0.00      0.00     -1.00      0.00     -0.17
                                                                          
                    0.00      1.86      0.00      1.60      0.00      1.51
          30        0.00     -0.33      0.00     -1.17      0.00     -0.67
                                                                          
Min_PostDose           D         V        CB        TA        AH         F
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OT Dose (24 IU) 
 
 
 
OT Dose (48 IU) 
 
  
                                                                          
                    0.45      1.67      0.00      1.30      0.00      1.10
         210       -0.20     -2.40      0.00     -0.80      0.00      1.20
                                                                          
                    0.84      2.19      0.82      1.60      0.00      3.43
         150       -0.50     -1.00      0.33     -0.17      0.00      0.17
                                                                          
                    0.52      1.94      0.00      1.21      0.00      2.00
          90       -0.33     -0.17      0.00     -0.67      0.00     -1.00
                                                                          
                    0.52      1.76      0.00      1.26      0.00      0.63
          30       -0.33     -1.50      0.00      0.00      0.00      0.00
                                                                          
Min_PostDose           D         V        CB        TA        AH         F
                                                                          
                    0.00      0.84      0.00      1.22      0.00      3.94
         210        0.00     -0.80      0.00      0.00      0.00      2.00
                                                                          
                    0.82      1.86      0.00      0.98      0.00      1.72
         150        0.33      0.33      0.00     -0.17      0.00      0.17
                                                                          
                    0.00      1.97      0.00      0.84      1.63      1.55
          90        0.00      1.33      0.00     -0.50      0.67      0.00
                                                                          
                    0.41      0.98      0.00      1.03      0.00      0.55
          30        0.17      0.83      0.00     -0.67      0.00     -0.50
                                                                          
Min_PostDose           D         V        CB        TA        AH         F
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A1.I Summary of POMS raw data  
D = Depression-Dejection; V = Vigor; Confusion = Confusion-Bewilderment; TA 
= Tension Anxiety; AH = Anger-Hostility; F = Fatigue. Min_PostDose = minutes 
since dose (-30 refers to the pre-dose values. 30, 60, 150, 210, refers to Post-
Dose session 1, 2, 3, 4, respectively). IU =international unit. 
Top number represents the mean. Bottom number represents the S.D.  
 
 
Placebo Dose 
 
 
 
 
OT Dose (12 IU) 
 
 
 
 
 
 
 
                                                                          
                    0.45      5.77      0.89      2.88      0.45      3.54
         210        0.20     10.60      0.40      2.40      0.20      4.00
                                                                          
                    2.42      8.69      0.82      1.21      0.82      2.32
         150        1.33      9.67      0.33      0.67      0.33      2.17
                                                                          
                    2.42      6.94      1.22      1.33      1.22      2.16
          90        1.33     12.83      0.50      0.83      0.50      2.33
                                                                          
                    3.35      6.21      0.82      0.82      1.22      1.47
          30        2.00     13.83      0.33      0.33      0.50      1.83
                                                                          
                    4.46      6.71      1.22      2.07      1.33      2.88
         -30        2.50     12.83      0.50      1.33      0.83      3.50
                                                                          
Min_PostDose           D         V        CB        TA        AH         F
                                                                          
                    0.89      6.91      0.00      1.95      0.89      3.81
         210        0.40      9.20      0.00      1.40      0.40      4.00
                                                                          
                    3.67      8.09      0.82      2.25      0.00      2.66
         150        1.50     11.33      0.33      1.67      0.00      2.67
                                                                          
                    3.27      7.22      0.82      0.84      0.00      1.79
          90        1.33     12.17      0.33      0.50      0.00      2.00
                                                                          
                    2.86      7.47      0.82      0.52      0.00      1.22
          30        1.17     11.83      0.33      0.33      0.00      1.50
                                                                          
                    2.86      6.85      0.82      1.87      0.00      2.14
         -30        1.17     12.17      0.33      1.50      0.00      2.17
                                                                          
Min_PostDose           D         V        CB        TA        AH         F
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OT Dose (24 IU) 
 
 
 
 
OT Dose (48 IU) 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                          
                    0.00      7.56      0.00      0.00      0.00      4.24
         210        0.00     10.80      0.00      0.00      0.00      4.00
                                                                          
                    2.04      6.63      1.63      1.22      0.00      3.41
         150        0.83     13.00      0.67      0.50      0.00      3.00
                                                                          
                    2.45      6.05      0.82      0.00      0.00      2.23
          90        1.00     13.83      0.33      0.00      0.00      1.83
                                                                          
                    2.45      6.92      0.82      1.21      0.00      4.02
          30        1.00     12.50      0.33      0.67      0.00      2.83
                                                                          
                    2.80      5.80      0.82      1.21      0.00      3.92
         -30        1.33     14.00      0.33      0.67      0.00      2.83
                                                                          
Min_PostDose           D         V        CB        TA        AH         F
                                                                          
                    0.00      7.13      0.00      1.41      0.00      5.10
         210        0.00     11.60      0.00      1.00      0.00      3.00
                                                                          
                    2.86      7.15      0.82      1.03      0.00      1.05
         150        1.17     12.50      0.33      0.67      0.00      1.50
                                                                          
                    2.04      6.09      0.82      0.52      1.63      1.21
          90        0.83     13.50      0.33      0.33      0.67      1.33
                                                                          
                    2.45      6.13      0.82      0.41      0.00      0.98
          30        1.00     13.00      0.33      0.17      0.00      0.83
                                                                          
                    2.04      6.22      0.82      0.98      0.00      1.51
         -30        0.83     12.50      0.33      0.83      0.00      1.33
                                                                          
Min_PostDose           D         V        CB        TA        AH         F
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A1.J Informed consent document 
 
 
 
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER - HOUSTON 
 
Oxytonin Effects on Computer-Based Social Interaction  
HSC-MS_12-0024 
 
INFORMED CONSENT FORM TO TAKE PART IN RESEARCH 
 
INVITATION TO TAKE PART 
You are invited to take part in a research project called, “Oxytonin Effects on Computer-Based 
Social Interaction,” conducted by Joseph L. Alcorn III and Dr. Scott Lane of the University of 
Texas Health Science Center Houston. For this research project, Joseph L. Alcorn III will be 
called the Principal Investigator.   
 
Your decision to take part is voluntary and you may refuse to take part, or choose to stop taking 
part, at any time. A decision not to take part or to stop being a part of the research project will not 
change the services available to you from your doctor, or the University of Texas Health Science 
Center.   
 
This research project has been reviewed by the Committee for the Protection of Human Subjects 
(CPHS) of the University of Texas Health Science Center at Houston as HSC-MS-10-0178. 
 
DESCRIPTION OF RESEARCH 
 
PURPOSE 
The purpose of this research is to examine how the drug, Syntocinon (synthetic oxytocin), affects 
people’s mood (e.g. anger, frustration, cooperativeness), and the way that people interact with 
each other during a computer task. This is a Food and Drug Administration (FDA) approved drug 
that has been shown in other studies to affect mood, personality, and emotional responses on the 
spectrum of behavior. This is a local study in Houston, Texas.  The study will enroll a total of 50 
people.  The National Institute of Health is paying for this study to be completed.   
 
PROCEDURES 
Before you can be enrolled in this study we made sure that you meet certain criteria. To ascertain 
this, we asked you to complete a physical exam, a mental health exam, and answer questions 
about drug use and medical history. You have met our health requirements, now we will ask if 
you wish to proceed to participate in this study. This study will last five days. On the first day you 
will not receive a drug or placebo dose. On the remaining four experimental days, you will be 
given a nasal spray containing either a dose of the drug Syntocinon or a placebo (nasal spray 
containing no Syntocinon). You will be asked to inhale a total volume of 1.5ml in both nostrils (at 
an approximate volume of 0.75 ml in each nostril) on days 2-5. Over the course of this study you 
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will receive both the study drug and the placebo, however, you will not know if you are taking the 
drug or the placebo at the time that you are taking the drug.  After taking the nasal spray, you will 
work on a task where you will interact with other people through a computer. Below is an outline 
of the study days:  
 
Outline of Study Days 
Day 1: Introduction to the computer task: no dose 
Day 2: Computer task: Syntocinon dose or placebo 
Day 3: Computer task: Syntocinon dose or placebo 
Day 4: Computer task: Syntocinon dose or placebo 
Day 5: Computer task: Syntocinon dose or placebo 
 
  Each day you will also be asked to provided a breath sample to test for recent alcohol use. The 
results of these tests will determine if you can take part in the study on that day. At 8:30am you 
will be given either the study medication, called Syntocinon or a placebo (a nasal spray not 
containing Syntocinon).  During testing you will be in a room with a computer monitor screen and 
a response panel with three buttons. The task will require that you push the buttons to earn 
money.  You will be paired with other people through the computer during the test session.  
Completing the task may cause you to react and may present a challenge to youThe way you 
interact with these other people may affect the amount of money you earn.  The sessions will be 
about 25 minutes each, and there will be a break in between test sessions. After each session 
you will be asked questions about your mood and then your heart rate and blood pressure will be 
measured and collected. At the end of each day, you will be paid the sum money earned during 
each session.  At the request of the FDA under the Division of Psychiatry Products (DPP) you will 
be asked questions pertaining to suicidal thought and behaviors. This is a recent policy of the 
DPP to monitor treatment-emergent suicidality and to ensure that volunteers in clinical research 
who are experiencing suicidality are detected and adequately managed.  Below is a typical daily 
schedule during the study.  
 
Daily Schedule  
8:00 am: Urine and expired breath sample collection.  
8:30 am: mood questionaires; heart rate/blood pressure; Placebo/dose administration (days 2-5) 
9:00 am:  Session #1 of computer task; mood questionaires; heart rate/blood pressure.  
10:00 am: Session #2 of computer task; mood questionaires; heart rate/blood pressure. 
11:00 am: Session #3 of computer task; mood questionaires; heart rate/blood pressure. 
12:00 pm: Session #4 of computer task; mood questionaires; heart rate/blood pressure. 
12:30 pm: Lunch 
1:00 pm: Impairment evaluation and questionnaires 
1:15 pm: Payment and release from laboratory. 
 
You are asked to not use alcohol or any other drug during the entire study. You are asked not to 
drink tea, coffee, or colas, smoke cigarettes, or eat food from outside during the test days. These 
requirements are very important to the study.  Every day you visit the medical center, you will be 
asked to provide a urine sample to test for recent drug use.  You may refuse to answer any 
questions asked or written on any forms. 
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TIME COMMITMENT 
You will be asked to come into the laboratory for 5 days, approximately 5-6 hours each day.  Your 
total time in the study should be about 1 week. 
 
BENEFITS: 
You may receive no direct benefit from participating in this study. However, you may learn new 
information regarding your physical and mental health status obtained during the screening 
procedures. You will be provided a referral service if one is available that might benefit you.   
 
RISKS AND DISCOMFORTS 
Taking part in this study involves the following risks:  
 
Syntocinon is a synthetic oxytocin approved by the FDA for the treatment for conditions, such as 
uterine haemorrhage and augmentation of labor. A single dose of Syntocinon is not expected to 
cause any serious changes to your health.  The most common side effects of Syntocinon 
reported by the manufacturer compared to placebo are lighthededness/headache, dry mouth, 
nasal irritation, and drowsiness.  Syntocinon should not be taken if you have a serve 
cardiovascular disorder or if you are allergic to oxytocin or preservatives (i.e. sodium acetate, 
glacial acetic acid, chlorbutol, and ethanol 94%).  Due to this fact you will not be able to take part 
in this study in you have a history of allergic reactions to oxytocin or preservatives, or if you have 
diabetes, chronic high blood pressure, glaucoma, or a cardiac disorder (e.g. arrhythmia). Risks 
may include the possible breach of confidentiality.  
 
ALTERNATIVES:   
The only alternative is not to take part in this study.  
 
STUDY WITHDRAWAL:   
You may withdraw at any time without any penalty or unfair outcomes should you choose to stop 
taking part in this study. You may be asked to leave the study for the following reasons:  
1. If alcohol is detected on your breath and/or drugs are found in your urine sample. 
2. You fail to show up for three scheduled appointments at the laboratory, and do not contact 
the laboratory. 
3. You experience side effects of Syntocinon that are considered to be unsafe for you to 
continue. 
 
IN CASE OF INJURY 
If you suffer any injury as a result of taking part in this research study, please understand that 
nothing has been arranged to provide free treatment of the injury or any other type of payment. 
However, all needed facilities, emergency treatment and professional services will be available to 
you, just as they are to the community in general. You should report any injury to Scott Lane at 
(713) 486-2535 and to the Committee for the Protection of Human Subjects at (713) 500-7943. 
You will not give up any of your legal rights by signing this consent form. 
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COSTS, REIMBURSEMENT, AND COMPENSATION 
Parking voucher or bus tokens and lunch will be provided.  You can expect to earn about $8-10 
per hour.  
It will not cost you anything to join this study. If you should receive a bill that you believe is related 
to your taking part in this research project, please contact, the Principal Investigator, Joseph L. 
Alcorn III at (713) 486-2613.  
 
You wll be paid for taking part in this project in the following amounts: 
1. On experimental days, you will earn about $5-7 per testing session, based on your 
performance. 
2. You will earn $20 each day that you arrive on time for scheduled appointment and your 
breath alcohol level and urine sample are free from drugs and alcohol. 
3. Upon completion of the experiment (on the last day), you will earn a completion bonus of 
$10 for each day that you took part (e.g., 5 days = $50). 
4. You will receive $8/hour for your time today, for the physical examination, and for the 
final day when you fill out questionnaires.  There is the possibility, but no guarantee, of 
earning up to $138 on the last day of study participation.  
 
CONFIDENTIALITY 
Please understand that representatives of the Food and Drug Administration, National Institute of 
Health (NIH) and the Committee for the Protection of Human Subjects may review your research 
and/or medical records for the purposes of verifying research data, and will see personal 
identifiers. However, identifying information will not appear on records retained by the sponsor, 
with the exception of treatment and service dates. You will not be personally identified in any 
reports or publications that may result from this study. There is a separate authorization form that 
you will be asked to sign which details the use and disclosure of your protected health 
information.  
 
 
QUESTIONS: 
The Principal Investigator, Joseph L. Alcorn III and his research staff will be glad to 
answer any questions regarding the study at any time. The staff may be reached at (713) 
486-2794. 
 
SIGNATURES: 
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Sign below only if you understand the information given to you about the research and choose to take part. Make 
sure that any questions have been answered and that you understand the study. If you have any questions or 
concerns about your rights as a research subject, call the Committee for the Protection of Human Subjects at (713) 
500-7943. You may also call the Committee if you wish to discuss problems, concerns, and questions; obtain 
information about the research; and offer input about current or past participation in a research study. If you decide to 
take part in this research study, a copy of this signed consent form will be given to you. 
 
  
Printed Name of Subject 
 
________________________________________      ___________________ 
Signature of Subject                                                      Date / Time 
 
 
________________________________________ 
Printed Name of Individual Obtaining Consent 
 
________________________________________      ___________________ 
Signature of Individual Obtaining Consent                       Date / Time 
 
 
 
CPHS STATEMENT: This study (HSC-XX-XX-XXXX) has been reviewed by the Committee for 
the Protection of Human Subjects (CPHS) of the Univeristy of Texas Health Science Center at 
Houston. For any questions about research subject’s rights, or to report a research-related injury, 
call the CPHS at (713) 500-7943.  
 
 
 
 
 
A1.K Point Subtraction Aggression Paradigm (PSAP) Instructions 
This computer task examines mood, motor responses (button pressing), 
and interaction with other people. Each session will last approximately25 
minutes. During the session you will be able to earn money by working at a 
response panel. This is a drawing of the response panel. As the drawing shows, 
the response panel has three buttons marked A, B, and C; a monitor, which will 
display the letters A, B, and C; and a money counter. When you press a button, 
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the letter corresponding to that button will remain on the screen and the other 
letters will go off the screen. So when you press the A button, the letters B and 
C will disappear. Pressing button B removes the letters A and C, and pressing 
button C removes letters A and B. When one only one letter is showing on the 
screen, the other buttons will not work. So, you can only change from one 
button to another button when all three letters are displayed on the screen. Your 
response panel is linked by a network to one of several other panels just like it. 
Other people like you will be seated at the same kind of panel. The panels are 
located in different locations. The other person will always be a (man/woman), 
as we pair people by the same gender in this task. When the session starts, the 
letters A, B, and C will be displayed and the money counter will begin at zero. If 
you press button A, letters B and C letter will disappear. Pressing button A 
approximately 100 times will add 15 cents to your counter (you don't need to 
count presses, the computer program will do it for you). Then the A, B, and C 
letters will come back on the screen, and you can continue to press button A or 
switch to buttons B or C. During the session, you may see the counter increase 
in size and start flashing off and on. Then 15 cents will then be subtracted from 
your counter, and the counter will return to its normal size. This means that the 
other person – whose computer in linked to yours – has subtracted 15 cents 
from your counter and added it to his counter by pressing button B on his 
response panel 10 times. So the other person can take 15 cents of your money 
and add it to his money by pressing B ten times, instead of pressing A 100 
times. 
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If YOU press button B, the A and C letters will disappear. Then pressing 
button B ten times will subtract 15 cents from the counter of the person who is 
connected to your panel. When the A, B, and C letters reappear, you can 
continue to press button B or switch to button A or C. However, if you subtract 
money from the other person, it will not be added to your counter – the money 
is just removed from the other person's counter. There are two conditions in the 
task. In condition 1, the person keeps the money that s/he subtracts. In 
condition 2, the money that is taken from the other person is simply gone. The 
conditions are determined randomly by the toss of a coin and you ended up in 
the condition 2 in which you do not keep the money you subtract. If you press 
button C, the A and B letters will disappear. Pressing button C until the letter C 
goes off the screen (approximately 10 times) will protect your counter from 
subtractions for a short period of time (about 2 minutes). When the A, B, and C 
letters reappear, you may continue to press button C or switch to button A or B. 
You will be paid the money showing on your counter at the end of each test 
session. This money will be paid at the end of the day, after you have 
completed your last session. How much you earn depends mostly on how fast 
you press the A button. As a general rule, the faster you press button A the 
more money you can earn. Please remain in the testing room until you see a 
message on the computer screen that reads “Session Over”. 
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APPENDIX MATERIAL FOR EXPERIMENT 2 (CHAPTER 3) 
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A2.A Summary of behavioral data (raw data) 
ButtonA = Monetary Response Rate (responses per second); ButtonB1 = 
Aggressive Response Rate (responses per minute) with the outlier; ButtonB2 = 
Aggressive Response Rate (responses per minute) without the outlier. 
Min_PostDose = minutes since dose (-30 refers to the Pre-Dose session. 30, 
60, 150, refers to Post-Dose sessions 1, 2, 3, respectively). IU =international 
unit. Top number represents the mean. Bottom number represents the S.D. 
 
Placebo Dose 
 
 
 
OT Dose (24 IU) 
 
 
  
                                              
                   10.24      6.07      5.05  
         150        7.16      9.11      8.23  
                                              
                    0.83      6.49      6.49  
          90        4.58      7.66      7.66  
                                              
                    0.74      4.66      4.66  
          30        4.61      7.52      7.52  
                                              
                    0.72      4.74      4.74  
         -30        4.62      7.83      7.83  
                                              
Min_PostDose     ButtonA  ButtonB1  ButtonB2  
                                              
                    0.71      4.38      4.38   
         150        4.71      7.49      7.49   
                                               
                    0.69      3.40      3.40   
          90        4.58      7.65      7.65   
                                               
                    0.60      2.68      2.68   
          30        4.59      6.98      6.98   
                                               
                    0.58      3.15      3.15   
         -30        4.59      7.66      7.66   
                                               
Min_PostDose     ButtonA  ButtonB1  ButtonB2   
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A2.B Summary of psychometric data (raw data) 
IM = interpersonal manipulation subscale; CA = callous affect subscale; ELS = 
erratic lifestyle subscale; CT = criminal tendencies; SRPIII = total score of the 
self-report of psychopathy III. Anger = anger subscale; Host = hostility subscale; 
Physical = physical aggression subscale; Verbal = verbal aggression subscale.  
 
 
Self-Report of Psychopathy III 
 
 
 
Buss-Perry Aggression Questionnaire 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                            
      sd        7.39      7.27      6.25      7.20     21.66
    mean       35.76     40.76     37.59     26.94    140.71
                                                            
   stats          IM        CA       ELS        CT    SRPIII
                                                            
      sd        3.00   4.30031      5.04      2.78     11.74
    mean       11.00   14.6471     18.59     11.88     56.12
                                                            
   stats       Anger      Host  Physical    Verbal      BPAQ
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A2.C Summary of “Likability” ratings (raw data) 
VAS1 = Social Visual Analog Scale, Likability ratings with the outlier.   VAS2 = 
Social Visual Analog Scale, Likability ratings without the outlier. Min_PostDose 
= minutes since dose (-30 refers to the Pre-Dose session. 30, 60, 150, refers to 
Post-Dose sessions 1, 2, 3, respectively). IU =international unit.Top number 
represents the mean. Bottom number represents the S.D. 
 
 
Placebo Dose 
 
 
 
OT Dose (24 IU) 
 
  
                                  
                    2.20      2.17
         150        2.62      2.80
                                  
                    1.99      1.99
          90        3.21      3.21
                                  
                    1.97      1.97
          30        3.00      3.00
                                  
                    1.77      1.77
         -30        3.44      3.44
                                  
Min_PostDose        VAS1      VAS2
                                  
                    2.00      2.00
         150        2.41      2.41
                                  
                    1.81      1.81
          90        2.47      2.47
                                  
                    2.18      2.18
          30        2.88      2.88
                                  
                    2.04      2.04
         -30        2.82      2.82
                                  
Min_PostDose        VAS1      VAS2
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Social Visual Analog Scale (VAS) 
 
 
A2.D Summary of cardiovascular data (raw data)  
HR1 = Heart Rate (beats per minute) with the outlier; HR2 = Heart Rate (beats 
per minute) without the outlier; SBP = Systolic Blood Pressure (mmHG); DBP1 
= Systolic Blood Pressure  (mmHG) with the outlier; DBP2 = Systolic Blood 
Pressure  (mmHG) without the outlier. Min_PostDose = minutes since dose (-30 
refers to the Pre-Dose session. 30, 60, 150, refers to Post-Dose sessions 1, 2, 
3, respectively). IU =international unit.Top number represents the mean. Bottom 
number represents the S.D. 
 
 
Placebo Dose 
 
 
 
 
 
OT Dose (24 IU) 
 
                                                                
                   11.86     11.86      9.57      8.43      8.43
         150       63.56     63.56    114.19     73.75     73.75
                                                                
                   11.39     11.39      9.83     10.31     10.61
          90       64.56     64.56    116.19     74.88     74.60
                                                                
                   13.63     12.97     11.40      9.04      9.04
          30       66.88     65.53    114.56     73.44     73.44
                                                                
                   11.74     11.74      9.82     10.46     10.46
         -30       69.63     69.63    110.63     69.31     69.31
                                                                
Min_PostDose          HR       HR2       SBP       DBP      DBP2
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                   12.60     12.60      9.47      8.83      8.83
         150       65.00     65.00    114.18     73.41     73.41
                                                                
                   13.61     13.61     10.13     10.20     10.20
          90       65.41     65.41    113.24     71.71     71.71
                                                                
                   13.12     13.12      9.92     11.25     11.25
          30       66.65     66.65    110.71     70.88     70.88
                                                                
                   11.69     11.69      9.39     11.20     11.20
         -30       69.59     69.59    111.00     70.65     70.65
                                                                
Min_PostDose          HR       HR2       SBP       DBP      DBP2
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A2.E Summary of temperature data (raw data) 
Temp = Oral body temperature (Fº).  Min_PostDose = minutes since dose (-30 
refers to the Pre-Dose session. 30, 60, 150, refers to Post-Dose sessions 1, 2, 
3, respectively). IU =international unit.Top number represents the mean. Bottom 
number represents the S.D. 
 
Placebo Dose 
 
 
 
 
OT Dose (24 IU) 
  
                        
                    0.89
         150       97.27
                        
                    0.79
          90       97.36
                        
                    0.78
          30       97.14
                        
                    0.92
         -30       97.29
                        
Min_PostDose        Temp
                        
                    0.70
         150       97.15
                        
                    0.70
          90       97.42
                        
                    0.89
          30       97.05
                        
                    0.80
         -30       97.49
                        
Min_PostDose        Temp
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A2.F Summary of POMS data (∆ Scores: Post-Dose minus Pre-Dose).  
 
D = Depression-Dejection; V = Vigor; Confusion = Confusion-Bewilderment; 
TA1 = Tension Anxiety with the outlier; TA2 = Tension Anxiety without the 
outlier; AH = Anger-Hostility; F = Fatigue. Min_PostDose = minutes since dose. 
30, 60, 150, refers to Post-Dose sessions 1, 2, 3, respectively). IU 
=international unit.Top number represents the mean. Bottom number 
represents the S.D. 
 
 
 
Placebo Dose 
 
 
 
 
OT Dose (24 IU) 
 
 
  
                                                                                    
                    0.56      3.04      0.68      0.93      0.96      0.85      1.74
         150        0.06     -0.62      0.31      0.13      0.13      0.31      1.19
                                                                                    
                    0.35      3.07      0.39      0.56      0.56      0.66      1.20
          90        0.00     -0.25      0.19     -0.06     -0.06      0.25      0.75
                                                                                    
                    0.24      2.12      0.00      0.43      0.43      0.00      1.49
          30       -0.06      0.56      0.00      0.25      0.25      0.00      0.68
                                                                                    
Min_PostDose           D         V        CB       TA1       TA2        AH         F
                                                                                    
                    0.56      5.12      0.50      0.83      0.83      1.14      1.50
         150       -0.24      1.24      0.00     -0.06     -0.06      0.06     -0.47
                                                                                    
                    0.53      2.29      0.33      1.90      1.00      0.75      2.08
          90       -0.18      0.88     -0.12      0.65      0.25     -0.06     -0.76
                                                                                    
                    0.39      2.19      0.33      0.61      0.61      0.53      1.37
          30       -0.18      0.94     -0.12      0.00      0.00     -0.18     -0.65
                                                                                    
Min_PostDose           D         V        CB       TA1       TA2        AH         F
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A2.G Summary of POMS (raw data) 
D = Depression-Dejection; V = Vigor; Confusion = Confusion-Bewilderment; 
TA1 = Tension Anxiety with the outlier; TA2 = Tension Anxiety without the 
outlier; AH = Anger-Hostility; F = Fatigue. Min_PostDose = minutes since dose 
(-30 refers to the Pre-Dose session. 30, 60, 150, refers to Post-Dose sessions 
1, 2, 3, respectively). IU =international unit.Top number represents the mean. 
Bottom number represents the S.D. 
 
 
Placebo Dose 
 
 
 
OT Dose (24 IU) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                    
                    0.65      7.89      0.98      1.19      1.19      0.92      2.09
         150        0.22     11.44      0.56      1.00      1.00      0.44      1.44
                                                                                    
                    0.32      7.18      0.78      1.17      1.17      0.78      1.35
          90        0.11     11.67      0.44      0.78      0.78      0.39      1.06
                                                                                    
                    0.00      6.99      0.43      1.31      1.31      0.24      1.75
          30        0.00     12.56      0.22      1.22      1.22      0.06      1.00
                                                                                    
                    0.24      7.37      0.43      1.21      1.21      0.24      0.70
         -30        0.06     12.06      0.22      0.94      0.94      0.06      0.39
                                                                                    
Min_PostDose           D         V        CB       TA1       TA2        AH         F
                                                                                    
                    0.00      6.78      0.43      1.17      1.17      0.94      1.32
         150        0.00     11.89      0.22      0.78      0.78      0.22      0.89
                                                                                    
                    0.24      7.39      0.32      2.25      1.25      0.47      0.86
          90        0.06     11.56      0.11      1.39      0.94      0.11      0.56
                                                                                    
                    0.32      7.04      0.47      1.11      1.11      0.00      1.14
          30        0.11     11.61      0.11      0.78      0.78      0.00      0.67
                                                                                    
                    0.69      7.76      0.55      1.11      1.11      0.51      2.21
         -30        0.33     10.72      0.22      0.78      0.78      0.17      1.22
                                                                                    
Min_PostDose           D         V        CB       TA1       TA2        AH         F
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A2.H Informed Consent Document 
 
 
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER - HOUSTON 
 
Oxytonin Effects on Computer-Based Social Interaction  
HSC-MS-12-0024 
 
INFORMED CONSENT FORM TO TAKE PART IN RESEARCH 
 
INVITATION TO TAKE PART 
You are invited to take part in a research project called, “Oxytonin Effects on Computer-Based 
Social Interaction,” conducted by Joseph L. Alcorn III and Dr. Scott Lane of the University of 
Texas Health Science Center Houston. For this research project, Joseph L. Alcorn III will be 
called the Principal Investigator.   
 
Your decision to take part is voluntary and you may refuse to take part, or choose to stop taking 
part, at any time. A decision not to take part or to stop being a part of the research project will not 
change the services available to you from your doctor, or the University of Texas Health Science 
Center.   
 
This research project has been reviewed by the Committee for the Protection of Human Subjects 
(CPHS) of the University of Texas Health Science Center at Houston as HSC-MS-10-0178. 
 
DESCRIPTION OF RESEARCH 
 
PURPOSE 
The purpose of this research is to examine how the drug, Syntocinon (synthetic oxytocin), affects 
people’s mood (e.g. anger, frustration, cooperativeness), and the way that people interact with 
each other during a computer task. This is a Food and Drug Administration (FDA) approved drug 
that has been shown in other studies to affect mood, personality, and emotional responses on the 
spectrum of behavior. This is a local study in Houston, Texas.  The study will enroll a total of 50 
people.  The National Institute of Health is paying for this study to be completed.   
 
PROCEDURES 
Before you can be enrolled in this study we made sure that you meet certain criteria. To ascertain 
this, we asked you to complete a physical exam, a mental health exam, and answer questions 
about drug use and medical history. You have met our health requirements, now we will ask if 
you wish to proceed to participate in this study. This study will last an expected five days (see 
Time Commitment section below for details). On the first day you will not receive a drug or 
placebo dose. On two of the remaining experimental days, you will be given a nasal spray 
containing either a dose of the drug Syntocinon or a placebo (nasal spray containing no 
Syntocinon). You will be asked to inhale a total volume of 1.5ml (≈ 0.3 tsp) in both nostrils (at an 
approximate volume of 0.75 ml (≈ 0.15 tsp) in each nostril).  On other days, you may simply 
 175  
 
participate in the computer tasks, and will not receive any nasal spray.  Over the course of this 
study you will receive both the study drug and the placebo, however, you will not know if you are 
taking the drug or the placebo at the time that you are taking the drug.  After taking the nasal 
spray, you will work on a task where you will interact with other people through a computer. 
Below is an outline of the study days:  
 
 
 
Outline of expected study Days 
Step 1: Introduction to the computer task: No dose (may last more than 1 day) 
Step 2: Computer task: Syntocinon dose or placebo 
Step 3: Computer task: No dose (may last more than 1 day) 
Step 4: Computer task: Syntocinon dose or placebo 
 
  Each day you will also be asked to provided a breath sample to test for recent alcohol 
use. The results of these tests will determine if you can take part in the study on that day. At 
8:30am you will be given either the study medication, called Syntocinon or a placebo (a nasal 
spray not containing Syntocinon).  During testing you will be in a room with a computer monitor 
screen and a response panel with three buttons. The task will require that you push the buttons to 
earn money.  You will be paired with other people through the computer during the test session.  
Completing the task may cause you to react and may present a challenge to you.  The way you 
interact with these other people may affect the amount of money you earn.  The sessions will be 
about 25 minutes each, and there will be a break in between test sessions. After each session 
you will be asked questions about your mood and then your heart rate and blood pressure will be 
measured and collected. At the end of each day, you will be paid the sum money earned during 
each session.  At the request of the FDA under the Division of Psychiatry Products (DPP) you will 
be asked questions pertaining to suicidal thought and behaviors. This is a recent policy of the 
DPP to monitor treatment-emergent suicidality and to ensure that volunteers in clinical research 
who are experiencing suicidality are detected and adequately managed.  Below is a typical daily 
schedule during the study.  
 
Expected daily Schedule  
8:00 am Urine and expired breath sample collection. 
8:30 am: Session #1 of computer task; mood questionaires; heart rate/blood pressure; 
temperature. 
9:00 am: Placebo/ Syntocinon dose administration (on scheduled days) 
9:30 am:  Session #2 of computer task; mood questionaires; heart rate/blood pressure; 
temperature.  
10:30 am: Session #3 of computer task; mood questionaires; heart rate/blood pressure; 
temperature. 
11:30 am: Session #4 of computer task; mood questionaires; heart rate/blood pressure; 
temperature. 
12:00 pm: Lunch 
12:30 pm: Impairment evaluation and questionnaires 
12:45 pm: Payment and release from laboratory. 
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You are asked to not use other drugs during the entire study.  On testing days, you are asked not 
to drink tea, coffee, or colas, smoke cigarettes, or eat food from outside before or during your 
participation (after you leave the laboratory these items are OK). These requirements are very 
important to the study.  Every day you visit the medical center, you will be asked to provide a 
urine sample to test for recent drug use.  You may refuse to answer any questions asked or 
written on any forms. 
 
TIME COMMITMENT 
You will be asked to come into the laboratory for an expected 5 days, approximately 5.5-6 hours 
each day.  Your total time in the study should be about 1 week. However, due to the fact that the 
we must synch up your behavioral data from the computer task with the behavioral data of the 
person who you are paired with missing data might occur. Therefore, we might sometimes ask 
you to repeat an experimental day. You will still be compensated as described in the costs, 
reimburstments, and compensations section below. As, such your participation in this study could 
take up to 20 days.  
 
BENEFITS: 
You may receive no direct benefit from participating in this study. However, you may learn new 
information regarding your physical and mental health status obtained during the screening 
procedures. You will be provided a referral service if one is available that might benefit you.   
 
RISKS AND DISCOMFORTS 
Taking part in this study involves the following risks:  
 
Syntocinon is a synthetic oxytocin approved by the FDA for the treatment for conditions, such as 
uterine hemorrhage and augmentation of labor. A single dose of Syntocinon is not expected to 
cause any serious changes to your health.  The most common side effects of Syntocinon 
reported by the manufacturer compared to placebo are lighthededness/headache, dry mouth, 
nasal irritation, and drowsiness.  Syntocinon should not be taken if you have a serve 
cardiovascular disorder or if you are allergic to oxytocin or preservatives (i.e. sodium acetate, 
glacial acetic acid, chlorbutol, and ethanol 94%).  Due to this fact you will not be able to take part 
in this study in you have a history of allergic reactions to oxytocin or preservatives, or if you have 
diabetes, chronic high blood pressure, glaucoma, or a cardiac disorder (e.g. arrhythmia). Risks 
may include the possible breach of confidentiality.  
 
ALTERNATIVES:   
The only alternative is not to take part in this study.  
 
STUDY WITHDRAWAL:   
You may withdraw at any time without any penalty or unfair outcomes should you choose to stop 
taking part in this study. You may be asked to leave the study for the following reasons:  
4. If alcohol is detected on your breath and/or drugs are found in your urine sample. 
5. You fail to show up for three scheduled appointments at the laboratory, and do not contact 
the laboratory. 
6. You experience side effects of Syntocinon that are considered to be unsafe for you to 
continue. 
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IN CASE OF INJURY 
If you suffer any injury as a result of taking part in this research study, please understand that 
nothing has been arranged to provide free treatment of the injury or any other type of payment. 
However, all needed facilities, emergency treatment and professional services will be available to 
you, just as they are to the community in general. You should report any injury to Scott Lane at 
(713) 486-2535 and to the Committee for the Protection of Human Subjects at (713) 500-7943. 
You will not give up any of your legal rights by signing this consent form. 
 
COSTS, REIMBURSEMENT, AND COMPENSATION 
Parking voucher or bus tokens and lunch will be provided.  You can expect to earn about $8-10 
per hour.  
It will not cost you anything to join this study. If you should receive a bill that you believe is related 
to your taking part in this research project, please contact, the Principal Investigator, Joseph L. 
Alcorn III at (713) 486-2613.  
 
You wll be paid for taking part in this project in the following amounts: 
5. On experimental days, you will earn about $5-7 per testing session, based on your 
performance. 
6. You will earn $20 each day that you arrive on time for scheduled appointment and your 
breath alcohol level and urine sample are free from drugs and alcohol. 
7. Upon completion of the experiment (on the last day), you will earn a completion bonus of 
$10 for each day that you took part (e.g., 4 days = $40). 
8. You will receive $8/hour for your time today, for the physical examination, and for the 
final day when you fill out questionnaires.  There is the possibility, but no guarantee, of 
earning up to $138 on the last day of study participation.  
 
If you receive payment for taking part in this study please be informed that you will be asked to 
complete a copy W-9 form that will be forwarded to the accounting department as a requirement 
by the Internal Revenue Service.  You will also be issued a 1099-Misc form from this study for tax 
reporting purposes. If you receive a bill that you believe is related to your taking part in this 
research study, please contact Joseph Alcorn III or research staff at  at (713) 486-2794 with any 
questions. 
CONFIDENTIALITY 
Please understand that representatives of the Food and Drug Administration, National Institute of 
Health (NIH) and the Committee for the Protection of Human Subjects may review your research 
and/or medical records for the purposes of verifying research data, and will see personal 
identifiers. However, identifying information will not appear on records retained by the sponsor, 
with the exception of treatment and service dates. You will not be personally identified in any 
reports or publications that may result from this study. There is a separate authorization form that 
you will be asked to sign which details the use and disclosure of your protected health 
information.  
 
QUESTIONS: 
The Principal Investigator, Joseph L. Alcorn III and his research staff will be glad to 
answer any questions regarding the study at any time. The staff may be reached at (713) 
486-2794. 
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SIGNATURES: 
Sign below only if you understand the information given to you about the research and choose to take part. Make 
sure that any questions have been answered and that you understand the study. If you have any questions or 
concerns about your rights as a research subject, call the Committee for the Protection of Human Subjects at (713) 
500-7943. You may also call the Committee if you wish to discuss problems, concerns, and questions; obtain 
information about the research; and offer input about current or past participation in a research study. If you decide to 
take part in this research study, a copy of this signed consent form will be given to you. 
 
  
Printed Name of Subject 
 
________________________________________      ___________________ 
Signature of Subject                                                      Date / Time 
 
 
________________________________________ 
Printed Name of Individual Obtaining Consent 
 
________________________________________      ___________________ 
Signature of Individual Obtaining Consent                       Date / Time 
 
 
 
CPHS STATEMENT: This study (HSC-MS-12-0024) has been reviewed by the Committee for the 
Protection of Human Subjects (CPHS) of the Univeristy of Texas Health Science Center at 
Houston. For any questions about research subject’s rights, or to report a research-related injury, 
call the CPHS at (713) 500-7943.  
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